
<html lang="en"     class="pb-page"  data-request-id="5e409058-1092-49b2-862a-2745c8ccae28"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.6b00487;issue:issue:10.1021/jmcmar.2016.59.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="Gregory R.  Ott" /></meta><meta name="dc.Creator" content="Mangeng  Cheng" /></meta><meta name="dc.Creator" content="Keith S.  Learn" /></meta><meta name="dc.Creator" content="Jason  Wagner" /></meta><meta name="dc.Creator" content="Diane E.  Gingrich" /></meta><meta name="dc.Creator" content="Joseph G.  Lisko" /></meta><meta name="dc.Creator" content="Matthew  Curry" /></meta><meta name="dc.Creator" content="Eugen F.  Mesaros" /></meta><meta name="dc.Creator" content="Arup K.  Ghose" /></meta><meta name="dc.Creator" content="Matthew R.  Quail" /></meta><meta name="dc.Creator" content="Weihua  Wan" /></meta><meta name="dc.Creator" content="Lihui  Lu" /></meta><meta name="dc.Creator" content="Pawel  Dobrzanski" /></meta><meta name="dc.Creator" content="Mark S.  Albom" /></meta><meta name="dc.Creator" content="Thelma S.  Angeles" /></meta><meta name="dc.Creator" content="Kevin  Wells-Knecht" /></meta><meta name="dc.Creator" content="Zeqi  Huang" /></meta><meta name="dc.Creator" content="Lisa D.  Aimone" /></meta><meta name="dc.Creator" content="Elizabeth  Bruckheimer" /></meta><meta name="dc.Creator" content="Nathan  Anderson" /></meta><meta name="dc.Creator" content="Jay  Friedman" /></meta><meta name="dc.Creator" content="Sandra V.  Fernandez" /></meta><meta name="dc.Creator" content="Mark A.  Ator" /></meta><meta name="dc.Creator" content="Bruce A.  Ruggeri" /></meta><meta name="dc.Creator" content="Bruce D.  Dorsey" /></meta><meta name="dc.Description" content="Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, p..." /></meta><meta name="Description" content="Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, p..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 15, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00487" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00487" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00487" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00487" /></link>
        
    
    

<title>Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00487" /></meta><meta property="og:title" content="Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0023.jpeg" /></meta><meta property="og:description" content="Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clinically derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK). FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis. The discovery of the clinical stage, dual FAK/ALK inhibitor 27b, including details surrounding SAR, in vitro/in vivo pharmacology, and pharmacokinetics, is reported herein." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00487"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00487">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00487&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00487&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00487&amp;href=/doi/10.1021/acs.jmedchem.6b00487" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7478-7496</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00475" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00509" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+R.++Ott">Gregory R. Ott</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mangeng++Cheng">Mangeng Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith+S.++Learn">Keith S. Learn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Wagner">Jason Wagner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Diane+E.++Gingrich">Diane E. Gingrich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+G.++Lisko">Joseph G. Lisko</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Curry">Matthew Curry</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eugen+F.++Mesaros">Eugen F. Mesaros</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arup+K.++Ghose">Arup K. Ghose</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Quail">Matthew R. Quail</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weihua++Wan">Weihua Wan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lihui++Lu">Lihui Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pawel++Dobrzanski">Pawel Dobrzanski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+S.++Albom">Mark S. Albom</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thelma+S.++Angeles">Thelma S. Angeles</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Wells-Knecht">Kevin Wells-Knecht</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zeqi++Huang">Zeqi Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+D.++Aimone">Lisa D. Aimone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Bruckheimer">Elizabeth Bruckheimer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathan++Anderson">Nathan Anderson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jay++Friedman">Jay Friedman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra+V.++Fernandez">Sandra V. Fernandez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Ator">Mark A. Ator</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+A.++Ruggeri">Bruce A. Ruggeri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+D.++Dorsey">Bruce D. Dorsey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Teva Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Champions Oncology, Inc., One University Plaza, Suite 307, Hackensack, New Jersey 07601, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">Thomas Jefferson University, 233 South 10th Street, 1002 BLSB, Philadelphia, Pennsylvania 19107, United States</span></div><div class="corresp-info"><strong>*</strong>Telephone: 1-610-738-6861. E-mail: <a href="/cdn-cgi/l/email-protection#04637661636b767d2a6b70704470617265746c6576692a676b69"><span class="__cf_email__" data-cfemail="5d3a2f383a322f24733229291d29382b3c2d353c2f30733e3230">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00487&amp;href=/doi/10.1021%2Facs.jmedchem.6b00487" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7478â7496</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 15, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 April 2016</li><li><span class="item_label"><b>Published</b> online</span>15 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 August 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00487</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7478%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGregory%2BR.%2BOtt%252C%2BMangeng%2BCheng%252C%2BKeith%2BS.%2BLearn%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D16%26contentID%3Dacs.jmedchem.6b00487%26title%3DDiscovery%2Bof%2BClinical%2BCandidate%2BCEP-37440%252C%2Ba%2BSelective%2BInhibitor%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%2Band%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7496%26publicationDate%3DAugust%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00487"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2638</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">43</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00487" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;R. Ott&quot;},{&quot;first_name&quot;:&quot;Mangeng&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;S. Learn&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Wagner&quot;},{&quot;first_name&quot;:&quot;Diane&quot;,&quot;last_name&quot;:&quot;E. Gingrich&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;G. Lisko&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Curry&quot;},{&quot;first_name&quot;:&quot;Eugen&quot;,&quot;last_name&quot;:&quot;F. Mesaros&quot;},{&quot;first_name&quot;:&quot;Arup&quot;,&quot;last_name&quot;:&quot;K. Ghose&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Quail&quot;},{&quot;first_name&quot;:&quot;Weihua&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Lihui&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Pawel&quot;,&quot;last_name&quot;:&quot;Dobrzanski&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;S. Albom&quot;},{&quot;first_name&quot;:&quot;Thelma&quot;,&quot;last_name&quot;:&quot;S. Angeles&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Wells-Knecht&quot;},{&quot;first_name&quot;:&quot;Zeqi&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;D. Aimone&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Bruckheimer&quot;},{&quot;first_name&quot;:&quot;Nathan&quot;,&quot;last_name&quot;:&quot;Anderson&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;Friedman&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;V. Fernandez&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Ator&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;A. Ruggeri&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;D. Dorsey&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;7478-7496&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00487&quot;},&quot;abstract&quot;:&quot;Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clinically derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK). FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis. The discovery of the clinical stage, dual FAK/ALK inhibitor 27b, including details surrounding SAR, in vitro/in vivo pharmacology, and pharmacokinetics, is reported herein.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00487&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00487" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00487&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00487" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00487&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00487" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00487&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00487&amp;href=/doi/10.1021/acs.jmedchem.6b00487" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00487" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00487" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26pmid%3D27527804%26genre%3Darticle%26aulast%3DOtt%26date%3D2016%26atitle%3DDiscovery%2Bof%2BClinical%2BCandidate%2BCEP-37440%252C%2Ba%2BSelective%2BInhibitor%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%2Band%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D16%26spage%3D7478%26epage%3D7496%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/jmcmar.2016.59.issue-16/20160825/jmcmar.2016.59.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0023.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor <b>1</b> were optimized for metabolic stability. The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clinically derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK). FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis. The discovery of the clinical stage, dual FAK/ALK inhibitor <b>27b</b>, including details surrounding SAR, in vitro/in vivo pharmacology, and pharmacokinetics, is reported herein.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The identification of tumor-specific genetic aberrations, their validation as druggable targets, and therapeutic interdiction with small molecule drugs and/or biologics has led to a distinct clinical benefit for specific, genetically defined patient populations and has further advanced the field of personalized medicine.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In particular, non-small-cell lung cancer (NSCLC) has seen the development of targeted small-molecule therapies to oncogenic driver mutations in the epidermal growth factor (EGFR) gene (gefitinib, erlotinib, afatinib),<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> the oncogenic fusion protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase gene (EML4-ALK) (crizotinib, certinib, alectinib),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> as well as other oncogenic proteins.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The emergence of tumor resistance through drug-induced activating mutations, gene amplification, and/or induced-resistance/alternative signaling pathways has led to extensive effort in developing second and third generation therapies.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6-9)</a> Despite the ability to genotype and stratify patients to tailored therapy, significant medical need exists in NSCLC to address the above-mentioned resistance to targeted therapy, metastasis, as well as other genetic drivers/variants of this disease that have not been clinically validated with small-molecule/biologic therapeutics (e.g., KRas).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">The biological rationale, therapeutic intervention, and clinical proof of concept data with smallâmolecule ALK inhibitors have been well documented.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> Current approaches toward ALK+ cancers have focused on improving potency toward drug-induced activating mutations as well as incorporation of ancillary activity against other oncogenic signaling mechanisms<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> to combat resistance and the recurrence of local disease and distal metastases. Our initial efforts in the ALK field led to the discovery of <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), a selective ALK inhibitor which advanced to preclinical development.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> Several distinct challenges for our next generation of inhibitors were readily apparent which included not only addressing the limitations of the lead molecule itself (e.g., metabolic stability, high plasma protein binding) but the broader, changing landscape of the small-molecule ALK inhibitor field, which has seen the approval of three distinct molecular entities to treat EML4-ALK defined NSCLC as first or second line therapy, as well as specific drug-induced resistance. Toward this end, a multipronged strategy was developed which included new chemical architecture by constraining the small-molecule ligands into the putative active conformation,<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> as well as fine-tuning the current lead series. This strategy made ample use of our broad knowledge base of structureâactivity relationships (SARs) which engendered cross-fertilization among the architecturally unique core scaffolds (<b>2</b>â<b>4</b>). Ultimately, we addressed the pharmaceutical liabilities, demonstrated in vitro activity against clinically relevant ALK mutations, and also capitalized upon SAR surrounding ancillary activity against focal adhesion kinase (FAK). In tumors, FAK activation mediates anchorage-independent cell survival, one of the hallmarks of cancer cells, as well as migration, invasion, and angiogenesis, all critical components in the process of metastatic progression. FAK overexpression and activation are indicative of multiple solid tumors, particularly those with a propensity for bone metastasis, specifically NSCL, breast, ovarian, prostate, and HNSCC carcinomas.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Interest in small molecule FAK inhibitors has grown and is currently being evaluated at the clinical level.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Furthermore, a very recent report identified FAK as a key mediator of the immune response in certain cancers and provides strong evidence that adjunctive administration of small-molecule FAK inhibitors would be beneficial with inhibitors of T-cell immune checkpoint antibodies (i.e., anti-PD-1, CTLA-4).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Teva small molecule ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Herein, we describe the SAR, in vitro and in vivo properties, and the discovery of a clinical level compound, <b>27b</b> (CEP-37440). Compound <b>27b</b> improved upon the pharmaceutic properties of <b>1</b> and also demonstrated an enhanced pharmacological and kinase selectivity profile with activity in ALK-positive NSCL tumor xenografts, favorable brain penetration, and both in vitro and in vivo biochemical and pharmacodynamic activity/antitumor efficacy against focal adhesion kinase (FAK) and FAK-dependent tumors. Furthermore, this activity is especially relevant to treating subsets of inflammatory breast cancer (IBC), an aggressive and highly metastatic subset of breast cancer that has recently been shown to have amplification FAK in the preponderance of tumors evaluated.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This selective, dual-action inhibitor provides a novel therapeutic opportunity to treat ALK- and FAK-driven malignancies particularly in NSCLC, IBC, and potentially as an adjunctive to immunotherapy.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our lead inhibitor <b>1</b>, as well as other known<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26-28)</a> ALK inhibitors, contains a diaminopyrimidine core motif. The synthetic strategy employed a highly convergent approach with fragment disconnections centered around the 5-chloro-2,6-diaminopyrimidine designated as <b>AâBâC</b> shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. The first disconnection at the 2-position affords amines <b>A</b> and advanced 6-amino-2,5-dichloro fragments <b>BâC</b>. Further disconnection yields starting 2,5,6-tricholoropyrimidine <b>B</b> and the amines <b>C</b>. The synthesis of the key amines <b>A</b> and the elaboration to the final diaminopyrimidines are shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>â<a class="ref internalNav" href="#sch4" aria-label="4">4</a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Retrosynthetic disconnections for 4-chloro-2,6-diaminopyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) morpholine, NaBH(OAc)<sub>3</sub>, AcOH, THF (99%); (b) KNO<sub>3</sub>, TFAA, MeCN (19%); (c) H<sub>2</sub>, Pd/C, EtOH (99%).</p></p></figure><div class="NLM_p">The intermediate aniline <b>8</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was derived from the known ketone <b>5</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> through reductive amination with morpholine to provide <b>6</b> in near quantitative yield. Nitration provided a mixture of 2-nitro (<b>7</b>) and 4-nitro isomers (approximately 1:1) which were separable by silica gel chromatography. Reduction of the nitro group provided racemic <b>8</b>.</div><div class="NLM_p">The 6-amino derivatives (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) were synthesized from known ketone <b>9</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> A diverse set of substituents were desired; thus nitration provided <b>10</b> and 4-nitro, which were separable on silica gel. Reductive amination provided amines <b>11b</b>â<b>d</b>; for <b>11a</b>, the process was reversed. Reduction of the nitro group gave <b>12a</b>â<b>d</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) KNO<sub>3</sub>, TFAA, MeCN (36%); (b) amine, NaBH(OAc)<sub>3</sub>, AcOH, THF (24â85%); (c) H<sub>2</sub>, Pd/C, EtOH (61â99%).</p></p></figure><div class="NLM_p">The intermediate <b>13</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) was independently reacted with <b>8</b> and <b>12a</b>â<b>d</b> to provide final compounds <b>14</b>â<b>18</b> via methanesulfonic acid promoted addition.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) methanesulfonic acid, 1-methoxy-2-propanol, Î or microwave.</p></p></figure><div class="NLM_p">Intermediates <b>21a</b>â<b>i</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) were available from anilines <b>19a</b>â<b>i</b> via base-promoted addition to 2,4,5-trichloropyrimidine. The final compounds <b>22</b>â<b>30</b> were then synthesized in an analogous fashion to that shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF; (b) <b>12a</b> or <b>12d</b> or (<i>R</i>)-<b>12d</b> or (<i>S</i>)-<b>12d</b>, methanesulfonic acid, 1-methoxy-2-propanol, Î or microwave.</p></p></figure><div class="NLM_p">Separation of racemic <b>12d</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) into individual enantiomers was accomplished using SFC (Chiralcel OJ-H). The individual enantiomers were then converted using procedures outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> to <b>27a</b>,<b>b</b>. The absolute stereochemistry was determined using X-ray (anomalous dispersion) of a single crystal of the bis-<i>p</i>-bromobenzoyl derivative <b>31</b>, which was available via reaction of the first eluting isomer with <i>p</i>-bromobenzoyl chloride.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Thus, the first eluting enantiomer used in the preparation of <b>27a</b> was determined to be the (<i>R</i>)-configuration; by analogy <b>27b</b> was assigned (<i>S</i>)-configuration.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) Chiralcel OJ-H (3 cm Ã 15 cm), 15% MeOH, 0.2% diethylamine, CO<sub>2</sub> (SFC); (b) <i>p</i>-Br-benzoyl chloride.</p></p></figure><div class="NLM_p">Concurrent with our strategy to advance backup compounds to the lead candidate by developing novel chemical architecture, we also focused on fine-tuning <b>1</b> by making minor structural modifications to address both pharmaceutical limitations and broader, pharmacological aspects. Despite moderate in vivo clearance values for <b>1</b> [CD-1 mouse, Cl = 29 mL min<sup>â1</sup> kg<sup>â1</sup>; rat, Cl = 17 mL min<sup>â1</sup> kg<sup>â1</sup>; cynomolgus monkey, Cl = 28 mL min<sup>â1</sup> kg<sup>â1</sup>], the in vitro liver microsome stability values [liver microsome <i>t</i><sub>1/2</sub> (min): CD-1 mouse, 13; rat, 7; human, 10] suggested room for improvement. Enhanced metabolic stability would potentially lead to lower in vivo clearance and thus increase overall exposure and bioavailability, since permeability and solubility were not limiting factors. Furthermore, identification of metabolic hotspots from liver microsome incubations provided clarity and direction for this approach. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, the two major locations for oxidative metabolism proved to be the morpholine ring, which was oxidized and degraded, and the olefin of the bicyclo[2.2.1] system which was epoxidized. The degree and location of metabolism in rat and human liver microsomes were quite similar and suggested that in vitro and in vivo screening in rats would be reasonably predictive.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major sites of metabolism from in vitro liver microsome incubation (10 Î¼M concentration for 120 min in the presence of NADPH and analysis by LC/MS/MS.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The in vitro potency and metabolic stability results for the initial series of analogues are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. A clear deleterious effect on potency was observed when the 6-position morpholine was moved to the Î±-position (relative to the morpholine of <b>1</b>) on the benzocycloheptane ring (<b>14</b>). In contrast, when the morpholine was moved to the Î±â²-position, providing the separable diastereomers <b>15a</b> and <b>15b</b>, potency was within 2- to 4-fold relative to <b>1</b>. Selectivity for the insulin receptor (INSR) was maintained, though unfortunately so was the short <i>t</i><sub>1/2</sub> in liver microsomes. We decided to further pursue C6-substituted analogs based upon the maintenance of potency/selectivity relative to <b>1</b>. A significant improvement in rat liver microsome stability was gained when the morpholine was switched to the <i>N</i>-methylpiperazine (<i>t</i><sub>1/2</sub> = 5 min for <b>15a</b>,<b>b</b>, <i>t</i><sub>1/2</sub> = 39â40 min for <b>16a</b>,<b>b</b>) without eroding the potency or selectivity. A similar result was observed by âopeningâ the morpholine to give methoxyethylamine derivative <b>17</b>. However, in each of these cases, the human liver microsome stability was still unfavorable (<i>t</i><sub>1/2</sub> â¤ 15 min).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of Position and Nature of Substituent on Benzocycloheptane Ring System</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0018.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values reported as the average (Â±SD if â¥3 determinations).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">LM = liver microsome.</p></div></div><div></div></div><div class="NLM_p">The inhibitors <b>16a</b>,<b>b</b> were put through an expanded in vitro and in vivo assay regimen to benchmark against <b>1</b>. <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> shows the in vitro and in vivo profiling of the two individual distereomers. Along with ALK (enzyme, cell assays), kinase selectivity was assessed against an internal panel (INSR, JAKs 1, 2, 3, PYK2, TYK2, FAK, and cMet)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> as well as an external panel (1 Î¼M concentration, DiscoveRx).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In vitro ADME/toxicology profiling was also completed (hERG, CYP inhibition, expanded liver microsome stability) as well as iv/po pharmacokinetics in rats. Relative to compound <b>1</b> (ALK IC<sub>50</sub> = 1.9 nM, cell IC<sub>50</sub> = 25 nM), <b>16a</b>,<b>b</b> were about 4-fold less potent in enzyme and 9- to 10-fold less potent in cells. Overall kinome selectivity (1 Î¼M screening concentration) was improved relative to <b>1</b> with <i>S</i>(90) < 0.10 for both. Surprisingly, the modification of moving the heterocycle from the 7-position to the Î±-position resulted in introduction of near equivalent activity against focal adhesion kinase (FAK) compared to the 60-fold separation for ALK over FAK observed for compound <b>1</b>. The structural basis of this activity will be discussed in the context of further optimized analogs (vide infra). Importantly, reasonable hERG selectivity and CYP inhibition profiles were maintained as well as an improvement in liver microsome stability in mouse and rat; however, monkey and human stability was less than desired. Pharmacokinetics in rat<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> demonstrated high iv AUCs and low Cl (data not shown) and reasonable oral AUCs for both compounds and thus low overall bioavailability (<i>F</i> = 11%).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Expanded Profiling of <b>16a</b> and <b>16b</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0019.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">ALK/cell,<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> IC<sub>50</sub>Â (nM)</th><th class="colsep0 rowsep0" align="center">INSR IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">FAK IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>S</i>(90)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> (1 Î¼M)</th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">CYP<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a> IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">LMÂ <i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t2fn7" aria-label="g">g</a>Â (min), M,Â R,Â Mo,Â H</th><th class="colsep0 rowsep0" align="center"><i>F</i>Â (%),<a class="ref internalNav" href="#t2fn8" aria-label="h">h</a> rat</th><th class="colsep0 rowsep0" align="center">oral AUC<a class="ref internalNav" href="#t2fn8" aria-label="h">h</a> (ngÂ·h/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1.9Â Â±Â 0.5/42</td><td class="colsep0 rowsep0" align="left">1257</td><td class="colsep0 rowsep0" align="left">25Â Â±Â 5</td><td class="colsep0 rowsep0" align="left">0.136<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8,Â 16,Â 17,Â 11</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1203Â Â±Â 221</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="left">14/200</td><td class="colsep0 rowsep0" align="left">382</td><td class="colsep0 rowsep0" align="left">8.5</td><td class="colsep0 rowsep0" align="left">0.093<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">40,Â 40,Â 9,Â 15</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">4405Â Â±Â 1704</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">9Â Â±Â 3/200</td><td class="colsep0 rowsep0" align="left">508Â Â±Â 209</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">0.057<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">7.9</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">40,Â 39,Â 7,Â 11</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">5526Â Â±Â 682</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are reported as the average (Â±SD if â¥3 determinations).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Biochemical cell activity measuring inhibition of NPM-ALK phosphorylation.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last"><i>S</i>(90) = no. kinases with >90% inhibition/total number kinases tested.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">DiscoveRx 256 kinase panel.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">DiscoveRx 402 kinase panel.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">CYP isozymes: 1A2, 2C9, 2C19, 2D6, 3A4.</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">LM (liver microsome): M = mouse, R = rat, Mo = monkey, H = human.</p></div><div class="footnote" id="t2fn8"><sup>h</sup><p class="last">1 mg iv dose, 5 mg/kg po dose.</p></div></div></div><div class="NLM_p">Upon the basis of these promising results, we focused our strategy on further improving the potency of these inhibitors for ALK, maintaining the ancillary FAK potency and improving upon the human liver microsome metabolic stability. A subtle, yet noteworthy, SAR point was identified in the series by changing the <i>N</i>-methyl substituent on the piperazine to a hydroxyethyl substituent. The resultant analogues <b>18a</b>,<b>b</b> proved to be slightly more potent in the enzyme assay and 4- to 5-fold more potent in cells, and potency was now in a similar range as <b>1</b>. Other properties remained similar including selectivity (INSR and kinome), hERG (IC<sub>50</sub> > 10 Î¼M), metabolic stability, and oral bioavailability (10%). As noted above, the other main metabolic hot spot in <b>1</b> proved to be the olefin of the bicyclo[2.2.1]heptene systems. Previous efforts<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and literature reports<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> had demonstrated that aromatic sulfonamides/sulfones as well as <i>N</i>-alkylsulfonamides and other hydrogen bond acceptor motifs<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> were acceptable substituents on the aromatic group in the 2-position. Toward defining the favored substituent on the piperazine, another direct comparator set was synthesized with the 2-(<i>N</i>-methylmethanesulfonamide)phenyl ring in place of the bicyco[2.2.1]heptene system (cf. <b>22</b> and <b>23</b>). This set proved equipotent against enzyme (ALK and FAK) and in ALK cells and demonstrated similar selectivity against INSR and the kinome. However, hydroxyethyl derivative <b>23</b> demonstrated roughly 3-fold higher oral exposure (<b>22</b>, AUC<sub>0â6h</sub> = 1300 ngÂ·h/mL, vs <b>23</b>, AUC<sub>0â6h</sub> = 3959 ngÂ·h/mL). This higher exposure resulted in about 4-fold enhanced oral bioavailability for <b>23</b> relative to <b>22</b>. In vitro liver microsome stability for <b>23</b> across multiple species, however, continued to show issues with metabolic liabilities. In rodent liver microsomes (mouse and rat) <b>23</b> was quite stable (<i>t</i><sub>1/2</sub> = 37 min each), but in higher species (cynomolgus monkey and human) half-lives were significantly lower (<i>t</i><sub>1/2</sub> = 8 and 13 min, respectively). Metabolite identification studies in liver microsomes <b>23</b> (data not shown) revealed that loss of the methyl group from the <i>N</i>-methylmethanesulfonamide was the major product in both human and monkey liver microsomes for <b>23</b>; this metabolite was minor in rodent liver microsomes. Upon the basis of these results, we profiled the des-methyl derivative <b>24</b>, which proved to be 9-fold less potent against ALK and outside our desired range (IC<sub>50</sub> < 10 nM). Another tactic to potentially circumvent this metabolism involved tying the methyl group back onto the sulfonamide to give a cyclic sultam (<b>25</b>). This proved to be acceptable for potency against ALK and FAK, as well as yielded acceptable oral bioavailability in rats (48%). However, metabolic stability was similar to the acylic variant (<i>t</i><sub>1/2</sub> = 16 min, hLM). Furthermore, hERG activity for this analog was noted (IC<sub>50</sub> = 2.7 Î¼M), potentially as a result of the increased lipophilicity. The 2-<i>N</i>,<i>N</i>-dimethylsulfonamide derivative (<b>26</b>) and the <i>N</i>-methylamide (<b>27</b>) demonstrated similar ALK enzyme and cell potency (IC<sub>50</sub> = 4 and 40 nM, respectively), and both showed decreased INSR selectivity in the enzymatic assay relative to the N-linked sulfonamides. Overall kinome selectivity was better for the <i>N</i>-methylamide <b>27</b> (<i>S</i><sub>90</sub> = 0.08 vs 0.16). Analogues <b>26</b> and <b>27</b> displayed acceptable oral bioavailability (28% and 47%, respectively), though hERG activity was an issue for <b>26</b> (IC<sub>50</sub> = 0.24 Î¼M) relative to <b>27</b> (IC<sub>50</sub> â¥ 10 Î¼M). Importantly, <b>27</b> demonstrated acceptable in vitro liver microsome stability across species (rat and human <i>t</i><sub>1/2</sub> > 40 min). The amide isostere derivatives pyrazole (<b>28</b>) and imidazole (<b>29</b>) provided similar ALK and FAK potencies and improved INSR selectivity to that of <b>27</b> but suffered from hERG activity for <b>28</b> (IC<sub>50</sub> = 3.7 Î¼M) and poor metabolic stability for <b>29</b> (hLM <i>t</i><sub>1/2</sub> = 18 min). Both analogues, though orally bioavailable (<i>F</i> = 19% for each), were inferior to <b>27</b>. The 2-methoxy derivative <b>30</b> was tested but proved to be significantly less active against ALK (IC<sub>50</sub> = 44 nM) (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimized Analogs at C2 and C7</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0020.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0021.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are the average of at least 2 determinations (Â±SD if â¥3 determinations).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Biochemical cell activity measuring inhibition of NPM-ALK phosphorylation.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">1 mg iv dose, 5 mg/kg po dose.</p></div></div><div></div></div><div class="NLM_p">As noted above, analogues <b>22</b>â<b>30</b> were screened as racemic mixtures to expedite discovery. Upon the basis of the overall profile of <b>27</b>, with the dual ALK and FAK activity, improved metabolic stability and promising oral PK profile, individual enantiomers <b>27a</b> and <b>27b</b> were synthesized from intermediates (<i>R</i>)- and (<i>S</i>)-<b>12d</b> that were separated using SFC (Chiralcel OJ-H). Expanded profiling of the two enantiomers is shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. The profiles for <b>27a</b> and <b>27b</b> are quite similar across on-target potency, off-target selectivity, and in vitro ADME/toxicity parameters. Given that the predicted binding mode of these inhibitors places the piperazinyl moiety in a solvent accessible region of the kinase, this similarity is not entirely surprising. However, what was unexpected were the oral PK profiles in which the (<i>S</i>)-enantiomer <b>27b</b> displayed a 2- to 3-fold improvement in oral biovailability and significantly higher oral AUC despite similar in vitro metabolic stability values; this result was also consistent with mouse PK/PD studies (data not shown). For both enantiomers, Caco-2 permeability was classified as high (<i>P</i><sub>app</sub>(AâB) > 1.0 Ã 10<sup>â6</sup> cm/s) with similar efflux ratios (<5) suggesting absorption was not limiting. Relative to <b>1</b>, <b>27b</b> displayed improved potency, additional activity against the oncogenic kinase FAK (in both enzyme and cellular formats), and superior kinome selectivity as well as in vitro/in vivo ADME properties. However, INSR enzyme selectivity for <b>27b</b> was only about 20-fold. In a cellular format, <b>27b</b> displayed an IC<sub>50</sub> of roughly 2 Î¼M, representing about a 30-fold shift relative to INSR enzyme. By comparison of cellular results, 25- to 50-fold margins for the INSR/FAK and INSR/ALK cell ratios were evident, and we felt that only at very high exposures would INSR exert a significant pharmacological influence. The full DiscoveRx kinase panel (442 kinases) and the <i>K</i><sub>d</sub> values for those kinases displaying >90% inhibition at the screening concentration of 1 Î¼M is in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a>. The following kinases in the panel demonstrated potency within 10-fold of ALK (DiscoveRx <i>K</i><sub>d</sub> = 2.3 nM): FAK (2Ã), FLT3(D835Y) (7Ã), LTK (4Ã), PLK4 (7Ã), PYK2 (3Ã), RSK1 (4Ã), RSK2 (1Ã), STK33 (4Ã), TNK1 (4Ã). These data confirmed the activity against FAK and also demonstrated that <b>27b</b> displays high selectivity for ALK and FAK with only RSK2 (kinase domain) having equipotency.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Expanded Profiling of Individual Enantiomers <b>27a</b>,<b>b</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0022.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">ALK IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">ALK cell<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">INSR IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">INSR cell<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">FAK IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">FAK cell<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>S</i>(90)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (atÂ 1Â Î¼M)</th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">CYPs<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a> IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">LM<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a>Â (<i>t</i><sub><b>1/2</b></sub>Â min), M,Â R,Â Mo,Â H</th><th class="colsep0 rowsep0" align="center"><i>F</i>Â (%),<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a> rat</th><th class="colsep0 rowsep0" align="center">oral<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a> AUC<sub>0ââ</sub> (ngÂ·h/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1.9Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">662</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">944</td><td class="colsep0 rowsep0" align="left">0.136<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8,Â 16,Â 17,Â 11</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1203</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>27a</b></td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.095<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>5.6</td><td class="colsep0 rowsep0" align="left">40,Â 40,Â 24,Â 40</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">1196</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>27b</b></td><td class="colsep0 rowsep0" align="left">3.1Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">65Â Â±Â 9</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">2.0Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">0.084<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>5.6</td><td class="colsep0 rowsep0" align="left">40,Â 40,Â 21,Â 40</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">8360</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are reported as the average (Â±SD if â¥3 determinations).</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Biochemical cell activity measuring inhibition of phosphorylation.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last"><i>S</i>(90) = no. kinases with >90% inhibition/total number kinases tested.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">DiscoveRx 256 linase panel.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">DiscoveRx 442 kinase panel.</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">CYP isosymes: 1A2, 2C9, 2C19, 2D6, 3A4.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">LM (liver microsome): M = mouse, R = rat, Mo = monkey, H = human.</p></div><div class="footnote" id="t4fn8"><sup>h</sup><p class="last">1 mg iv dose and 5 mg/kg, po dose.</p></div></div></div><div class="NLM_p">Given the clinically derived mutations that have been reported for patients undergoing treatment with small-molecule ALK inhibitors, compound <b>27b</b> was screened for activity using the DiscoveRx platform against known ALK activating mutations. Shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> are the activities with DiscoveRx ALK (WT) as a benchmark (<i>K</i><sub>d</sub> = 3.6 nM); this result is in good agreement with our internal isolated enzyme assay (IC<sub>50</sub> = 3.1 nM) and that reported from previous independent experiments at DiscoveRx (<i>K</i><sub>d</sub> = 2.6 nM). Of particular note, <b>27b</b> displayed similar potencies for the ALK mutants tested, ALK(1151Tins)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>K</i><sub>d</sub> = 2.6 nM, ALK(C1156Y)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a><i>K</i><sub>d</sub> = 1.6 nM, ALK(F1174L)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><i>K</i><sub>d</sub> = 1.1 nM, as well as the gatekeeper mutation ALK(L1196M)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><i>K</i><sub>d</sub> = 3.3 nM.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. DiscoveRx Profiling of <b>27b</b> against WT ALK and ALK Mutations</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub>Â (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK (WT)</td><td class="colsep0 rowsep0" align="char" char=".">3.6<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK(1151Tins)</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK(C1156Y)</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK(F1174L)</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK(L1196M)</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Average value (<i>n</i> = 2).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Data from independent experiment.</p></div></div></div><div class="NLM_p">The majority of analogues in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> displayed similar ALK and FAK potency in contrast to <b>1</b>. Examination of the structural basis for the dual ALK/FAK potency via docking into published crystal structures found a potentially significant set of molecular interactions to explain this activity. Shown below (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) are both <b>1</b> and <b>27b</b> docked (Glide XP) in crystal structures of ALK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LZT">3LZT</a>) and FAK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BZ3">3BZ3</a>). By examination of the ALK structure, an acidic residue in the solvent exposed region is within reasonable distance to the basic heterocyclic amine of both <b>1</b> (yellow) and <b>27b</b> (gray) to pick up an interaction from Glu1210. This type of interaction is supported with other ALK ligand/protein structures.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> On the right side of <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> is the docking in a crystal structure of FAK. Since the FAK activity was highly determinant on the location of the heterocycle attached to the benzocycloheptane and appeared to have little activity dependence on the amine attached to the chloropyrimidine core, we were not surprised to find an acidic residue, Glu506, in this region with which the amine of the piperazine of <b>27b</b> (gray) could potentially form a favorable interaction. However, the morpholine of <b>1</b> (yellow) is displayed in an alternative trajectory and would not be able to form this same interaction. Furthermore, in FAK, the residue corresponding to Glu1210 in ALK is Val513 which offers a potential explanation as to the decreased activity of <b>1</b> in FAK. There are reports that suggest that the high energetic penalty due to desolvation could be overcome by free energy binding gains with such favorable electrostatic interactions.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In the absence of other obvious ligand/protein structural features impacting the observed selectivity, the modeling offers a potential explanation.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Glide docking of <b>27b</b> (gray) and <b>1</b> (yellow): left panel, ALK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LZT">3LZT</a>); right panel, FAK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BZ3">3BZ3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vivo pharmacokinetic parameters for <b>27b</b> in three species (CD-1 mouse, Sprague-Dawley rat, and cynomolgus monkey) are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. Following iv dosing, low clearance was noted in rodents and moderate to high clearance was seen in monkey which is consistent with the liver microsome results. Volume of distribution (Vd) was also significantly higher in monkeys. It was unclear why there was such a large shift in Vd between rodents and non-human primates. Oral bioavailability was acceptable across all three species with CD-1 mouse roughly 2-fold that of rat and cynomolgus monkey. Overall plasma exposure was lower in cynomolgus monkey (both iv and oral) relative to the rodents, ostensibly due to the higher clearance and very high distribution, since oral bioavailability was similar to that of rat. Importantly, from tissue distribution studies in rats at 30 mg/kg oral dose, total brain exposure relative to plasma was roughly 1.5- to 2-fold [brain <i>C</i><sub>max</sub> (3160 ng/g) vs plasma <i>C</i><sub>max</sub> (2116 ng/g); brain AUC<sub>0â48h</sub> (61â¯584 ngÂ·h/mL) vs plasma AUC<sub>0â48h</sub> (31â¯539 ngÂ·h/mL)] which is significant, since one aspect of clinically derived resistance of NSCLC to crizotinib is manifested in the emergence of brain metastases.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Compared to <b>1</b>, a significant improvement in multiple pharmacokinetic parameters was noted across species.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> For example, <b>27b</b> displays lower iv clearance values in CD-1 mouse (10 mL min<sup>â1</sup> kg<sup>â1</sup> vs 29 mL min<sup>â1</sup> kg<sup>â1</sup>) and rat (3 mL min<sup>â1</sup> kg<sup>â1</sup> versus 17 mL min<sup>â1</sup> kg<sup>â1</sup>) and similar values to cyno (30 mL min<sup>â1</sup> kg<sup>â1</sup> vs 28 mL min<sup>â1</sup> kg<sup>â1</sup>). Furthermore, higher oral (dose normalized) AUC values<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> across all three species were observed for <b>27b</b> vs <b>1</b> in mouse (1643 ngÂ·h/mL vs 299 ngÂ·h/mL), rat (1672 ngÂ·h/mL vs 246 ngÂ·h/mL) and cyno (276 ngÂ·h/mL vs 95 ngÂ·h/mL).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters of <b>27b</b> in CD-1 Mouse, Sprague-Dawley (SD) Rats, and Cynomolgus Monkeys</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center">CD-1 mouse<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">SD rat<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">cynomolgus monkey<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">dose<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mg/kg)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">2Â Â±Â 0.4</td><td class="colsep0 rowsep0" align="left">5.4Â Â±Â 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AUC<sub>0ââ</sub>Â (ngÂ·h/mL)</td><td class="colsep0 rowsep0" align="left">1612</td><td class="colsep0 rowsep0" align="left">4005Â Â±Â 237</td><td class="colsep0 rowsep0" align="left">554Â Â±Â 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Vd (L/kg)</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">0.8Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">13.2Â Â±Â 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CL (mLÂ min<sup>â1</sup>Â kg<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">4Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">30Â Â±Â 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po</td><td class="colsep0 rowsep0" align="left">dose<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mg/kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">1533</td><td class="colsep0 rowsep0" align="left">1340Â Â±Â 107</td><td class="colsep0 rowsep0" align="left">239Â Â±Â 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3.3Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AUC<sub>0ââ</sub>Â (ngÂ·h/mL)</td><td class="colsep0 rowsep0" align="left">16429</td><td class="colsep0 rowsep0" align="left">8360Â Â±Â 540</td><td class="colsep0 rowsep0" align="left">2757Â Â±Â 114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>F</i>Â (%)</td><td class="colsep0 rowsep0" align="left">102</td><td class="colsep0 rowsep0" align="left">42Â Â±Â 3</td><td class="colsep0 rowsep0" align="left">50Â Â±Â 3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Values are the mean from three animals from each time point.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Values Â± SEM are the mean from three animals.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Formulated as solutions: iv, 3% DMSO, 30% Solutol, 67% PBS (mouse, rat), dH<sub>2</sub>O (monkey); oi, dH<sub>2</sub>O (mouse, monkey), PEG400 (rat).</p></div></div></div><div class="NLM_p">To support the advancement of <b>27b</b> and position the clinical program appropriately, it was profiled in a variety of in vitro assays and in vivo pharmacological models pertaining to the ALK component (NPM-ALK+ ALCL models, EML4-ALK+ NSCLC cancer models). Furthermore, <b>27b</b> was evaluated in FAK-activated in vivo tumor models (both xenograft and patient derived xenografts<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>) and demonstrated robust activity.</div><div class="NLM_p"><b>27b</b> was screened against both NPM-ALK+ ALCL cell lines (Sup-M2 and Karpas-299) and NPM-ALKâ hematologic cell lines (Hut-102 and K562) and demonstrated selective cytotoxicity in the oncogene-addicted cell lines (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The calculated cellular IC<sub>50</sub> values for cell growth inhibition by <b>27b</b> were 84 nM (<i>n</i> = 2) in Sup-M2 cells and 131 nM (<i>n</i> = 2) in Karpas-299 cells. Furthermore, this concentration-dependent induction of proapoptotic caspases was also observed for the ALK+ cell lines but was absent in tumor cell lines lacking oncogenic ALK fusion proteins. These data suggest that this selectivity is driven through inhibition of ALK kinase activity. Furthermore, <b>27b</b> inhibited EML4-ALK tyrosine phosphorylation in two different EML4-ALK+ NSCLC-derived cell lines, NCI-H2228 and NCI-H3122, with mean IC<sub>50</sub> values of 175 nM (<i>n</i> = 2) and 85 nM (<i>n</i> = 2), respectively. Inhibition of EML4-ALK phosphorylation in H2228 and NCI-H3122 cells by <b>27b</b> resulted in concentration-related cytotoxicity and growth inhibition, with a mean IC<sub>50</sub> values (<i>n</i> = 2) of 2900 nM in H2228 cells and 1779 nM in H3122 cells. The shift in IC<sub>50</sub> values between biochemical inhibition and the cytotoxicity/growth inhibition was more significant for the EML4-ALK+ NSCLC lines; however, tumor growth inhibition was still robust (see <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro cytotoxicity and caspase 3/7 activation results for <b>27b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Prior PK/PD and efficacy studies in NPM-ALK ALCL models demonstrated that sustained and significant (>90%) target inhibition was required in vivo to elicit a robust antitumor response.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Furthermore, we were hoping to improve upon the activity of compound <b>1</b>, which demonstrated target inhibition following a single, oral dose of 30 mg/kg out to 12 h and thus required b.i.d. dosing of 30 mg/kg to achieve robust responses. Upon the basis of the improvement in pharmacokinetic parameters in mice, we predicted that sustained and prolonged plasma levels would be achieved at this dose. Indeed, a single oral dose (30 mg/kg) with <b>27b</b> in an NPM-ALK+ ALCL tumor xenograft (Sup-M2) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) demonstrated significant (>85%) knockdown of NPM-ALK phosphorylation out to 24 h. Plasma and tumor levels remained high to this time point.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK/PD of <b>27b</b> (single 30 mg/kg, po dose) in NPM-ALK+ ALCL tumor xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dose-dependent antitumor efficacy of <b>27b</b> with oral dosing was confirmed in the NPM-ALK+ ALCL Sup-M2 model (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, left panel) with dosing at 3 mg/kg (b.i.d.), 10 mg/kg (b.i.d), 30 mg/kg (b.i.d and q.d.), and 55 mg/kg (q.d.). As expected, the once daily 30 mg/kg dose resulted in tumor regressions during the 12-day dosing paradigm. Furthermore, the higher 55 mg/kg once daily regimen effected complete tumor ablation. No significant effect was observed with the 3 and 10 mg/kg b.i.d. regimens. In an EML4-ALK+ NSCLC H2228 tumor xenograft (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, right panel), oral dosing at 30 and 55 mg/kg (b.i.d.) and 55 mg/kg (q.d.) demonstrated significant tumor responses at all doses. On day 12, all animals were switched to the 55 mg/kg, q.d. dosing regimen and continued to day 40. The animals were followed out to day 80 with no tumor reemergence.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>27b</b> on ALK+ ALCL and NSCLC animal xenograft models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Upon the basis of the in vitro enzyme and cellular activity against FAK, <b>27b</b> was evaluated for single dose PK/PD effects (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) in the CWR22 prostate CA xenograft which had very high expression levels of both total and activated (pFAK) FAK. Time-dependent inhibition of FAK phosphorylation at a 55 mg/kg oral dose out to 24 h was observed; this PD effect was comparable but of slightly diminished magnitude to the pALK inhibition profile in ALK-positive ALCL xenografts over a similar time course, consistent with the differences in cellular potency of <b>27b</b> for ALK versus FAK.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PK/PD of <b>27b</b> (single 55 mg/kg, po dose) in FAK+ CWR22 tumor xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The CWR22 PK/PD study validated the in vivo biochemical FAK activity of <b>27b</b>. Since <b>27b</b> was going to be positioned clinically in NSCLC and inflammatory breast cancer, we decided to explore efficacy in those preclinical models with the reasonable assumption that <b>27b</b> would display similar PK/PD effects as those reported above. Toward this end <b>27b</b> was evaluated for biochemical inhibition of phospho-FAK in HCC-827 cells that have high levels of constitutively activated FAK (ELM4-ALK negative) and displayed an IC<sub>50</sub> = 357 nM which is reasonably consistent with the IC<sub>50</sub> in our screening assay (IC<sub>50</sub> = 82 nM). Thus, in vivo antitumor efficacy in a HCC-827 NSCLC tumor xenograft (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) was evaluated in SCID mice at 30 and 55 mg/kg (b.i.d) oral doses of <b>27b</b>. Dose-related antitumor efficacy was observed with 60% incidence of partial tumor regressions at 55 mg/kg (b.i.d.) and significant tumor growth inhibitory activity at 30 mg/kg (b.i.d.). The dosing regimens were well-tolerated, with no overt toxicity or weight loss. <b>27b</b> does not inhibit EGFR phosphorylation in HCC-827 cells (activated EGF-R due to E746-A750 deletion), which suggests the activity is related to FAK inhibition.</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Activity of <b>27b</b> in HCC-827 human NSCLC xenograft (ALKâ/FAK+).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The tumor PD response observed in the FAK+ CWR22 tumor xenograft and the marked antitumor activity achieved in the FAK activated HCC-827 NSCLC xenograft led us to further explore the FAK inhibitory component of <b>27b</b> in patient-derived xenograft (PDX) models<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> that had a defined pFAK expression profile. Shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a> are the screening results at a single dose (55 mg/kg, b.i.d.) from two separate PDX models, CTG-0142 squamous cell carcinoma head and neck (SCCHN) and CTG-0785 sarcoma model. Relative to undosed control mice, significant tumor growth inhibitory activity (<i>p</i> < 0.05) was observed in both PDX models. In the left-hand panel, over 28 days of dosing at of 55 mg/kg (b.i.d), tumor stasis and a 75% TGI were observed. In the sarcoma PDX, a 70% TGI was realized with only 13 days of dosing.</div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Activity of <b>27b</b> in CTG-0977 human SCCHN PDX (ALKâ/FAK+) and CTG-0785 sarcoma PDX (ALKâ/FAK+).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Finally, in regard to the pharmacology of <b>27b</b> and FAK inhibition, a potentially attractive therapeutic avenue for the dual ALK and FAK activity is in inflammatory breast cancer (IBC), a particularly aggressive subtype of breast cancer refractory to conventional treatment regimens.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Elevated levels of pFAK have also been recently identified in a subset of IBC (in the absence of ALK activity).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In vitro testing of <b>27b</b> against a panel of FAK-activated IBC cell lines demonstrated concentration dependent inhibition of cell proliferation as well as robust in vivo antitumor activity against mammary gland-implanted xenografts in SCID mice and importantly the absence of brain metastases relative to control.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have advanced <b>27b</b>, a selective inhibitor of FAK and ALK, as a novel anticancer therapeutic. Following a rational approach, liabilities associated with the advanced lead <b>1</b> were diminished, including specific metabolic liabilities of both amino moieties attached to the pyrimidine core ring system. Furthermore, we identified a small structural change on the benzocycloheptyl ring that provided consistent, potent FAK inhibition while maintaining high levels of kinome selectivity. The structural basis for this potency was identified through molecular docking experiments. Compound <b>27b</b> displayed favorable in vitro ADME properties and acceptable oral bioavailability in three species. Furthermore, <b>27b</b> imparts equipotent in vitro activity against clinically-derived resistance mutations and favorable brain exposure which may impact physiologically relevant escape pathways such as brain metastases. Dose-dependent antitumor efficacy was observed in multiple animal models of ALK+ and FAK-driven cancers. This dual FAK and ALK active compound is of unique interest in light of the recent findings in inflammatory breast cancer where subsets have ALK or FAK oncogenic components. Additionally, exploration of the clinical significance of FAK inhibition in conjunction with the recent findings in immunotherapy is warranted. <b>27b</b> is currently undergoing human clinical trials.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise indicated, all reagents and solvents were obtained from commercial sources and used as received. <sup>1</sup>H and <sup>13</sup>C NMRs were obtained on a Bruker Avance at 400 and 101 MHz, respectively, in the solvent indicated with tetramethylsilane as an internal standard. Analytical HPLC was run using a Zorbax RX-C8, 5 mm Ã 150 mm column, eluting with a mixture of acetonitrile and water containing 0.1% trifluoroacetic acid with a gradient of 10â100% over 5 or 20 min, wavelength of 254 and 290 nm to assess purity of final targets. LC/MS results were obtained on either of two instruments. LC/MS analysis was performed on a Waters Aquity Ultra Performance LC with a 2.1 mm Ã 50 mm Waters Aquity UPLC BEH C18 1.7 Î¼m column. The target column temperature was 45 Â°C, with a run time of 2 min, a flow rate of 0.600 mL/min, and a solvent mixture of 5% (0.1% formic acid/water):95% (acetonitrile/0.1% formic acid). The mass spectrometry data were acquired on a Micromass LC-ZQ 2000 quadrupole mass spectrometer. Alternatively, LCMS analysis was performed on a Bruker Esquire 200 ion trap. Purity was determined for final compounds using a combination of the analytical HPLC methods described above. All final compounds were determined to have â¥95% purity as assessed by area percent (A%) as noted in the tabular data. Automated column chromatography (SiO<sub>2</sub>) was performed on a CombiFlash Companion (ISCO, Inc.). Reverse phase HPLC was carried out on Gilson GX-281 series HPLC with Phenomenex Gemini-NX, C18 reverse phase 150 mm Ã 30 mm, 5 Î¼m column, acetonitrile/water gradient, 0.1% TFA modifier gradient elution with automatic fraction collection. Melting points were taken on a Mel-Temp apparatus and are uncorrected.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Procedure for Reductive Amination</h3><div class="NLM_p last">Ketone (1 equiv) and amine (1.1 equiv) were treated with sodium triacetoxyborohydride (1.4 equiv) and acetic acid (1 equiv) in THF (10 mL/mmol substrate) and stirred at room temperature until completion. The reaction mixture was then concentrated and partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic phase was washed with water, dried on MgSO<sub>4</sub>, and concentrated. Automated flash chromatography purification (ISCO, silica cartridge; gradient elution, 0â10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> or 10â100% ethyl acetateâhexane) afforded amine products.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Procedure for Nitration<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></h3><div class="NLM_p last">Aromatic substrate (1 equiv) was treated with trifluoroacetic anhydride (30 equiv) and potassium nitrate (1 equiv) in acetonitrile (3 mL/mmol) at 0 Â°C for 3 h. The reaction mixture was partitioned between sodium bicarbonate solution and dichloromethane and the aqueous phase extracted with additional dichloromethane. The organics were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. Automated flash chromatography purification (ISCO, silica cartridge; gradient elution, 0â10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> or 10â100% ethyl acetateâhexane) afforded separated nitro regioisomers.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedure for Hydrogenation</h3><div class="NLM_p last">Nitro compound (1 equiv), 10% palladium on carbon (50% wet) (0.1 equiv), and ethanol (20 mL/mmol substrate) were combined and subjected to hydrogenation at 50 psi in a Parr apparatus until hydrogenation was complete. The reaction mixture was filtered through Celite. Evaporation of solvent under reduced pressure provided the amines which were generally used without further purification.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure for S<sub>N</sub>Ar Displacement on 2,4,5-Trichloropyrimidine</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (1 equiv), 2-pyrazol-1-ylphenylamine (1 equiv), <i>N</i>,<i>N</i>-dimethylformamide (10 mL/mmol substrate), and potassium carbonate (1.3 equiv) were combined and stirred heated to 75 Â°C until completion. The mixture was poured onto ice and stirred until all the ice had melted. The mixture was filtered on a Buchner and air-dried and the solid used without further purification or purified by automated flash chromatography purification (ISCO, silica cartridge; gradient elution, 0â10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> or 10â100% ethyl acetateâhexane).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure for S<sub>N</sub>Ar Displacement on 2,5-Dichloro-<i>N</i>-arylpyrimidin-4-amines</h3><div class="NLM_p last">Amine (0.468 mmol), 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine (0.312 mmol), 1-methoxy-2-propanol (1 mL/mmol), and methanesulfonic acid (0.111 mL, 1.71 mmol) were combined in a sealed tube and heated at 90 Â°C o/n. The reaction mixture was diluted with DCM and washed with saturated aq NaHCO<sub>3</sub>. The organic layer was dried, filtered, and concentrated. Purification via reverse phase HPLC (Gilson GX-281 series HPLC with Phenomenex Gemini-NX, C18 reverse phase 150 mm Ã 30 mm, 5 Î¼m column, 5â50% acetonitrile/water gradient, 0.1% TFA modifier). The desired fractions were either lyophilized to give the desired product as a trifluoroacetic acid salt or free-based (partitioned between dichloromethane and saturated aq NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated).</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (<b>6</b>) 4-(4-Methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)morpholine</h3><div class="NLM_p last">Using the general procedure for reductive amination, 4-methoxy-5,7,8,9-tetrahydrobenzocyclohepten-6-one (<b>5</b>) (2.25 g, 11.8 mmol) and morpholine (1.13 mL, 13.0 mmol) gave <b>6</b> as a white solid (3.09 g, 99% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 262.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.06 (t, <i>J</i> = 8.0 Hz, 1H), 6.72 (dd, <i>J</i> = 11.0, 8.0 Hz, 2H), 3.82 (s, 3H), 3.74 (dt, <i>J</i> = 5.7, 3.7 Hz, 4H), 3.61 (br d, <i>J</i> = 12.9 Hz, 1H), 2.81â2.66 (m, 4H), 2.56â2.48 (m, 2H), 2.37â2.29 (m, 1H), 2.27â2.19 (m, 1H), 2.08â1.98 (m, 2H), 1.89â1.76 (m, 1H), 1.48â1.34 (m, 1H).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<b>7</b>) 4-(4-Methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)morpholine</h3><div class="NLM_p last">Using the general procedure for nitration, 4-(4-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)morpholine <b>(6)</b> (2.00 g, 7.65 mmol) gave <b>7</b> (second eluting peak) isolated as a yellow oil (0.43 g, 19%). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 307.05 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.59 (d, <i>J</i> = 8.3 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 3.89 (s, 3H), 3.78â3.67 (m, 4H), 3.50 (br d, <i>J</i> = 13.4 Hz, 1H), 2.87â2.70 (m, 4H), 2.61â2.47 (m, 3H), 2.30 (br t, <i>J</i> = 10.5 Hz, 1H), 2.15â2.03 (m, 2H), 1.93â1.78 (m, 1H), 1.47â1.32 (m, 1H).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<b>8</b>) 4-Methoxy-6-morpholino-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-3-amine</h3><div class="NLM_p last">Using the general procedure for hydrogenation, 4-(4-methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-6-yl)morpholine (<b>7</b>) (0.44 g, 1.42 mmol) provided <b>8</b> (0.39 g, 99% yield) as a light tan solid which was used without further purification. LC/MS (ESI+): 277.07 (M + H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.67 (d, <i>J</i> = 7.8 Hz, 1H), 6.51 (d, <i>J</i> = 7.8 Hz, 1H), 3.80â3.66 (broad m, 9H), 3.44 (br d, <i>J</i> = 12.9 Hz, 1H), 2.76 (br s, 2H), 2.67â2.52 (m, 4H), 2.44â2.26 (m, 2H), 2.13â1.96 (m, 2H), 1.85â1.72 (m, 1H), 1.42â1.29 (m, 1H).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<b>10</b>) 1-Methoxy-2-nitro-5,7,8,9-tetrahydrobenzo[7]annulen-6-one</h3><div class="NLM_p last">Using the general procedure for nitration, 1-methoxy-5,7,8,9-tetrahydrobenzo[7]annulen-6-one (25 g, 0.131 mol) provided <b>10</b> (10.7 g, 34.6% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 3.92 (s, 3H), 3.80 (s, 2H), 3.13â3.09 (m, 2H), 2.60 (t, <i>J</i> = 7.0 Hz, 2H), 2.10â2.03 (m, 2H).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<b>11a</b>) 4-(1-Methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)morpholine</h3><div class="NLM_p last">Using the general procedure for reductive amination followed by the general procedure for nitration, 1-methoxy-5,7,8,9-tetrahydrobenzo[7]annulen-6-one <b>(9)</b> (0.51 g, 1.95 mmol) provided <b>11a</b> as a yellow oil (0.18 g, 24%, 2 steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.09 (t, <i>J</i> = 7.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 6.76 (d, <i>J</i> = 8.1 Hz, 1H), 3.81 (d, <i>J</i> = 1.3 Hz, 3H), 3.75 (t, <i>J</i> = 4.2 Hz, 4H), 3.40 (dd, <i>J</i> = 14.0, 7.2 Hz, 1H), 2.94â2.83 (m, 2H), 2.74â2.66 (m, 2H), 2.61â2.54 (m, 2H), 2.44â2.36 (m, 1H), 2.35â2.26 (m, 1H), 2.14â2.00 (m, 1H), 1.87â1.75 (m, 1H), 1.38â1.25 (m, 1H).</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<b>11b</b>) 1-(1-Methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)-4-methylpiperazine</h3><div class="NLM_p last">Following the general procedure for reductive amination, 1-methoxy-2-nitro-5,7,8,9-tetrahydrobenzo[7]annulen-6-one <b>(10)</b> (3.09 g, 13.1 mmol) and 1-methylpiperazine (13.1 g, 131 mmol) provided <b>11b</b> (4.19 g, 99%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 3.86 (s, 3H), 3.31 (br dd, <i>J</i> = 14.7, 7.6 Hz, 1H), 3.03â2.88 (m, 2H), 2.81â2.68 (m, 2H), 2.60 (br dd, <i>J</i> = 10.4, 4.8 Hz, 2H), 2.54â2.37 (m, 6H), 2.32 (s, 3H), 2.19â2.07 (m, 2H), 1.93â1.80 (m, 1H), 1.45â1.25 (m, 1H).</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<b>11c</b>) 1-Methoxy-<i>N</i>-(2-methoxyethyl)-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-amine</h3><div class="NLM_p last">Following a general procedure for reductive amination, 1-methoxy-2-nitro-5,7,8,9-tetrahydrobenzo[7]annulen-6-one (<b>10</b>) (1.85 g, 7.87 mmol) and 2-methoxyethylamine (5.91 g, 78.7 mmol) were converted to <b>11c</b> (1.86 g, 80% yield) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 3.93â3.85 (m, 3H), 3.31 (br dd, <i>J</i> = 14.7, 7.6 Hz, 1H), 3.02â2.88 (m, 2H), 2.78â2.70 (m, 2H), 2.60 (br dd, <i>J</i> = 10.4, 4.8 Hz, 2H), 2.54â2.38 (m, 4H), 2.32 (s, 4H), 2.17â2.05 (m, 2H), 1.95â1.79 (m, 1H), 1.44â1.26 (m, 1H).</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<b>11d</b>) 2-[4-(1-Methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for reductive amination, 1-methoxy-2-nitro-5,7,8,9-tetrahydrobenzo[7]annulen-6-one <b>(10)</b> (15.1 g, 64.2 mmol) and 2-piperazin-1-ylethanol provided <b>11d</b> (19 g, 85% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> = 350 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.00 (d, <i>J</i> = 8.2 Hz, 1H), 3.82 (s, 3H), 3.63â3.06 (m, 2H), 3.29â3.24 (m, 1H), 3.00â2.86 (m, 3H), 2.72â2.67 (m, 2H), 2.60â2.51 (m, 8H), 2.46â2.37 (m, 2H), 2.12â2.07 (m, 2H), 1.87â1.78 (m,1H), 1.37â1.29 (m, 1H).</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<b>12a</b>) 1-Methoxy-6-morpholino-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-amine</h3><div class="NLM_p last">Following the general procedure for hydrogenation, 4-(1-4-(1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)morpholine (<b>11a</b>) (1.5 g, 4.9 mmol) gave <b>12a</b> as a light brown solid (0.8 g, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.76 (d, <i>J</i> = 8.1 Hz, 1H), 6.54 (d, <i>J</i> = 8.1 Hz, 1H), 3.76â3.72 (m, 5H), 3.71 (d, <i>J</i> = 1.3 Hz, 3H), 3.23 (br dd, <i>J</i> = 14.5, 7.2 Hz, 1H), 2.92â2.64 (m, 4H), 2.63â2.53 (m, 2H), 2.44â2.30 (m, 2H), 2.16â2.03 (m, 2H), 1.84â1.71 (m, 1H), 1.42â1.29 (m, 1H).</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<b>12b</b>) 1-Methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-amine</h3><div class="NLM_p last">Following the general procedure for hydrogenation, 1-(1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)-4-methylpiperazine (<b>11b</b>) (1.18 g, 3.68 mmol) was hydrogenated to give <b>12b</b> (1.1 g, 99% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.76 (d, <i>J</i> = 7.8 Hz, 1H), 6.53 (d, <i>J</i> = 8.1 Hz, 1H), 3.67 (s, 3H), 3.23 (br dd, <i>J</i> = 14.1, 7.1 Hz, 1H), 2.76 (br d, <i>J</i> = 13.6 Hz, 4H), 2.67â2.59 (m, 2H), 2.57â2.46 (m, 3H), 2.45â2.34 (m, 3H), 2.32 (s, 3H), 2.16â2.03 (m, 2H), 1.85â1.72 (m, 2H), 1.42â1.30 (m, 2H).</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<b>12c</b>) 1-Methoxy-<i>N</i>6-(2-methoxyethyl)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulene-2,6-diamine</h3><div class="NLM_p last">Following the general procedure for hydrogenation, 1-methoxy-<i>N</i>-(2-methoxyethyl)-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-amine (<b>11c</b>) (1.86 g, 6.31 mmol) was hydrogenated to give <b>12c</b> (1.61 g, 97% yield) as a tan solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.83 (d, <i>J</i> = 8.1 Hz, 1H), 6.52 (d, <i>J</i> = 8.1 Hz, 1H), 3.80 (br t, <i>J</i> = 5.1 Hz, 2H), 3.68 (s, 3H), 3.47 (s, 3H), 3.35 (s, 3H), 3.22 (t, <i>J</i> = 5.2 Hz, 2H), 3.16 (br s, 4H), 2.51 (br t, <i>J</i> = 12.9 Hz, 1H), 2.42 (br d, <i>J</i> = 10.6 Hz, 1H), 2.05 (br d, <i>J</i> = 7.6 Hz, 2H), 1.50â1.36 (m, 1H).</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<b>12d</b>) 2-[4-(2-Amino-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for hydrogenation, 2-[4-(1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl)piperazin-1-yl]ethanol (<b>11d</b>) (19.0 g, 54.4 mmol) gave <b>12d</b> as a foamy white solid (17.25 g, 99% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> = 320 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 6.76 (d, <i>J</i> = 7.9 Hz, 1H), 6.53 (d, <i>J</i> = 7.9 Hz, 1H), 3.72 (broad s, 3H), 3.71 (s, 3H),3.64 (t, <i>J</i> = 5.4 Hz, 2H), 3.26â3.20 (m, 1H), 2.84â2.72 (m, 5H), 2.62â2.56 (m, 8H), 2.42â2.35 (m, 2H), 2.40â2.37 (m, 1H), 1.81â1.74 (m, 1H), 1.70 (broad s,1H), 1.41â1.33 (m, 1H).</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-<b>12d</b> and (<i>S</i>)-<b>12d</b></h3><div class="NLM_p last">An amount of 34 g of racemic <b>12d</b> was separated using SFC (supercritical fluid CO<sub>2</sub>) chromatography using a Chiralcel OJ-H (3 cm Ã 15 cm) 808041 column with 15% methanol (0.2% DEA)/CO<sub>2</sub>, 100 bar eluent at 80 mL/min flow rate, monitoring the wavelength of 220 nm with an injection volume of 0.5 mL, 20 mg/mL ethanol. 16.9 g of the first-enantiomer and 17 g of the second eluting enantiomer were isolated with a chemical purity of >99% and an enantiomeric excess (ee) of >99% (measured using a Chiralcel OJ-H analytical column). NMR and mass spectrometry results were equivalent to those of the racemic material.</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<b>14</b>) (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[(4-methoxy-6-morpholino-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-3-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine, <b>8</b> (150 mg, 0.54 mmol) and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[(2,5-dichloropyrimidin-4-yl)amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide (<b>13</b>) (162 mg, 0.54 mmol) gave <b>14</b> as a light tan solid (155 mg, 53% yield) as an inseparable â¼1:1 mixture of diastereomers. Mp: 139â148 Â°C; LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 539.16 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) 8.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.89 (s, 1H), 7.37 (s, 1H), 6.97 (m, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 1H), 6.37 (m, 1H), 6.31 (m, 1H), 5.61 (br, 1H), 5.38 (br s, 1H), 4.36 (m, 1H), 3.76 (s, 3H), 3.74 (br s, 4H), 3.43 (d, <i>J</i> = 13.1 Hz, 1H), 3.07 (s, 1H), 2.94 (s, 1H), 2.72 (m, 4H), 2.58 (m, 2H), 2.49 (m, 2H), 2.33 (m, 1H), 2.23 (d, <i>J</i> = 9.2 Hz, 1H), 2.07 (m, 2H), 1.79 (m, 1H), 1.62 (m, 1H), 1.39 (m, 1H). HPLC purity: 98 A%.</div></div><div id="sec4_5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<b>15a</b> and <b>15b</b>) (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>S</i>)-1-methoxy-6-morpholino-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>R</i>)-1-methoxy-6-morpholino-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine, <b>112a</b> (200 mg, 0.70 mmol) and <b>13</b> (190 mg, 0.65 mmol) gave <b>15a</b> (48 mg, 14% yield) as a mauve solid as the first eluting diastereomer from the RP-HPLC. The stereochemistry at the 6-position was not assigned. Mp 146â148 Â°C. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 539 (M + 1); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 8.21 (d, <i>J</i> = 8 Hz, 1H), 7.91 (s, 1H), 7.42 (s, 1H), 7.01 (br s, 1H), 6.93 (d, <i>J</i> = 8 Hz, 1H), 6.40 (m, 1H), 6.34 (m, 1H), 4.37 (t, <i>J</i> = 8 Hz, 1H), 3.74 (m, 7H), 3.23 (m, 1H), 3.09 (s, H), 2.96 (s, 1H), 2.85 (m, 2H), 2.71 (m, 2H), 2.60 (m, 2H), 2.51 (d. <i>J</i> = 8 Hz, 1H), 2.42 (m, 2H), 2.26 (d, <i>J</i> = 9 Hz, 1H), 2.14 (m, 2H), 1.81 (m, 1H), 1.64 (d, <i>J</i> = 9 Hz, 1H), 1.40 (m, 1H). HPLC purity: 99 A%. The second eluting diastereomer <b>15b</b> (65 mg, 18% yield) was isolated as a white solid. Mp 148â51 Â°C. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 539 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 8.21 (d, <i>J</i> = 8 Hz, 1H), 7.90 (s, 1H), 7.42 (s, 1H), 7.03 (d, <i>J</i> = 8 Hz, 1H), 6.93 (d, <i>J</i> = 8 Hz, 1H), 6.39 (m, 1H), 6.34 (m, 1H), 4.37 (t, <i>J</i> = 8 Hz, 1H), 3.73 (m, 7H), 3.23 (m, 1H), 3.08 (s, H), 2.96 (s, 1H), 2.88 (m, 2H), 2.69 (m, 2H), 2.56 (m, 2H), 2.50 (d. <i>J</i> = 8 Hz, 1H), 2.37 (m, 2H), 2.25 (d, <i>J</i> = 9 Hz, 1H), 2.12 (m, 2H), 1.81 (m, 1H), 1.64 (d, <i>J</i> = 9 Hz, 1H), 1.34 (m, 1H). HPLC purity: 97 A%.</div></div><div id="sec4_5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<b>16a</b> and <b>16b</b>) (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>S</i>)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>S</i>)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine, <b>12b</b> (3.82 g, 13.2 mmol) and <b>13</b> (3.95 g, 13.2 mmol) gave two separable diastereomers. The stereochemistry at the 6-position was not assigned. First eluting diasteromer from RP-HPLC, <b>16a</b> (0.850 g, 12% yield): LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 552.22 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.20 (d, <i>J</i> = 8.1 Hz, 1H), 7.90 (s, 1H), 7.40 (s, 1H), 6.97 (br d, <i>J</i> = 7.3 Hz, 1H), 6.92 (d, <i>J</i> = 8.3 Hz, 1H), 6.41â6.37 (m, 1H), 6.35â6.31 (m, 1H), 5.60 (br s, 1H), 5.35 (br d, <i>J</i> = 6.1 Hz, 1H), 5.31 (s, 3H), 4.37 (t, <i>J</i> = 7.3 Hz, 1H), 3.72 (s, 3H), 3.28â3.21 (m, 1H), 3.08 (br s, 1H), 2.95 (br s, 1H), 2.89â2.83 (m, 2H), 2.73 (br d, <i>J</i> = 5.1 Hz, 2H), 2.65 (br s, 2H), 2.55â2.39 (m, 5H), 2.32 (s, 3H), 2.25 (d, <i>J</i> = 9.3 Hz, 1H), 2.13 (br d, <i>J</i> = 12.1 Hz, 2H), 1.85â1.71 (m, 1H), 1.68â1.53 (m, 2H), 1.42â1.29 (m, 1H). HPLC purity 95 A%. Second eluting diastereomer from RP-HPLC, <b>16b</b> (0.52 g, 7% yield): LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 552.24; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.20 (d, <i>J</i> = 8.3 Hz, 1H), 7.90 (s, 1H), 7.41 (s, 1H), 6.99 (br d, <i>J</i> = 8.1 Hz, 1H), 6.93 (d, <i>J</i> = 8.3 Hz, 1H), 6.41â6.37 (m, 1H), 6.35â6.32 (m, 1H), 5.68 (br s, 1H), 5.46 (br s, 1H), 4.40â4.34 (m, 1H), 3.73 (s, 3H), 3.25 (br dd, <i>J</i> = 13.8, 7.2 Hz, 1H), 3.09 (br s, 1H), 2.96 (br s, 1H), 2.90â2.85 (m, 2H), 2.73 (br d, <i>J</i> = 5.3 Hz, 2H), 2.68â2.64 (m, 2H), 2.63 (s, 2H), 2.56â2.37 (m, 5H), 2.32 (s, 3H), 2.26 (d, <i>J</i> = 9.3 Hz, 1H), 2.13 (br dd, <i>J</i> = 10.5, 4.7 Hz, 2H), 1.91â1.72 (m, 2H), 1.65 (br d, <i>J</i> = 9.1 Hz, 1H), 1.43â1.25 (m, 1H). HPLC purity: 96 A%.</div></div><div id="sec4_5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<b>17</b>) (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[1-methoxy-6-(2-methoxyethylamino)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine, <b>12c</b> (0.2 g, 0.8 mmol) and <b>13</b> (0.3 g, 0.8 mmol) gave <b>17</b> as a tan solid (30 mg, 8%). NMR and HPLC appeared coincident for diastereomers. Mp 98â99 Â°C; LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 527 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 8.20 (m, 1H), 7.92 (s, 1H), 7.43 (s, 1H), 7.00 (d, <i>J</i> = 8 Hz, 1H), 6.91 (d, <i>J</i> = 8 Hz, 1H), 6.40 (m, 1H), 6.35 (m, 1H), 5.70 (br s, 1H), 5.56 (br s, 1H), 4.37 (m, 1H), 3.73 (s, 3H), 3.52 (m, 2H), 3.37 (s, 3H), 3.10 (m, 2H), 2.96â2.82 (m, 5H), 2.62 (m, 2H), 2.51 (d, <i>J</i> = 8 Hz, 1H), 2.25 (d, <i>J</i> = 8 Hz, 1H), 2.10 (m, 1H), 1.96 (m, 1H), 1.77 (m, 2H), 1.64 (d, <i>J</i> = 8 Hz, 1H), 1.50 (m, 1H). HPLC purity: 95 A%</div></div><div id="sec4_5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<b>18a</b> and <b>18b</b>) (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>S</i>)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[[5-Chloro-2-[[(6<i>R</i>)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amine, <b>12c</b> (0.2 g, 0.8 mmol) and <b>13</b> (0.2 g, 0.8 mmol) gave a diastereomeric mixture which was not separable using C18 RP-HPLC but could be separated employing SFC (Chiralpak AD-H column and 40% ethanol, 0.1% DEA modifier). The stereochemistry at the 6-position was not assigned. The first eluting peak <b>18a</b> (108 mg, 30% yield) was isolated as a tan foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 582.16 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.22 (d, <i>J</i> = 8.1 Hz, 1H), 7.91 (s, 1H), 7.42 (s, 1H), 7.00 (br d, <i>J</i> = 9.9 Hz, 1H), 6.94 (d, <i>J</i> = 7.6 Hz, 1H), 6.39 (br d, <i>J</i> = 3.3 Hz, 1H), 6.37â6.32 (m, 1H), 5.62 (br s, 1H), 5.35 (br s, 1H), 4.42â4.35 (m, 1H), 3.74 (s, 3H), 3.65 (br s, 2H), 3.32â3.22 (m, 1H), 3.09 (br s, 1H), 2.96 (br s, 1H), 2.91â2.84 (m, 2H), 2.74 (br s, 3H), 2.59 (broad m, 8H), 2.52 (br d, <i>J</i> = 9.1 Hz, 1H), 2.48â2.38 (m, 2H), 2.26 (br d, <i>J</i> = 9.9 Hz, 1H), 2.13 (br d, <i>J</i> = 10.6 Hz, 2H), 1.84â1.75 (m, 1H), 1.65 (br d, <i>J</i> = 9.6 Hz, 1H), 1.43â1.33 (m, 1H). HPLC purity: 99 A%. The second eluting peak <b>18b</b> (102 mg, 28% yield) was isolated as of a tan foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 582.15 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.23 (d, <i>J</i> = 8.3 Hz, 1H), 7.91 (s, 1H), 7.42 (s, 1H), 7.05â6.98 (m, 1H), 6.94 (d, <i>J</i> = 8.1 Hz, 1H), 6.43â6.38 (m, 1H), 6.35 (br d, <i>J</i> = 2.8 Hz, 1H), 5.61 (br s, 1H), 5.34 (br s, 1H), 4.38 (t, <i>J</i> = 7.5 Hz, 1H), 3.73 (s, 3H), 3.69â3.63 (m, 2H), 3.30â3.22 (m, 1H), 3.09 (br s, 1H), 2.96 (br s, 1H), 2.91â2.82 (m, 2H), 2.79â2.71 (m, 2H), 2.60 (br s, 8H), 2.52 (d, <i>J</i> = 7.8 Hz, 2H), 2.44 (br d, <i>J</i> = 11.6 Hz, 2H), 2.27 (d, <i>J</i> = 9.3 Hz, 1H), 2.11 (m, 2H), 1.87â1.74 (m, 1H), 1.65 (br d, <i>J</i> = 8.3 Hz, 1H), 1.44â1.34 (m, 1H). HPLC purity 95 A%.</div></div><div id="sec4_5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<b>21d</b>) 2,5-Dichloro-<i>N</i>-[2-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]pyrimidin-4-amine</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,4,5-trichloropyrimidine, 2-(1,1-dioxo-1,2-thiazolidin-2-yl)aniline <b>19d</b> (1.0 g, 5.4 mmol) and 2,4,5-trichloropyrimidine <b>20</b> (1.2 g, 5.6 mmol) gave <b>21d</b> (1.15 g, 60% yield) as a yellow solid. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 358.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.04 (s, 1H), 8.44 (s, 1H), 7.94 (d, <i>J</i> = 8.1 Hz, 1H), 7.54 (br d, <i>J</i> = 7.8 Hz, 1H), 7.47 (br t, <i>J</i> = 7.7 Hz, 1H), 7.37â7.28 (m, 1H), 3.71 (t, <i>J</i> = 6.3 Hz, 2H), 3.45 (br t, <i>J</i> = 7.3 Hz, 2H), 2.37 (quin, <i>J</i> = 6.9 Hz, 2H).</div></div><div id="sec4_5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<b>21g</b>) 2,5-Dichloro-<i>N</i>-(2-pyrazol-1-ylphenyl)pyrimidin-4-amine</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,4,5-trichloropyrimidine, 2-pyrazol-1-ylphenylamine <b>19g</b> (2.00 g, 12.6 mmol) and 2,4,5-trichloropyrimidine <b>20</b> (2.30 g, 12.6 mmol) gave <b>21g</b> as a tan solid (1.82 g, 47% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 306.03. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): Î´ 10.88 (s, 1H), 8.57 (d, <i>J</i> = 8.3 Hz, 1H), 8.19 (s, 1H), 7.85 (dd, <i>J</i> = 1.0, 6.44 Hz, 2H); 7.46 (t, <i>J</i> = 8.3 Hz, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.28â7.235 (m, 1H), 6.54 (s, 1H).</div></div><div id="sec4_5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<b>21h</b>) 2,5-Dichloro-<i>N</i>-[2-(1-methylimidazol-2-yl)phenyl]pyrimidin-4-amine</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,4,5-trichloropyrimidine, 2-(1-methylimidazol-2-yl)aniline, <b>19h</b> (220 mg, 1.27 mmol) and 2,4,5-trichloropyrimidine <b>20</b> (233 mg, 1.27 mmol) gave <b>21h</b> (140 mg, 33% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 320.06 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.69â11.37 (broad s, 1H), 8.40 (s, 1H), 8.33 (dd, <i>J</i> = 8.3, 1.0 Hz, 1H), 7.70 (dd, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.52 (ddd, <i>J</i> = 8.5, 7.3, 1.5 Hz, 1H), 7.35 (d, <i>J</i> = 1.3 Hz, 1H), 7.31 (td, <i>J</i> = 7.6, 1.1 Hz, 1H), 7.14 (d, <i>J</i> = 1.3 Hz, 1H), 3.78 (s, 3H).</div></div><div id="sec4_5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<b>22</b>) <i>N</i>-[2-[[5-Chloro-2-[[1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]phenyl]-<i>N</i>-methylmethanesulfonamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12b</b> (63 mg, 0.22 mmol) and <b>21b</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (75 mg, 0.22 mmol) gave <b>22</b> (72 mg, 46% yield) isolated as a tan lyophilate, TFA salt. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 600.10 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.42 (s, 1H), 8.58 (d, <i>J</i> = 8.3 Hz, 1H), 8.17 (s, 1H), 8.03 (d, <i>J</i> = 8.3 Hz, 1H), 7.90 (d, <i>J</i> = 8.1 Hz, 1H), 7.64 (br t, <i>J</i> = 8.8 Hz, 1H), 7.51 (s, 1H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 4.14 (q, <i>J</i> = 7.2 Hz, 1H), 3.75 (s, 3H), 3.65 (br s, 2H), 3.31â3.22 (m, 1H), 2.93â2.83 (m, 2H), 2.77 (s, 6H), 2.59 (m, 5H), 2.50â2.36 (m, 2H), 2.19â2.08 (m, 2H), 1.86â1.75 (m, 1H), 1.57 (br s, 3H), 1.43â1.33 (m, 1H), 1.28 (t, <i>J</i> = 7.1 Hz, 1H). HPLC purity >95 A%</div></div><div id="sec4_5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<b>23</b>) <i>N</i>-[2-[[5-Chloro-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]phenyl]-<i>N</i>-methylmethanesulfonamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (68 mg 0.22 mmol) and <b>21b</b> (75 mg, 0.22 mmol) gave <b>23</b> (106 mg, 65% yield) as a tan lyophilate, TFA salt. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 630.16 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.44â10.37 (m, 1H), 9.15 (s, 1H), 8.06â7.99 (m, 1H), 7.97 (s, 1H), 7.63 (d, <i>J</i> = 8.6 Hz, 1H), 7.39 (d, <i>J</i> = 1.3 Hz, 3H), 6.81 (d, <i>J</i> = 8.3 Hz, 1H), 4.08â4.02 (m, 3H), 3.83 (br s, 4H), 3.73 (s, 4H), 3.39 (br dd, <i>J</i> = 14.4, 7.1 Hz, 1H), 3.31 (s, 6H), 3.19 (br s, 3H), 3.11â3.02 (m, 1H), 2.99 (s, 3H), 2.45â2.36 (m, 2H), 2.34â2.24 (m, 1H), 1.97â1.82 (m, 1H), 1.51â1.34 (m, 1H). HPLC purity 99 A%</div></div><div id="sec4_5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<b>24</b>) <i>N</i>-[2-[[5-Chloro-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (190 mg, 0.59 mmol) and <b>21c</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (132 mg, 0.40 mmol) gave 24 (65 mg, 26% yield) as an off-white foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 616.18 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.13 (s, 1H), 7.71 (s, 2H), 7.57â7.53 (m, 1H), 7.51 (s, 1H), 7.46 (s, 1H), 7.41â7.35 (m, 2H), 6.73 (d, <i>J</i> = 8.3 Hz, 1H), 3.70 (s, 3H), 3.65 (t, <i>J</i> = 5.4 Hz, 2H), 3.51 (s, 1H), 3.26â3.17 (m, 1H), 2.94 (s, 3H), 2.86â2.79 (m, 2H), 2.72 (br d, <i>J</i> = 5.1 Hz, 2H), 2.66â2.53 (m, 8H), 2.45â2.34 (m, 2H), 2.10 (br d, <i>J</i> = 10.9 Hz, 2H), 1.78 (q, <i>J</i> = 11.2 Hz, 1H), 1.40â1.26 (m, 1H). HPLC purity >95 A%.</div></div><div id="sec4_5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<b>25</b>) 2-[4-[2-[[5-Chloro-4-[2-(1,1-dioxo-1,2-thiazolidin-2-yl)anilino]pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (0.18 g, 0.57 mmol) and <b>21d</b> (0.12 g, 0.33 mmol) gave <b>25</b> (73.6 mg, 34% yield) as a white foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 642 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.41â8.35 (m, 2H), 8.11 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 1H), 7.46 (br s, 3H), 7.27â7.20 (m, 1H), 6.87 (d, <i>J</i> = 8.3 Hz, 1H), 3.76â3.69 (m, 5H), 3.65 (t, <i>J</i> = 5.3 Hz, 2H), 3.46 (t, <i>J</i> = 7.7 Hz, 2H), 3.25 (br dd, <i>J</i> = 14.3, 6.9 Hz, 1H), 2.93â2.80 (m, 2H), 2.74 (br d, <i>J</i> = 5.1 Hz, 2H), 2.67â2.55 (m, 10H), 2.48â2.37 (m, 2H), 2.18â2.07 (m, 2H), 1.87â1.73 (m, 2H), 1.36 (br d, <i>J</i> = 11.9 Hz, 1H). HPLC purity >95 A%.</div></div><div id="sec4_5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<b>26</b>) 2-[[5-Chloro-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (92 mg, 0.3 mmol) and <b>21e</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (0.1 g, 0.3 mmol) gave <b>26</b> (76 mg, 24% yield) as a tan solid. Mp 196â197 Â°C; LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 630.18 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.42 (s, 1H), 8.57 (d, <i>J</i> = 8.3 Hz, 1H), 8.16 (s, 1H), 8.02 (d, <i>J</i> = 8.1 Hz, 1H), 7.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.52 (s, 1H), 7.31â7.25 (m, 2H), 6.92â6.87 (m, 1H), 3.74 (s, 3H), 3.69 (br t, <i>J</i> = 5.2 Hz, 2H), 3.26 (br dd, <i>J</i> = 14.1, 6.8 Hz, 1H), 2.95â2.82 (br s, 4H), 2.76 (s, 6H), 2.75â2.61 (m, 8H), 2.54â2.37 (m, 2H), 2.20â2.10 (m, 2H), 1.82 (br s, 1H), 1.45â1.30 (m, 1H). HPLC purity 98 A%.</div></div><div id="sec4_5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<b>27</b>) 2-[[5-Chloro-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-<i>N</i>-methylbenzamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (0.13 g, 0.42 mmol) and <b>21f</b> (0.10 g, 0.30 mmol) gave <b>27</b> (39 mg, 20% yield) as a pale yellow foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 580.17 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 11.02 (s, 1H), 8.69 (d, J = 8.9 Hz, 1H), 8.13 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H),7.59â7.50(m, 2H), 7.41 (s, 1H), 7.13 (t, J = 7.4 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.21 (s, 1H), 3.74 (m, 3H), 3.66â3.63 (m, 2H), 3.29â3.23 (m, 1H), 3.06 (d, J = 4.3 Hz, 3H), 2.92â2.72 (m, 5H), 2.66â2.55 (m, 8H), 2.48â2.39 (m, 2H), 2.16â2.10 (m, 2H), 1.87â1.77 (m, 1H), 1.42â1.32 (m, 1H). HPLC purity 99 A%.</div></div><div id="sec4_5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<b>27a</b>) 2-[[5-Chloro-2-[[(6<i>R</i>)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-<i>N</i>-methylbenzamide</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, (<i>R</i>)-<b>12d</b> (91 mg, 0.28 mmol) and <b>21f</b> (56 mg, 0.19 mmol gave <b>27a</b> (56 mg, 50% yield). LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 580.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 11.02 (s, 1H), 8.69 (d, <i>J</i> = 8.9 Hz, 1H), 8.13 (s, 1H), 8.08 (d, <i>J</i> = 8.4 Hz, 1H),7.59â7.50(m, 2H), 7.41 (s, 1H), 7.13 (t, <i>J</i> = 7.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.1 Hz, 1H), 6.21 (s, 1H), 3.74 (m, 3H), 3.66â3.63 (m, 2H), 3.29â3.23 (m, 1H), 3.06 (d, J = 4.3 Hz, 3H), 2.92â2.72 (m, 5H), 2.66â2.55 (m, 8H), 2.48â2.39 (m, 2H), 2.16â2.10 (m, 2H), 1.87â1.77 (m, 1H), 1.42â1.32 (m, 1H). HPLC purity: 95 A%.</div></div><div id="sec4_5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<b>27b</b>) 2-[[5-Chloro-2-[[(6<i>S</i>)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-<i>N</i>-methylbenzamide</h3><div class="NLM_p last">To a sealed vessel (<i>S</i>)-<b>12d</b> (2.69 g, 8.41 mmol) and <b>21f</b> (2.00 g, 6.73 mmol) were combined in 1-methoxy-2-propanol (120 mL) followed by the addition of methanesulfonic acid (2.44 mL, 37.7 mmol). The reaction was then heated at 90 Â°C for 18 h. The reaction mixture was added to a separatory funnel and diluted with sat. aq NaHCO<sub>3</sub> until a cloudy precipitate formed. This was extracted 3Ã with dichloromethane. The organic layer was then washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was pumped dry and then purified by automated flash chromatography (ISCO, gradient elution 0â10% dichloromethane/10% NH<sub>4</sub>OH in MeOH). The desired product eluted around 9â10%, and the 10% gradient was held until product eluted completely. Mixed fractions were concentrated and were purified by RP-HPLC (gradient elution, 0â40% CH<sub>3</sub>CN/water). Chromatography was repeated using normal phase silica and reverse phase HPLC to effect further purification as desired. Following neutralization and concentration of all the material, the resulting solid was obtained by taking the foam up into EtOAc and concentrating to dryness several times to give <b>27b</b> (1.1 g, 28%) as an off-white foamy solid. LC/MS (ESI+) <i>m</i>/<i>z</i> = 580.0 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 11.02 (s, 1H), 8.69 (d, <i>J</i> = 8.9 Hz, 1H), 8.13 (s, 1H), 8.08 (d, <i>J</i> = 8.4 Hz, 1H), 7.59â7.50 (m, 2H), 7.41 (s, 1H), 7.13 (t, <i>J</i> = 7.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.1 Hz, 1H), 6.21 (s, 1H), 3.74 (m, 3H), 3.66â3.63 (m, 2H), 3.29â3.23 (m, 1H), 3.06 (d, <i>J</i> = 4.3 Hz, 3H), 2.92â2.72 (m, 5H), 2.66â2.55 (m, 8H), 2.48â2.39 (m, 2H), 2.16â2.10 (m, 2H), 1.87â1.77 (m, 1H), 1.42â1.32 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 168.9, 158.5, 155.0, 154.7, 149.0, 139.3, 137.3, 135.6, 131.4, 130.3, 127.9, 124.4, 121.8, 121.3, 120.5, 104.8, 63.1, 61.0, 60.4, 58.5, 53.8, 47.7, 38.1, 33.9, 26.4, 26.3, 25.7, 25.5. High resolution mass spectrum <i>m</i>/<i>z</i> 580.2807 [(M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>39</sub>ClN<sub>7</sub>O<sub>3</sub> 580.2803]. HPLC purity: 99 A%.</div></div><div id="sec4_5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<b>28</b>) 2-[4-[2-[[5-Chloro-4-(2-pyrazol-1-ylanilino)pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (0.19 g, 0.59 mmol) and <b>21g</b> (0.12 g, 0.40 mmol) gave <b>28</b> (81 mg, 35% yield) as a white foam. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 589.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.19 (s, 1H), 8.53 (d, <i>J</i> = 8.1 Hz, 1H), 8.10â8.05 (m, 2H), 7.84 (dd, <i>J</i> = 17.2, 1.5 Hz, 2H), 7.47â7.38 (m, 3H), 7.27â7.21 (m, 1H), 6.90 (d, <i>J</i> = 8.1 Hz, 1H), 6.53 (s, 1H), 3.72 (s, 3H), 3.65 (t, <i>J</i> = 5.3 Hz, 2H), 3.25 (br dd, <i>J</i> = 14.1, 7.1 Hz, 1H), 2.95â2.82 (m, 2H), 2.75 (br d, <i>J</i> = 5.3 Hz, 2H), 2.69â2.54 (m, 8H), 2.49â2.37 (m, 2H), 2.12 (br d, <i>J</i> = 11.1 Hz, 2H), 1.87â1.75 (m, 1H), 1.44â1.32 (m, 1H). HPLC purity >95 A%.</div></div><div id="sec4_5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<b>29</b>) 2-[4-[2-[[5-Chloro-4-[2-(1-methylimidazol-2-yl)anilino]pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (0.15 g, 0.49) and <b>21h</b> (0.10 g, 0.31 mmol) gave 29 (52 mg, 26% yield) as white crystals. Mp 95â96 Â°C. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 603 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.70 (s, 1H), 8.60 (d, <i>J</i> = 8.3 Hz, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 8.06 (s, 1H), 7.51â7.41 (m, 3H), 7.25 (s, 1H), 7.24â7.19 (m, 1H), 7.02 (s, 1H), 6.92 (d, <i>J</i> = 8.3 Hz, 1H), 3.79 (s, 3H), 3.73 (s, 3H), 3.65 (t, <i>J</i> = 5.3 Hz, 2H), 3.50 (q, <i>J</i> = 7.0 Hz, 1H), 3.25 (br dd, <i>J</i> = 14.1, 6.8 Hz, 1H), 2.94â2.70 (m, 4H), 2.67â2.55 (m, 8H), 2.49â2.37 (m, 2H), 2.17â2.08 (m, 2H), 1.82â1.79 (m, 1H), 1.37 (q, <i>J</i> = 11.8 Hz, 1H). HPLC purity >95 A%.</div></div><div id="sec4_5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<b>30</b>) 2-[4-[2-[[5-Chloro-4-(2-methoxyanilino)pyrimidin-2-yl]amino]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl]piperazin-1-yl]ethanol</h3><div class="NLM_p last">Following the general procedure for S<sub>N</sub>Ar displacement on 2,5-dichloro-<i>N</i>-arylpyrimidin-4-amines, <b>12d</b> (0.14 g, 0.45 mmol) and <b>21i</b> (0.08 g, 0.30 mmol) gave <b>30</b> (74 mg. 45% yield) as a yellow solid. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 553.17 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.47 (br d, <i>J</i> = 8.1 Hz, 1H), 8.10â8.06 (m, 2H), 7.82 (s, 1H), 7.43 (s, 1H), 7.16â7.07 (m, 1H), 7.06â6.99 (m, 1H), 6.95 (br dd, <i>J</i> = 14.0, 8.2 Hz, 2H), 3.96 (s, 3H), 3.74 (s, 3H), 3.65 (br t, <i>J</i> = 4.7 Hz, 2H), 3.26 (br dd, <i>J</i> = 14.0, 6.4 Hz, 1H), 2.97â2.80 (m, 3H), 2.75 (br d, <i>J</i> = 4.5 Hz, 2H), 2.68â2.54 (m, 8H), 2.49â2.37 (m, 2H), 2.12 (br d, <i>J</i> = 11.1 Hz, 2H), 1.81 (q, <i>J</i> = 11.6 Hz, 1H), 1.38 (br d, <i>J</i> = 11.6 Hz, 1H). HPLC purity 90 A%.</div></div><div id="sec4_5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<b>31</b>) 2-[4-[(6<i>R</i>)-2-[(4-Bromobenzoyl)amino]-1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-6-yl]piperazin-1-yl]ethyl 4-Bromobenzoate</h3><div class="NLM_p last"><b>12d</b> (0.38 g, 0.75 mmol) was treated with 4-bromobenzoyl chloride, (0.20 g, 0.90 mmol), triethylamine (0.16 mL, 1.13 mmol) in dichloromethane (40 mL) at 0 Â°C, warmed to room temperature, and stirred overnight. The mixture was partitioned between sat. aq NaHCO<sub>3</sub> and dichloromethane. The organics were washed with water and brine, filtered, and concentrated. The solid was recrystallized from methanol to afford <b>31</b> (404 mg, 80% yield). Several of the crystals were suitable for X-ray. LC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 686 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.42 (s, 1H), 8.19 (br d, <i>J</i> = 8.1 Hz, 1H), 7.92 (br d, <i>J</i> = 7.3 Hz, 2H), 7.77 (br d, <i>J</i> = 7.3 Hz, 2H), 7.66 (br d, <i>J</i> = 7.8 Hz, 2H), 7.61 (br d, <i>J</i> = 8.1 Hz, 2H), 7.00 (br d, <i>J</i> = 7.8 Hz, 1H), 4.48 (br t, <i>J</i> = 5.3 Hz, 2H), 3.75 (s, 3H), 3.21 (br dd, <i>J</i> = 14.7, 6.1 Hz, 1H), 2.97â2.70 (m, 6H), 2.64 (br s, 6H), 2.51â2.37 (m, 2H), 2.12 (br d, <i>J</i> = 11.4 Hz, 2H), 1.88â1.75 (m, 1H), 1.37 (br d, <i>J</i> = 10.6 Hz, 1H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> In Vitro and in Vivo Screening Assays and in Silico Modeling</h3><div class="NLM_p">Experimental details regarding enzymatic, cellular, ADME screening assays, and in silico modeling have been reported previously; see refs <a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref28 ref33 ref46'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref28 ref33 ref46">16â20, 28, 33, 46</a> and references therein. All in vivo experiments were conducted in accordance with Teva IUCUC protocols.</div><div class="NLM_p"><i>Representative Procedures for Measuring FAK Activity in Vitro and in Vivo.</i> the human prostate carcinoma cell lines, CWR22 and human non-small-cell lung cancer cell line HCC-827 were obtained from American Tissue Culture Collection (ATCC, Manassas, VA) and were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS). The rabbit phospho-FAK(Tyr397) (catalog no. 3283) and FAK antibodies (catalog no. 3285) were purchased from Cell Signaling Technology (Beverly, MA). Immunoblot analyses of phospho-FAK and total FAK were carried out according to the protocols provided by the antibody suppliers (Cell Signaling Technology). In brief, 2 mL of cells (at a density of 0.75 Ã 10<sup>6</sup> cells/mL in RPMI medium containing 10% FBS (regular culture medium) or 75% murine or human plasma diluted in regular culture medium were seeded in each well of 6-well plates and an amount of 2 mL of test compound diluted in culture medium at 2Ã indicated final concentrations was added to each well. After incubation for 2â2.5 h, the cells were collected into 15 mL centrifuge tubes. The cells were spun down by centrifugation at 233<i>g</i> for 5 min, the medium was aspirated, the cells were resuspended in 1 mL of PBS, transferred to 1.5 mL microcentrifuge, and centrifuged at 10â¯621<i>g</i> for 2 min at 40 Â°C. The cells were then lysed in 150 Î¼L of Frak lysis buffer [10 mM Tris, pH 7.5, 1% Triton X-100, 50 mM sodium chloride, 20 mM sodium fluoride, 2 mM sodium pyrophosphate, 0.1% BSA, plus freshly prepared 1 mM activated sodium vanadate, 1 mM DTT, and 1 mM PMSF and the protease inhibitor cocktail III (1:100 dilution)] on ice for 10 min. After brief sonication, lysates were cleared by centrifugation at 20â¯817<i>g</i> for 10 min at 4 Â°C. The supernatants (90 Î¼L) were transferred to fresh 1.5 mL microcentrifuge tubes containing 30 Î¼L of 4Ã LDS sample buffer. The samples were heat-inactivated at 90 Â°C for 5 min; 20 Î¼L of each sample was resolved by NuPAGE 7% Tris-acetate gels at 150 V until the dye front was out of the gels. The gels were transferred to nitrocellulose membranes for 2 h at 30 V constant using a wet XCell II blot module. The membranes were blocked in Tris-buffered saline (TBS) containing 0.2% Tween-20 (TBST) and 3% Nestle Carnation nonfat milk (Nestle USA Inc., Solon, OH) at room temperature (rt) for 1 h. The membranes were incubated with antiphospho-FAK (Tyr397) antibody (diluted 1:1000 in TBST containing 3% bovine serum albumin) for 1.5 h at rt or overnight at 4 Â°C while rocking gently. After washing 3 times with TBST for 10 min each time, the membranes were incubated with goat-anti-rabbit antibody conjugated with horseradish peroxidase (HRP) diluted in TBST containing 3% nonfat milk for 1 h at rt while rocking gently. After washing 3 times with TBST for 10 min each time and one time with TBS for 5 min, the membranes were incubated with 5 mL of ECL-Western blotting detection reagents for 5 min and exposed to Kodak chemiluminescence BioMax films for visualization. The membranes were then stripped by incubating with stripping buffer (62.5 mM Tris HCl, pH 6.8, 2% SDS, and 100 mM 2-mercaptoethanol) for 30 min at 56 Â°C and reblotted with anti-FAK antibody similarly as described above for phospho-FAK antibody.</div><div class="NLM_p"><i>Generation of Subcutaneous Human Tumor Xenografts in SCID/Beige or Nu/Nu Mice Female.</i> SCID/Beige (6â8 weeks, Taconic, Hudson, NY) or Nu/Nu mice (6â8 weeks, Charles River Laboratory, Wilmington, MA) were maintained 5/cage in microisolator units on a standard laboratory diet (Teklad Labchow, Harlan Teklad, Madison, WI). Animals were housed under humidity- and temperature-controlled conditions and the light/dark cycle was set at 12 h intervals. Mice were quarantined at least 1 week prior to experimental manipulation. Briefly, the cells were collected and resuspended in RPMI medium at a density of 5 Ã 10<sup>7</sup>/mL, and an aliquot (100 Î¼L) of the cell suspension (5 Ã 10<sup>6</sup> cells) was inoculated subcutaneously to the left flank of each mouse with a 23 G needle. The mice were then monitored daily. When the tumor xenograft volumes reached approximately 300â500 mm<sup>3</sup>, the mice received a single oral administration of either PEG-400 vehicle or test compound at100 Î¼L/dose. At indicated time point(s) after dosing, the mice (3â4 mice at each time point) were sacrificed and the blood was collected in 1.5 mL microcentrifuge tubes containing 20 Î¼L of heparin sodium (10â¯000 unit/mL in H<sub>2</sub>O) and left on ice briefly. The tubes were centrifuged at 20â¯817<i>g</i> for 8 min at 4 Â°C, and the plasma was collected and transferred to 1.5 mL microcentrifuge tubes, which were then stored at â80 Â°C. The tumors were excised and weighed, cut into small pieces with a scalpel, and placed into a round-bottom 14 mL tube on ice. Two volumes of completed FRAK lysis buffer without detergent [10 mM Tris, pH 7.5, 50 mM sodium chloride, 20 mM sodium fluoride, 2 mM sodium pyrophosphate, 0.1% BSA, plus freshly prepared 1 mM activated sodium vanadate, 4 mM DTT, 1 mM PMSF, and the protease inhibitor cocktail III (1:100 dilution)] were added to 1 volume of tumor (e.g., an amount of 500 Î¼L of FRAK lysis buffer was added to 250 mg of tissue). The tissues were then disrupted with a hand-held tissue blender 2â3 times, 10â15 s each time with 1â2 min interval. The lysates were then sonicated twice, 4â5 strokes each time. The tissue lysates were transferred to 1.5 mL microcentrifuge tubes and centrifuged at 20â¯817<i>g</i> for 10 min at 4 Â°C. The supernatants (12 Î¼L) were transferred to 1.5 mL microcentrifuge tubes containing 108 Î¼L of FRAK lysis buffer and 40 Î¼L of 4Ã LDS sample buffer with freshly added 100 nM dithiotreitol. The samples were subjected for phospho-FAK and total FAK detection with immunoblotting as described above. The remaining tumor lysates were stored at â80 Â°C. The compound levels in both plasma and tumor lysates were measured by LCâMS/MS.</div><div class="NLM_p last"><i>Antitumor Activity Study with Test Compound with Oral Administration.</i> The tumor-bearing mice were randomized into different treatment groups (8â10 mice/group) and were administered orally with either vehicle (PEG-400) or test compound formulated in PEG-400 at indicated doses (expressed as mg/kg equivalents of free base) and with indicated dosing frequency, with 100 Î¼L per dosing volume. The length (<i>L</i>) and width (<i>W</i>) of each tumor was measured with a vernier caliper, and the mouse body weight was determined every 2â3 days. The tumor volumes were then calculated with the formula 0.5236<i>LW</i>(<i>L</i> + <i>W</i>)/2. Statistical analyses of tumor volumes and mouse body weight were carried out using the MannâWhitney rank sum test. The TGI values were calculated at the end of study by comparing the tumor volumes (TV) of each treatment group with those of vehicle-treated group with the following formula: [1 â (the last day TV of compound-treated group/the last day TV of vehicle treated group)] Ã 100.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00487">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00487" class="ext-link">10.1021/acs.jmedchem.6b00487</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental conditions for X-ray data collection and solution, PK for compound <b>1</b>, DiscoveRx kinase selectivity data for <b>27b</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf">jm6b00487_si_001.pdf (282.91 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00487" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory R. Ott</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4d2a3f282a223f34632239390d39283b2c3d252c3f20632e2220"><span class="__cf_email__" data-cfemail="3c5b4e595b534e45125348487c48594a5d4c545d4e51125f5351">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mangeng Cheng</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith S. Learn</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Wagner</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Diane E. Gingrich</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph G. Lisko</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Curry</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eugen F. Mesaros</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arup K. Ghose</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Quail</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weihua Wan</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihui Lu</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pawel Dobrzanski</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark S. Albom</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thelma S. Angeles</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Wells-Knecht</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zeqi Huang</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa D. Aimone</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Bruckheimer</span> - <span class="hlFld-Affiliation affiliation">Champions
Oncology, Inc., One University
Plaza, Suite 307, Hackensack, New Jersey 07601, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathan Anderson</span> - <span class="hlFld-Affiliation affiliation">Champions
Oncology, Inc., One University
Plaza, Suite 307, Hackensack, New Jersey 07601, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay Friedman</span> - <span class="hlFld-Affiliation affiliation">Champions
Oncology, Inc., One University
Plaza, Suite 307, Hackensack, New Jersey 07601, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra V. Fernandez</span> - <span class="hlFld-Affiliation affiliation">Thomas
Jefferson University, 233 South 10th Street, 1002 BLSB, Philadelphia, Pennsylvania 19107, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Ator</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce A. Ruggeri</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce D. Dorsey</span> - <span class="hlFld-Affiliation affiliation">Teva
Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d134e4977-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87258" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87258" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Mark Olsen and Emily Kordwitz (SFC separations), Damaris Rolon-Steele (PK), Kelly Ziegler (PK), Maxime Siegler (Johns Hopkins University, X-ray) for their assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i54" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i54"> Abbreviations Used</h2><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">c-MET</td><td class="NLM_def"><p class="first last">mesenchymal epithelial transition factor</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">EML4-ALK</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IBC</td><td class="NLM_def"><p class="first last">inflammatory breast cancer</p></td></tr><tr><td class="NLM_term">INSR</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">KRas</td><td class="NLM_def"><p class="first last">Kirsten rat sarcoma virus</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsome</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">PYK</td><td class="NLM_def"><p class="first last">pyruvate kinase</p></td></tr><tr><td class="NLM_term">TYK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77021" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77021" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Jackson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, J. D.</span><span> </span><span class="NLM_article-title">Personalised cancer medicine</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">266</span><span class="refDoi">Â DOI: 10.1002/ijc.28940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fijc.28940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=24789362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=262-266&author=S.+E.+Jacksonauthor=J.+D.+Chester&title=Personalised+cancer+medicine&doi=10.1002%2Fijc.28940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Personalised cancer medicine</span></div><div class="casAuthors">Jackson, Sarah E.; Chester, John D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-266</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The evolving field of personalised medicine is playing an increasingly important role in cancer prevention, diagnosis, prognosis and therapeutics.  Its importance in clin. management is demonstrated by the recent introduction into routine clin. practice of various individualised, molecularly targeted therapies with increased efficacy and/or reduced toxicity.  The identification of cancer predisposition genes, such as the BRCA genes in breast cancer, permits screening programs to identify patients "at-risk" of developing cancer and helps them make decisions on individual risk-modification behaviors.  Personalised medicine also plays an increasingly important role in cancer treatment.  It is increasingly clear that there are molecularly distinct subtypes of various common cancers, with different therapeutic approaches required for each subtype, for example, the use of the monoclonal antibodies (trastuzumab and cetuximab) in HER2-pos. breast cancer and wild-type KRAS colorectal cancer; tyrosine kinase inhibitors (imatinib, gefitinib, erlotinib and crizotinib) in chronic myeloid leukemia, gastrointestinal stromal tumors and non-small-cell lung cancer and intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast and prostate cancer.  The efficacy of various targeted therapies in such disparate tumors suggests that we are entering an era in which treatment decisions will be based on tumor mol. abnormality profile or "signature," rather than tumor tissue type or anatomical site of origin, improving patient prognosis and quality of life.  This mini review focuses on the role of personalised medicine in cancer prevention and treatment as well as its future direction in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkKhyy6q2P7Vg90H21EOLACvtfcHk0lhomtQ8gyc2ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWrs70%253D&md5=d578457bd70e94b526810de9df34cfdf</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fijc.28940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28940%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BE.%26aulast%3DChester%26aufirst%3DJ.%2BD.%26atitle%3DPersonalised%2520cancer%2520medicine%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D262%26epage%3D266%26doi%3D10.1002%2Fijc.28940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Russo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franchina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricciardi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosaria, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toscano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): Old successes and future perspectives</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26814</span><span class="NLM_x">â</span> <span class="NLM_lpage">26825</span><span class="refDoi">Â DOI: 10.18632/oncotarget.4254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.18632%2Foncotarget.4254" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=26814-26825&author=A.+Russoauthor=T.+Franchinaauthor=G.+Ricciardiauthor=R.+Rosariaauthor=A.+Piconeauthor=G.+Ferraroauthor=M.+Zanghiauthor=G.+Toscanoauthor=V.+Adamoauthor=A.+Giordano&title=A+decade+of+EGFR+inhibition+in+EGFR-mutated+non-small+cell+lung+cancer+%28NSCLC%29%3A+Old+successes+and+future+perspectives&doi=10.18632%2Foncotarget.4254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4254%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%26aulast%3DRosaria%26aufirst%3DR.%26aulast%3DPicone%26aufirst%3DA.%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DZanghi%26aufirst%3DM.%26aulast%3DToscano%26aufirst%3DG.%26aulast%3DAdamo%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DA%2520decade%2520of%2520EGFR%2520inhibition%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520Old%2520successes%2520and%2520future%2520perspectives%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D26814%26epage%3D26825%26doi%3D10.18632%2Foncotarget.4254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Tan, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilligan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacey, S.</span><span> </span><span class="NLM_article-title">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">e447</span><span class="NLM_x">â</span> <span class="NLM_lpage">e459</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00246-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2FS1470-2045%2815%2900246-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26370354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=e447-e459&author=C.-S.+Tanauthor=D.+Gilliganauthor=S.+Pacey&title=Treatment+approaches+for+EGFR-inhibitor-resistant+patients+with+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2815%2900246-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span></div><div class="casAuthors">Tan, Chee-Seng; Gilligan, David; Pacey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e447-e459</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant non-small-cell lung cancer (NSCLC).  At present, first-line treatment with EGFR TKIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.  These agents improve response rates, time to progression, and overall survival.  Unfortunately, patients develop resistance, limiting patient benefit and posing a challenge to oncologists.  Optimum treatment after progression is not clearly defined.  A more detailed understanding of the biol. of EGFR-mutant NSCLC and the mechanisms of resistance to targeted therapy mean that an era of treatment approaches based on rationally developed drugs or therapeutic strategies has begun.  Combination approaches-eg, dual EGFR blockade-to overcome resistance have been trialled and seem to be promising but are potentially limited by toxicity.  Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumors, the most common mechanism of EGFR TKI resistance, have entered clin. trials, and exciting, albeit preliminary, efficacy data have been reported.  In this Review, we summarise the scientific literature and evidence on therapy options after EGFR TKI treatment for patients with NSCLC, aiming to provide a guide to oncologists, and consider how to maximise therapeutic advances in outcomes in this rapidly advancing area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CJqM1DDS3rVg90H21EOLACvtfcHk0lhomtQ8gyc2ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM&md5=1e04e573a62e12a4abeb88e0c4f8acb2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900246-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900246-6%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DGilligan%26aufirst%3DD.%26aulast%3DPacey%26aufirst%3DS.%26atitle%3DTreatment%2520approaches%2520for%2520EGFR-inhibitor-resistant%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3De447%26epage%3De459%26doi%3D10.1016%2FS1470-2045%2815%2900246-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span><span class="refDoi">Â DOI: 10.1038/clpt.2013.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fclpt.2013.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=24091716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyrt77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=15-23&author=B.+Solomonauthor=K.+D.+Wilnerauthor=A.+T.+Shaw&title=Current+Status+of+Targeted+Therapy+for+Anaplastic+Lymphoma+Kinase-Rearranged+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fclpt.2013.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Solomon, B.; Wilner, K. D.; Shaw, A. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in â¼3-5Ì of non-small cell lung cancer (NSCLC) tissues and the demonstration that the first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for NSCLC.  Single-arm studies demonstrating rapid and durable responses in the majority of ALK-pos. NSCLC patients treated with crizotinib have been followed by a randomized phase III clin. trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-pos. NSCLC patients.  However, despite the initial responses, most patients develop acquired resistance to crizotinib.  Several novel therapeutic approaches targeting ALK-pos. NSCLC are currently under evaluation in clin. trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802802), and AP26113, and heat shock protein 90 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYefH2xXnpLVg90H21EOLACvtfcHk0li5ceSh3OgP6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyrt77E&md5=2e551a95ae9b6862cdc487b122720d55</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.200%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DCurrent%2520Status%2520of%2520Targeted%2520Therapy%2520for%2520Anaplastic%2520Lymphoma%2520Kinase-Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D95%26spage%3D15%26epage%3D23%26doi%3D10.1038%2Fclpt.2013.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Scarborough, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGregori, J.</span><span> </span><span class="NLM_article-title">Personalized one-two punches for lung cancer</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span><span class="refDoi">Â DOI: 10.1038/cr.2014.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fcr.2014.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25547118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Chsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=269-270&author=H.+A.+Scarboroughauthor=P.+A.+Bunnauthor=J.+DeGregori&title=Personalized+one-two+punches+for+lung+cancer&doi=10.1038%2Fcr.2014.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized one-two punches for lung cancer</span></div><div class="casAuthors">Scarborough, Hannah A.; Bunn, Paul A.; DeGregori, James</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-270</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Genetic characterization of tumors and the subsequent use of TKIs as targeted therapies has become a mainstream treatment modality for a subset of non-small cell lung cancer (NSCLC).  Patients with NSCLCs harboring EGFR activating mutations or ALK translocations often respond initially to TKIs but, in what has become a common storyline of many oncogene-driven cancers, varied mechanisms of resistance develop and relapse inevitably occurs.  Resistance usually occurs in one of two ways: 1) as a result of a secondary mutation in the oncogene that prevents inhibition by the targeted agent (e.g., EGFR T790M1,2 and ALK L1196M3,4) or 2) through accessing a compensatory signaling pathway that bypasses the necessity of the oncogene for proliferation and survival5 (Figure 1).  An understanding of these "bypass tracks" is driving current efforts to develop drug combinations that overcome resistance in NSCLC.  These efforts have historically taken two forms: recapitulating the development of resistance in vitro using cell lines, and performing genetic anal. on biopsies to identify new drivers of resistance.  While the identification of resistance mechanisms that develop in vitro provides insight into the range of such mechanisms, such discoveries are of limited clin. relevance for individual patients.  On the other hand, genetic anal. of individual patient biopsies can reveal post-resistance mutations that can be treated with specific second- and third-generation inhibitors, which can produce high response rates6.  In a recent study published in Science, Crystal et al.7 describe a methodol. to screen individual patient biopsies for drug combinations that overcome clin.-developed resistance.  The authors take advantage of methods recently described in Liu et al.8 that allowed them to create cell lines directly from patient specimens with a 50% success rate, which conferred the power of cell culture models to patient-derived tumor cells.  They tested a panel of 76 targeted agents (in various phases of FDA approval) in the presence and absence of the original TKI against these patient-derived resistant lines, (11 EGFR-resistant and 9 ALK-resistant) and in vitro derived resistant lines, and detd. the resultant change in cell viability and growth using in vitro proliferation assays.  To compare the information yielded by genetic anal. to that yielded by their panel, they analyzed each of the patient-derived models by next-generation sequencing.  The extensive drug panel includes agents that target other receptor tyrosine kinases (RTKs; e.g., ErbB2, Flt3, FGFR), components of the original target's signaling pathway (e.g., PI3K, BRAF) and master regulators of proliferation and survival (e.g., STAT, Survivin, AKT).  The panel also includes regulators of apoptosis, transcription, protein-folding machinery and DNA damage sensors.  These drug targets represent crit. components of pathways that could be activated in lung cancers to provide resistance to the original targeted therapy.  As proof of concept, the authors performed the screen on five previously-established cell lines with known mechanisms of resistance, and found that drugs that target those mechanisms were among those producing the greatest responses.  Among the 60 models screened, a total of 201 "hits" were identified, and at least one hit was identified in 50 of 60 lines.  Hits were identified for 83% (8/11) of the EGFR-TKI resistant models and 89% (8/9) of the ALK-TKI resistant models.  The screen demonstrated considerable robustness; drugs known to have overlapping specificity were found to have overlapping activity across cell lines, and consistent with previously published reports, EGFR inhibitors tended to be hits in both ALK- and MET-driven resistant lines.  Addnl., three patient-derived and two in vitro derived lines were tested as xenografts and demonstrated substantial tumor regression only when treated with the drug combination revealed through this screen.  Importantly, the authors identified SRC family kinase inhibitors as hits across several patient-derived ALK-pos. resistance models, for the first time implicating SRC signaling as a potential mechanism of resistance to ALK inhibition.  Overexpression of kinase-dead SRC and shRNA-mediated knockdown of SRC recapitulated the effects of pharmacol. SRC inhibitors, validating SRC as the relevant target.  In subsequent expts., they showed that both direct inhibition of ALK and inhibition of its downstream pathways in these cells resulted in robust upregulation of SRC activity.  Suppression of redundant tyrosine kinases by an oncogene-driven cancer (and their subsequent reactivation upon oncogenic inhibition) is a well-established mechanism of intrinsic TKI resistance in EGFR-driven cancers9.  Their findings here support a model in which ALK activity broadly suppresses SRC activity in ALK-driven cancers.  Clin. protocols at many sites call for targeted genetic typing of resistant biopsies.  Importantly, this study demonstrated the inadequacy of genetic profiling in identifying effective drug combinations.  Despite the fact that multiple SRC family kinase inhibitors were effective across several patient-derived resistant models, next-generation sequencing failed to identify mutations in these genes or other known regulators of SRC activity.  Addnl., a MEK inhibitor, selumetinib was revealed to be a potent hit in one line derived from an ALK-pos. cancer that had become resistant to ceritinib (a second-generation ALK inhibitor).  Next-generation sequencing revealed no mutations in MEK, but did reveal a MAP2K1 mutation and an activating JAK3 mutation (V722I).  MAP2K1 (an activator of MEK10) has not previously been described in the setting of resistance to ALK inhibition and thus would likely not have registered as an actionable mutation from the genetic screen.  Of note, the JAK3 inhibitor tofacitinib was not a hit in the screen, and the cells did not express a high level of JAK3.  This was also the first report of the use of a MEK inhibitor to resensitize ALK-pos. cancers to ALK inhibitors and was obsd. only in one patient-derived line, illustrating the potential for this approach to identify efficacious, patient-specific drug combinations.  In summary, this study presents a potentially interesting methodol. that can contribute to both the identification of effective drug combinations in TKI-resistant NSCLCs and the discovery of novel mechanisms of resistance, though some addnl. issues need to be addressed.  Despite the innovations of the authors' approach, there remain questions of this platform's applicability in the clinic.  It took 2-6 mo to establish the biopsies as cell lines, a timeline which may not allow for fast enough turnaround to inform clin. decisions.  Further studies comparing clin. outcomes based on strategies derived from relapsed tumors to those from the method presented here are needed before it is clear how these approaches can affect patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHj_0euIe51LVg90H21EOLACvtfcHk0li5ceSh3OgP6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Chsw%253D%253D&md5=a87d2e3b2e1208b58d49f50b8d19bc79</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fcr.2014.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2014.168%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DH.%2BA.%26aulast%3DBunn%26aufirst%3DP.%2BA.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DPersonalized%2520one-two%2520punches%2520for%2520lung%2520cancer%26jtitle%3DCell%2520Res.%26date%3D2015%26volume%3D25%26spage%3D269%26epage%3D270%26doi%3D10.1038%2Fcr.2014.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popat, S.</span><span> </span><span class="NLM_article-title">Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer</span> <span class="citation_source-journal">Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">295</span><span class="refDoi">Â DOI: 10.2147/PGPM.S55339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.2147%2FPGPM.S55339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25278773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSjsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=285-295&author=T.+A.+Yapauthor=S.+Popat&title=Toward+precision+medicine+with+next-generation+EGFR+inhibitors+in+non-small-cell+lung+cancer&doi=10.2147%2FPGPM.S55339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer</span></div><div class="casAuthors">Yap, Timothy A.; Popat, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics and Personalized Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">PPMHAD</span>;
        ISSN:<span class="NLM_cas:issn">1178-7066</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The use of genomics to discover novel targets and biomarkers has placed the field of oncol. at the forefront of precision medicine.  First-generation epidermal growth factor receptor (EGFR) inhibitors have transformed the therapeutic landscape of EGFR mutant non-small-cell lung carcinoma through the genetic stratification of tumors from patients with this disease.  Somatic EGFR mutations in lung adenocarcinoma are now well established as predictive biomarkers of response and resistance to small-mol. EGFR inhibitors.  Despite early patient benefit, primary resistance and subsequent tumor progression to first-generation EGFR inhibitors are seen in 10%-30% of patients with EGFR mutant non-small-cell lung carcinoma.  Acquired drug resistance is also inevitable, with patients developing disease progression after only 10-13 mo of antitumor therapy.  This review details strategies pursued in circumventing T790M-mediated drug resistance to EGFR inhibitors, which is the most common mechanism of acquired resistance, and focuses on the clin. development of second-generation EGFR inhibitors, exemplified by afatinib (BIBW2992).  We discuss the rationale, mechanism of action, clin. efficacy, and toxicity profile of afatinib, including the LUX-Lung studies.  We also discuss the emergence of third-generation irreversible mutant-selective inhibitors of EGFR and envision the future management of EGFR mutant lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwLvdY0f8G7Vg90H21EOLACvtfcHk0li5ceSh3OgP6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSjsr7E&md5=001e2f061e439b7a316d95b3ed5605f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S55339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S55339%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DPopat%26aufirst%3DS.%26atitle%3DToward%2520precision%2520medicine%2520with%2520next-generation%2520EGFR%2520inhibitors%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2014%26volume%3D7%26spage%3D285%26epage%3D295%26doi%3D10.2147%2FPGPM.S55339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">â</span> <span class="NLM_lpage">965</span><span class="refDoi">Â DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0lic4zg4T7P_ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passiglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germonpre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil-Bazo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaenepoel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wilde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronte, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Meerbeeck, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span> </span><span class="NLM_article-title">ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.3978/j.issn.2218-6751.2014.03.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.3978%2Fj.issn.2218-6751.2014.03.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25806308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=250-261&author=C.+Rolfoauthor=F.+Passigliaauthor=M.+Castigliaauthor=L.+E.+Raezauthor=P.+Germonpreauthor=I.+Gil-Bazoauthor=K.+Zwaenepoelauthor=A.+De+Wildeauthor=G.+Bronteauthor=A.+Russoauthor=J.+P.+Van+Meerbeeckauthor=P.+Van+Schilauthor=P.+Pauwels&title=ALK+and+crizotinib%3A+after+the+honeymoon...what+else%3F+Resistance+mechanisms+and+new+therapies+to+overcome+it&doi=10.3978%2Fj.issn.2218-6751.2014.03.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it</span></div><div class="casAuthors">Rolfo, Christian; Passiglia, Francesco; Castiglia, Marta; Raez, Luis E.; Germonpre, Paul; Gil-Bazo, Ignacio; Zwaenepoel, Karen; De Wilde, Annemieke; Bronte, Giuseppe; Russo, Antonio; Van Meerbeeck, Jan P.; Van Schil, Paul; Pauwels, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">250-261</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of "oncogenic drivers" and the subsequent development of targeted therapies.  The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC and the subsequent clin. development of crizotinib has been an amazing success story in lung cancer translational-research, and its accelerated approval [only 4 years from the discovery of ALK rearrangement in NSCLC to the approval by the Food and Drug Administration (FDA)] marked the beginning of the new decade of targeted therapy.  However, common to all targeted therapies, despite an initial benefit, patients inevitably experience tumor progression, due to the development of resistance.  Several mol. mechanisms are responsible for acquired resistance, such as secondary mutations of ALK kinase domain or amplification of ALK fusion gene, or the activation of other oncogenic drivers, which may cause resistance independently of ALK genetic alterations.  Pre-clin. data and early clin. trials showed the promising efficacy of a new class of ALK-inhibitors in overcoming acquired resistance.  The inhibition of the mol. chaperone, HSP90, represents another promising strategy to overcome crizotinib resistance in ALK-rearranged NSCLC.  Several mols. are currently under investigation in order to establish their specific role in the treatment of ALK-rearranged NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBSgZUk10SYLVg90H21EOLACvtfcHk0lic4zg4T7P_ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7rK&md5=596bcc9dee00ec764635a66eaf1e37e7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.03.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.03.01%26sid%3Dliteratum%253Aachs%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DPassiglia%26aufirst%3DF.%26aulast%3DCastiglia%26aufirst%3DM.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DGermonpre%26aufirst%3DP.%26aulast%3DGil-Bazo%26aufirst%3DI.%26aulast%3DZwaenepoel%26aufirst%3DK.%26aulast%3DDe%2BWilde%26aufirst%3DA.%26aulast%3DBronte%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DVan%2BMeerbeeck%26aufirst%3DJ.%2BP.%26aulast%3DVan%2BSchil%26aufirst%3DP.%26aulast%3DPauwels%26aufirst%3DP.%26atitle%3DALK%2520and%2520crizotinib%253A%2520after%2520the%2520honeymoon...what%2520else%253F%2520Resistance%2520mechanisms%2520and%2520new%2520therapies%2520to%2520overcome%2520it%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2014%26volume%3D3%26spage%3D250%26epage%3D261%26doi%3D10.3978%2Fj.issn.2218-6751.2014.03.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Costa, D. B.</span><span> </span><span class="NLM_article-title">Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">375</span><span class="refDoi">Â DOI: 10.3978/j.issn.2218-6751.2014.08.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.3978%2Fj.issn.2218-6751.2014.08.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25806324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=373-375&author=D.+B.+Costa&title=Clinical+development+and+approval+of+second+generation+ALK+inhibitors+for+ALK+rearranged+lung+cancer&doi=10.3978%2Fj.issn.2218-6751.2014.08.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer</span></div><div class="casAuthors">Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">373-375</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">This article discusses about the clin. development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXaMn6tWwAx7Vg90H21EOLACvtfcHk0lic4zg4T7P_ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7nK&md5=7c64737722f7bdd2474b2dce2d4db722</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.08.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.08.01%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DClinical%2520development%2520and%2520approval%2520of%2520second%2520generation%2520ALK%2520inhibitors%2520for%2520ALK%2520rearranged%2520lung%2520cancer%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2014%26volume%3D3%26spage%3D373%26epage%3D375%26doi%3D10.3978%2Fj.issn.2218-6751.2014.08.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Singh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B. A.</span><span> </span><span class="NLM_article-title">Improving Prospects for Targeting RAS</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3650</span><span class="NLM_x">â</span> <span class="NLM_lpage">3659</span><span class="refDoi">Â DOI: 10.1200/JCO.2015.62.1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1200%2FJCO.2015.62.1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26371146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ciu7rM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3650-3659&author=H.+Singhauthor=D.+L.+Longoauthor=B.+A.+Chabner&title=Improving+Prospects+for+Targeting+RAS&doi=10.1200%2FJCO.2015.62.1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improving prospects for targeting RAS</span></div><div class="casAuthors">Singh, Harshabad; Longo, Dan L.; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3650-3659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">RAS mutations are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors and around a fifth of common myeloid malignancies, but they have evaded therapeutic interventions, despite being the focus of intense research over the last three decades.  Recent discoveries lend new understanding about the structure, function, and signaling of RAS and have opened new avenues for development of much needed new therapies.  We discuss the various approaches under investigation to target mutant RAS proteins.  The recent development of direct RAS inhibitors specific to KRAS G12C mutations represents a landmark discovery that promises to change the perception about RAS's druggability.  Multiple clin. trials targeting synthetically lethal partners and/or downstream signaling partners of RAS are underway.  Novel inhibitors targeting various arms ofRAS processing and signaling have yielded encouraging results in the lab., but refinement of the drug-like properties of these mols. is required before they will be ready for the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_bVkE2AIejLVg90H21EOLACvtfcHk0lix3alzLXNB_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ciu7rM&md5=fb3835d9053ae4cf95abe0271f9c62aa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.62.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.62.1052%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DLongo%26aufirst%3DD.%2BL.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DImproving%2520Prospects%2520for%2520Targeting%2520RAS%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3650%26epage%3D3659%26doi%3D10.1200%2FJCO.2015.62.1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cameron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">â</span> <span class="NLM_lpage">1070</span><span class="refDoi">Â DOI: 10.1007/s40265-015-0415-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs40265-015-0415-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1059-1070&author=L.+Cameronauthor=B.+Solomon&title=Treatment+of+ALK-Rearranged+Non-Small+Cell+Lung+Cancer%3A+Recent+Progress+and+Future+Directions&doi=10.1007%2Fs40265-015-0415-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0415-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0415-9%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DL.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520ALK-Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Recent%2520Progress%2520and%2520Future%2520Directions%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1059%26epage%3D1070%26doi%3D10.1007%2Fs40265-015-0415-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">â</span> <span class="NLM_lpage">2235</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+Targeting+of+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer%3A+A+Paradigm+for+Precision+Cancer+Medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0lix3alzLXNB_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%253A%2520A%2520Paradigm%2520for%2520Precision%2520Cancer%2520Medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Gainor, J. F.; Shaw, A. T.</span><span> </span><span class="NLM_article-title">Targeting ALK rearrangements</span>. In  <span class="citation_source-book">Lung Cancer</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_contrib-group">Roth, J. A.; Hong, W. K.; Komaki, R. U.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">541</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span>, DOI: <span class="refDoi">Â DOI: 10.1002/9781118468791.ch35</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2F9781118468791.ch35" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=541-556&author=J.+F.+Gainor&author=A.+T.+Shawauthor=J.+A.+Roth&author=W.+K.+Hong&author=R.+U.+Komaki&title=Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2F9781118468791.ch35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118468791.ch35%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26atitle%3DTargeting%2520ALK%2520rearrangements%26btitle%3DLung%2520Cancer%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2014%26spage%3D541%26epage%3D556%26doi%3D10.1002%2F9781118468791.ch35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amzallag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalsy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Caraballo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elamine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faber, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Patient-derived models of acquired resistance can identify effective drug combinations for cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x"> (</span><span class="NLM_issue">6216</span><span class="NLM_x">) </span> <span class="NLM_fpage">1480</span><span class="NLM_x">â</span> <span class="NLM_lpage">1486</span><span class="refDoi">Â DOI: 10.1126/science.1254721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1126%2Fscience.1254721" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1480-1486&issue=6216&author=A.+S.+Crystalauthor=A.+T.+Shawauthor=L.+V.+Sequistauthor=L.+Fribouletauthor=M.+J.+Niederstauthor=E.+L.+Lockermanauthor=R.+L.+Friasauthor=J.+F.+Gainorauthor=A.+Amzallagauthor=P.+Greningerauthor=D.+Leeauthor=A.+Kalsyauthor=M.+Gomez-Caraballoauthor=L.+Elamineauthor=E.+Howeauthor=W.+Hurauthor=E.+Lifshitsauthor=H.+E.+Robinsonauthor=R.+Katayamaauthor=A.+C.+Faberauthor=M.+M.+Awadauthor=S.+Ramaswamyauthor=M.+Mino-Kenudsonauthor=A.+J.+Iafrateauthor=C.+H.+Benesauthor=J.+A.+Engelman&title=Patient-derived+models+of+acquired+resistance+can+identify+effective+drug+combinations+for+cancer&doi=10.1126%2Fscience.1254721"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1254721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1254721%26sid%3Dliteratum%253Aachs%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DGomez-Caraballo%26aufirst%3DM.%26aulast%3DElamine%26aufirst%3DL.%26aulast%3DHowe%26aufirst%3DE.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DRobinson%26aufirst%3DH.%2BE.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DPatient-derived%2520models%2520of%2520acquired%2520resistance%2520can%2520identify%2520effective%2520drug%2520combinations%2520for%2520cancer%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6216%26spage%3D1480%26epage%3D1486%26doi%3D10.1126%2Fscience.1254721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchionni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3392</span><span class="NLM_x">â</span> <span class="NLM_lpage">3408</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+As+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0lgPwPD77CTnhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520As%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haltiwanger, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">4580</span><span class="NLM_x">â</span> <span class="NLM_lpage">4593</span><span class="refDoi">Â DOI: 10.1021/jm201550q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201550q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4580-4593&issue=10&author=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+A.+Curryauthor=M.+Chengauthor=M.+Quailauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+C.+Haltiwangerauthor=K.+Wells-Knechtauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=M.+A.+Atorauthor=B.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+an+Orally+Efficacious+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm201550q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201550q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201550q%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4580%26epage%3D4593%26doi%3D10.1021%2Fjm201550q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">â</span> <span class="NLM_lpage">679</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+Highly+Potent+and+Selective+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-11-0776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0lgs8Y7BNW8RhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679%26doi%3D10.1158%2F1535-7163.MCT-11-0776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haltiwanger, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-tetraazatetracyclo[14.3.1.1<sup>3,7</sup>.1<sup>9,13</sup>]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">464</span><span class="refDoi">Â DOI: 10.1021/jm201333e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201333e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=449-464&author=H.+J.+Breslinauthor=B.+M.+Laneauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=M.+Chengauthor=W.+Wanauthor=R.+C.+Haltiwangerauthor=K.+J.+Wells-Knechtauthor=B.+D.+Dorsey&title=Design%2C+Synthesis%2C+and+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitory+Activity+for+a+Novel+Series+of+2%2C4%2C8%2C22-tetraazatetracyclo%5B14.3.1.13%2C7.19%2C13%5Ddocosa-1%2820%29%2C3%2822%29%2C4%2C6%2C9%2821%29%2C10%2C12%2C16%2C18-nonaene+Macrocycles&doi=10.1021%2Fjm201333e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm201333e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201333e%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DLane%26aufirst%3DB.%2BM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitory%2520Activity%2520for%2520a%2520Novel%2520Series%2520of%25202%252C4%252C8%252C22-tetraazatetracyclo%255B14.3.1.13%252C7.19%252C13%255Ddocosa-1%252820%2529%252C3%252822%2529%252C4%252C6%252C9%252821%2529%252C10%252C12%252C16%252C18-nonaene%2520Macrocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D449%26epage%3D464%26doi%3D10.1021%2Fjm201333e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with In Vivo Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">â</span> <span class="NLM_lpage">6341</span><span class="refDoi">Â DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+New+Variant+of+an+Old+Template+and+Application+to+the+Discovery+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+In+Vivo+Antitumor+Activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0li0oPeNOE9P4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520New%2520Variant%2520of%2520an%2520Old%2520Template%2520and%2520Application%2520to%2520the%2520Discovery%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520In%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Learn, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: Identification of potent inhibitors of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">â</span> <span class="NLM_lpage">1142</span><span class="refDoi">Â DOI: 10.1039/c2md20061a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1039%2Fc2md20061a" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1138-1142&author=K.+S.+Learnauthor=J.+C.+Wagnerauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=A.+K.+Ghoseauthor=W.+Wanauthor=M.+Chengauthor=B.+D.+Dorseyauthor=G.+R.+Ott&title=Design+of+7-amino-6-chloro-3H-imidazo%5B4%2C5-b%5Dpyridine+scaffold+from+5-chloro-2%2C4-diaminopyrimidine+pharmacophore%3A+Identification+of+potent+inhibitors+of+Anaplastic+Lymphoma+Kinase&doi=10.1039%2Fc2md20061a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc2md20061a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20061a%26sid%3Dliteratum%253Aachs%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%2BC.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DDesign%2520of%25207-amino-6-chloro-3H-imidazo%255B4%252C5-b%255Dpyridine%2520scaffold%2520from%25205-chloro-2%252C4-diaminopyrimidine%2520pharmacophore%253A%2520Identification%2520of%2520potent%2520inhibitors%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1138%26epage%3D1142%26doi%3D10.1039%2Fc2md20061a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span> </span><span class="NLM_article-title">Signal transduction by focal adhesion kinase in cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">49</span><span class="refDoi">Â DOI: 10.1007/s10555-008-9165-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10555-008-9165-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=19169797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hslSrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=35-49&author=J.+Zhaoauthor=J.+L.+Guan&title=Signal+transduction+by+focal+adhesion+kinase+in+cancer&doi=10.1007%2Fs10555-008-9165-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by focal adhesion kinase in cancer</span></div><div class="casAuthors">Zhao Jihe; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer metastasis reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">35-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cellular interactions with extracellular matrix play essential roles in tumor initiation, progression and metastasis.  Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase identified as a key mediator of signaling by integrins, a major family of cell surface receptors for extracellular matrix, as well as other receptors in both normal and cancer cells.  FAK is activated by integrins through disruption of an auto-inhibitory intra-molecular interaction between its kinase domain and the amino terminal FERM domain.  The activated FAK forms a binary complex with Src family kinases which can phosphorylate other substrates and trigger multiple intracellular signaling pathways to regulate various cellular functions.  Subcellular localization of FAK in focal adhesions is essential for FAK signaling, which is another distinguishing feature of the kinase.  Integrin-FAK signaling has been shown to activate a number of signaling pathways through phosphorylation and protein-protein interactions to promote tumorigenesis.  FAK also plays a prominent role in tumor progression and metastasis through its regulation of both cancer cells and their microenvironments including cancer cell migration, invasion, epithelial to mesenchymal transition, and angiogenesis.  More recently, a role for FAK in tumor initiation and progression has been demonstrated directly using xenograft as well as conditional knockout mouse models.  In agreement with these experimental data, overexpression and activation of FAK have been found in a variety of human cancers.  A number of small molecule inhibitors for FAK have been developed and in various phases of testing for cancer treatments.  Overall, the intensive research on FAK signaling in cancer have yielded a wealth of information on this pivotal kinase and these and future studies are leading to potentially novel therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgWNHWmc0hKDjk2McQZ6XmfW6udTcc2ebsjK5olbdbE7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hslSrtA%253D%253D&md5=d2e0e4cb32e0c691eb8ed45a239fd7d0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9165-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9165-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DSignal%2520transduction%2520by%2520focal%2520adhesion%2520kinase%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2009%26volume%3D28%26spage%3D35%26epage%3D49%26doi%3D10.1007%2Fs10555-008-9165-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Schwock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D. W.</span><span> </span><span class="NLM_article-title">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span><span class="refDoi">Â DOI: 10.1517/14728220903460340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1517%2F14728220903460340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=20001212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=77-94&author=J.+Schwockauthor=N.+Dhaniauthor=D.+W.+Hedley&title=Targeting+focal+adhesion+kinase+signaling+in+tumor+growth+and+metastasis&doi=10.1517%2F14728220903460340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span></div><div class="casAuthors">Schwock, Joerg; Dhani, Neesha; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-94</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Focal adhesion kinase (FAK), a crucial mediator of integrin and growth factor signaling, is a novel and promising target in cancer therapy.  FAK resides within focal adhesions which are contact points between extracellular matrix (ECM) and cytoskeleton, and increased expression of the kinase has been linked with cancer cell migration, proliferation and survival.  The aim of this review is to summarize the current research in the area and to assess the potential of different FAK-targeting strategies for cancer therapy.  Areas covered in this review: We briefly examine the evidence pointing towards FAK as potential anti-cancer target since its discovery in 1992.  Then, we summarize different approaches developed to interfere with FAK signaling and important results reported from these expts.  Finally, we discuss the potential of these strategies to accomplish inhibition of tumor growth and distant spread as well as potentially meaningful combinations with other therapeutic modalities in the context of the currently available evidence.  What the reader will gain: The review emphasizes the link between FAK biol. and the consequences of interference with FAK signaling.  Based on this foundation an opinion is formed with regard to the future of FAK as therapeutic target.  Take home message: Inhibition of FAK harbors the potential to restrain malignant growth and progression with minimal side effects in normal tissues.  Small mol. inhibitors of the kinase should be examd. in further clin. studies and combinations with existing therapies need to be explored.  More efforts are required to identify markers which predict response towards FAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSMva2-GtqbVg90H21EOLACvtfcHk0ljIyAjcqXzQsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM&md5=feed68cfd6aece3dc89d3568a16c1b36</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14728220903460340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903460340%26sid%3Dliteratum%253Aachs%26aulast%3DSchwock%26aufirst%3DJ.%26aulast%3DDhani%26aufirst%3DN.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520signaling%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2010%26volume%3D14%26spage%3D77%26epage%3D94%26doi%3D10.1517%2F14728220903460340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lee, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timpson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span> </span><span class="NLM_article-title">FAK signaling in human cancer as a target for therapeutics</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">â</span> <span class="NLM_lpage">149</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.pharmthera.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25316657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=132-149&author=B.+Y.+Leeauthor=P.+Timpsonauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=FAK+signaling+in+human+cancer+as+a+target+for+therapeutics&doi=10.1016%2Fj.pharmthera.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in human cancer as a target for therapeutics</span></div><div class="casAuthors">Lee, Brian Y.; Timpson, Paul; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-149</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key regulator of growth factor receptor- and integrin-mediated signals, governing fundamental processes in normal and cancer cells through its kinase activity and scaffolding function.  Increased FAK expression and activity occurs in primary and metastatic cancers of many tissue origins, and is often assocd. with poor clin. outcome, highlighting FAK as a potential determinant of tumor development and metastasis.  Indeed, data from cell culture and animal models of cancer provide strong lines of evidence that FAK promotes malignancy by regulating tumorigenic and metastatic potential through highly-coordinated signaling networks that orchestrate a diverse range of cellular processes, such as cell survival, proliferation, migration, invasion, epithelial-mesenchymal transition, angiogenesis and regulation of cancer stem cell activities.  Such an integral role in governing malignant characteristics indicates that FAK represents a potential target for cancer therapeutics.  While pharmacol. targeting of FAK scaffold function is still at an early stage of development, a no. of small mol.-based FAK tyrosine kinase inhibitors are currently undergoing pre-clin. and clin. testing.  In particular, PF-00562271, VS-4718 and VS-6063 show promising clin. activities in patients with selected solid cancers.  Clin. testing of rationally designed FAK-targeting agents with implementation of predictive response biomarkers, such as merlin deficiency for VS-4718 in mesothelioma, may help improve clin. outcome for cancer patients.  In this article, we have reviewed the current knowledge regarding FAK signaling in human cancer, and recent developments in the generation and clin. application of FAK-targeting pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnxnFQsOShLVg90H21EOLACvtfcHk0ljIyAjcqXzQsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN&md5=7359c2a7671631f97a9d46ccef1ab68f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFAK%2520signaling%2520in%2520human%2520cancer%2520as%2520a%2520target%2520for%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D146%26spage%3D132%26epage%3D149%26doi%3D10.1016%2Fj.pharmthera.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Serrels, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lund, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kriegsheim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Cuadrado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunton, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frame, M. C.</span><span> </span><span class="NLM_article-title">Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">â</span> <span class="NLM_lpage">173</span><span class="refDoi">Â DOI: 10.1016/j.cell.2015.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.cell.2015.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26406376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=160-173&author=A.+Serrelsauthor=T.+Lundauthor=B.+Serrelsauthor=A.+Byronauthor=R.+C.+McPhersonauthor=A.+von+Kriegsheimauthor=L.+Gomez-Cuadradoauthor=M.+Canelauthor=M.+Muirauthor=J.+E.+Ringauthor=E.+Maniatiauthor=A.+H.+Simsauthor=J.+A.+Pachterauthor=V.+G.+Bruntonauthor=N.+Gilbertauthor=S.+M.+Andertonauthor=R.+J.+B.+Nibbsauthor=M.+C.+Frame&title=Nuclear+FAK+Controls+Chemokine+Transcription%2C+Tregs%2C+and+Evasion+of+Anti-tumor+Immunity&doi=10.1016%2Fj.cell.2015.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity</span></div><div class="casAuthors">Serrels, Alan; Lund, Tom; Serrels, Bryan; Byron, Adam; McPherson, Rhoanne C.; von Kriegsheim, Alexander; Gomez-Cuadrado, Laura; Canel, Marta; Muir, Morwenna; Ring, Jennifer E.; Maniati, Eleni; Sims, Andrew H.; Pachter, Jonathan A.; Brunton, Valerie G.; Gilbert, Nick; Anderton, Stephen M.; Nibbs, Robert J. B.; Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) promotes anti-tumor immune evasion.  Specifically, the kinase activity of nuclear-targeted FAK in squamous cell carcinoma (SCC) cells drives exhaustion of CD8+ T cells and recruitment of regulatory T cells (Tregs) in the tumor microenvironment by regulating chemokine/cytokine and ligand-receptor networks, including via transcription of Ccl5, which is crucial.  These changes inhibit antigen-primed cytotoxic CD8+ T cell activity, permitting growth of FAK-expressing tumors.  Mechanistically, nuclear FAK is assocd. with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression.  Furthermore, FAK's immuno-modulatory nuclear activities may be specific to cancerous squamous epithelial cells, as normal keratinocytes do not have nuclear FAK.  Finally, the authors show that a small-mol. FAK kinase inhibitor, VS-4718, which is currently in clin. development, also drives depletion of Tregs and promotes a CD8+ T cell-mediated anti-tumor response.  Therefore, FAK inhibitors may trigger immune-mediated tumor regression, providing previously unrecognized therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6uPdKmBkvArVg90H21EOLACvtfcHk0ljQ2zGNOjkrBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrrL&md5=1dbae170a594fbdab85c77fa53607248</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DSerrels%26aufirst%3DA.%26aulast%3DLund%26aufirst%3DT.%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DByron%26aufirst%3DA.%26aulast%3DMcPherson%26aufirst%3DR.%2BC.%26aulast%3Dvon%2BKriegsheim%26aufirst%3DA.%26aulast%3DGomez-Cuadrado%26aufirst%3DL.%26aulast%3DCanel%26aufirst%3DM.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DManiati%26aufirst%3DE.%26aulast%3DSims%26aufirst%3DA.%2BH.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DGilbert%26aufirst%3DN.%26aulast%3DAnderton%26aufirst%3DS.%2BM.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DNuclear%2520FAK%2520Controls%2520Chemokine%2520Transcription%252C%2520Tregs%252C%2520and%2520Evasion%2520of%2520Anti-tumor%2520Immunity%26jtitle%3DCell%26date%3D2015%26volume%3D163%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.cell.2015.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fernandez, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburto-Chumpitaz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, K. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boley, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span> </span><span class="NLM_article-title">Inflammatory breast cancer (IBC): clues for targeted therapies</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span><span class="refDoi">Â DOI: 10.1007/s10549-013-2600-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10549-013-2600-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=23784380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaju73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=23-33&author=S.+V.+Fernandezauthor=F.+M.+Robertsonauthor=J.+Peiauthor=L.+Aburto-Chumpitazauthor=Z.+Muauthor=K.+Chuauthor=R.+K.+Alpaughauthor=Y.+Huangauthor=Y.+Caoauthor=Z.+Yeauthor=K.+Q.+Caiauthor=K.+M.+Boleyauthor=A.+J.+Klein-Szantoauthor=K.+Devarajanauthor=S.+Addyaauthor=M.+Cristofanilli&title=Inflammatory+breast+cancer+%28IBC%29%3A+clues+for+targeted+therapies&doi=10.1007%2Fs10549-013-2600-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory breast cancer (IBC): clues for targeted therapies</span></div><div class="casAuthors">Fernandez, Sandra V.; Robertson, Fredika M.; Pei, Jianming; Aburto-Chumpitaz, Lucy; Mu, Zhaomei; Chu, Khoi; Alpaugh, R. K.; Huang, Yong; Cao, Yu; Ye, Zaiming; Cai, Kathy Q.; Boley, Kimberly M.; Klein-Szanto, Andres J.; Devarajan, Karthik; Addya, Sankar; Cristofanilli, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis.  Since there are few preclin. models of IBC, there is a general lack of understanding of the complexity of the disease.  Recently, we have developed a new model of IBC derived from the pleural effusion of a woman with metastatic secondary IBC.  FC-IBC02 cells are triple neg. and form clusters (mammospheres) in suspension that are strongly pos. for E-cadherin, Î²-catenin and TSPAN24, all adhesion mols. that play an important role in cell migration and invasion.  FC-IBC02 cells expressed stem cell markers and some, but not all of the characteristics of cells undergoing epithelial mesenchymal transition (EMT).  Breast tumor FC-IBC02 xenografts developed quickly in SCID mice with the presence of tumor emboli and the development of lymph node and lung metastases.  Remarkably, FC-IBC02 cells were able to produce brain metastasis in mice on intracardiac or i.p. injections.  Genomic studies of FC-IBC02 and other IBC cell lines showed that IBC cells had important amplification of 8q24 where MYC, ATAD2 and the focal adhesion kinase FAK1 are located.  MYC and ATAD2 showed between 2.5 and 7 copies in IBC cells.  FAK1, which plays important roles in anoikis resistance and tumor metastasis, showed 6-4 copies in IBC cells.  Also, CD44 was amplified in triple-neg. IBC cells (10-3 copies).  Addnl., FC-IBC02 showed amplification of ALK and NOTCH3.  These results indicate that MYC, ATAD2, CD44, NOTCH3, ALK and/or FAK1 may be used as potential targeted therapies against IBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9sCvV9l7U7Vg90H21EOLACvtfcHk0ljQ2zGNOjkrBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaju73N&md5=c221114e258bbafd11a884b10a72252b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2600-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2600-4%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DRobertson%26aufirst%3DF.%2BM.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DAburto-Chumpitaz%26aufirst%3DL.%26aulast%3DMu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DBoley%26aufirst%3DK.%2BM.%26aulast%3DKlein-Szanto%26aufirst%3DA.%2BJ.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DCristofanilli%26aufirst%3DM.%26atitle%3DInflammatory%2520breast%2520cancer%2520%2528IBC%2529%253A%2520clues%2520for%2520targeted%2520therapies%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26spage%3D23%26epage%3D33%26doi%3D10.1007%2Fs10549-013-2600-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">211</span><span class="refDoi">Â DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+inhibitory+activities+against+both+wild-type+and+mutant+ALK+kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520inhibitory%2520activities%2520against%2520both%2520wild-type%2520and%2520mutant%2520ALK%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwight, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4948</span><span class="NLM_x">â</span> <span class="NLM_lpage">4964</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.+S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lgGiEGRx18E0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span><span class="refDoi">Â DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lgGiEGRx18E0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjork, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csoregh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helander, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenne, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anden, N.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span> </span><span class="NLM_article-title">(R)- and (S)-5,6,7,8-Tetrahydro-l-hydroxy-N,N-dipropyl-9H-benzocyclohepten-8-ylamine. Stereoselective Interactions with 5-HT1A receptors in the Brain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2311</span><span class="NLM_x">â</span> <span class="NLM_lpage">2318</span><span class="refDoi">Â DOI: 10.1021/jm00130a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00130a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2311-2318&author=Y.+Liuauthor=C.+Mellinauthor=L.+Bjorkauthor=B.+Svenssonauthor=I.+Csoreghauthor=A.+Helanderauthor=L.+Kenneauthor=N.-E.+Andenauthor=U.+Hacksell&title=%28R%29-+and+%28S%29-5%2C6%2C7%2C8-Tetrahydro-l-hydroxy-N%2CN-dipropyl-9H-benzocyclohepten-8-ylamine.+Stereoselective+Interactions+with+5-HT1A+receptors+in+the+Brain&doi=10.1021%2Fjm00130a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00130a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00130a015%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMellin%26aufirst%3DC.%26aulast%3DBjork%26aufirst%3DL.%26aulast%3DSvensson%26aufirst%3DB.%26aulast%3DCsoregh%26aufirst%3DI.%26aulast%3DHelander%26aufirst%3DA.%26aulast%3DKenne%26aufirst%3DL.%26aulast%3DAnden%26aufirst%3DN.-E.%26aulast%3DHacksell%26aufirst%3DU.%26atitle%3D%2528R%2529-%2520and%2520%2528S%2529-5%252C6%252C7%252C8-Tetrahydro-l-hydroxy-N%252CN-dipropyl-9H-benzocyclohepten-8-ylamine.%2520Stereoselective%2520Interactions%2520with%25205-HT1A%2520receptors%2520in%2520the%2520Brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2311%26epage%3D2318%26doi%3D10.1021%2Fjm00130a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvidsson, L.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. L. G.</span><span> </span><span class="NLM_article-title">Monophenolic 2-( Dipropylamino)indans and Related Compounds: Central Dopamine-Receptor Stimulating Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">434</span><span class="refDoi">Â DOI: 10.1021/jm00136a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00136a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=429-434&author=U.+Hacksellauthor=L.-E.+Arvidssonauthor=U.+Svenssonauthor=J.+L.+G.+Nilsson&title=Monophenolic+2-%28+Dipropylamino%29indans+and+Related+Compounds%3A+Central+Dopamine-Receptor+Stimulating+Activity&doi=10.1021%2Fjm00136a012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm00136a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00136a012%26sid%3Dliteratum%253Aachs%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DArvidsson%26aufirst%3DL.-E.%26aulast%3DSvensson%26aufirst%3DU.%26aulast%3DNilsson%26aufirst%3DJ.%2BL.%2BG.%26atitle%3DMonophenolic%25202-%2528%2520Dipropylamino%2529indans%2520and%2520Related%2520Compounds%253A%2520Central%2520Dopamine-Receptor%2520Stimulating%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D429%26epage%3D434%26doi%3D10.1021%2Fjm00136a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="note"><p class="first last">Unless otherwise noted in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, intermediates were commercially available.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">For experimental details and results, see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a>. The coordinates of compound <b>31</b> have been deposited in the CCDB.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Zificsak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theroff, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâKane, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.bmcl.2011.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22169263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=133-137&author=C.+A.+Zificsakauthor=D.+E.+Gingrichauthor=H.+J.+Breslinauthor=D.+D.+Dunnauthor=K.+L.+Milkiewiczauthor=J.+P.+Theroffauthor=T.+V.+Thieuauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+Savilleauthor=J.+Hustenauthor=T.+S.+Angelesauthor=J.+P.+Finnauthor=M.+Janauthor=T.+M.+O%E2%80%99Kaneauthor=P.+Dobrzanskiauthor=B.+D.+Dorsey&title=Optimization+of+a+novel+kinase+inhibitor+scaffold+for+the+dual+inhibition+of+JAK2+and+FAK+kinases&doi=10.1016%2Fj.bmcl.2011.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span></div><div class="casAuthors">Zificsak, Craig A.; Gingrich, Diane E.; Breslin, Henry J.; Dunn, Derek D.; Milkiewicz, Karen L.; Theroff, Jay P.; Thieu, Tho V.; Underiner, Ted L.; Weinberg, Linda R.; Aimone, Lisa D.; Albom, Mark S.; Mason, Jennifer L.; Saville, Lisa; Husten, Jean; Angeles, Thelma S.; Finn, James P.; Jan, Mahfuza; O'Kane, Teresa M.; Dobrzanski, Pawel; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjTGeVZ-5KLVg90H21EOLACvtfcHk0ljys3mIM0sR1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D&md5=849448a392e70c11a0b1df1c9d54e8b5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%2BD.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DSaville%26aufirst%3DL.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DFinn%26aufirst%3DJ.%2BP.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DT.%2BM.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DOptimization%2520of%2520a%2520novel%2520kinase%2520inhibitor%2520scaffold%2520for%2520the%2520dual%2520inhibition%2520of%2520JAK2%2520and%2520FAK%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D133%26epage%3D137%26doi%3D10.1016%2Fj.bmcl.2011.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="note"><p class="first last">For a list of kinases tested, % inhibition, and <i>K</i><sub>d</sub> values see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">The rat PK parameters for <b>1</b> in this manuscript that are used for comparison were performed using the same protocol design (1 mg/kg, iv and 5 mg/kg, po doses) as that for all other analogues tested. It is of note that this protocol differs from that reported for compound <b>1</b> in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a> with respect to dosage. Differences were noted between the two independent studies. See <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a> for the parameters used in this study.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structureâactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2- (isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">â</span> <span class="NLM_lpage">5690</span><span class="refDoi">Â DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N4-%282-+%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N4-%25282-%2520%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lisko, J. G.; Gingrich, D. E.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Galinis, D.; Ott, G. R.; Parrish, J.; Weinberg, L. R.; Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Imidazoles and other heterocycles as amide bioisosteres for the inhibition of anaplastic lymphoma kinase (ALK)</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 241st National Meeting and Exposition of the American Chemical Society, Anaheim, CA, U.S., 2011; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>MEDI-256.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+G.+Lisko&author=D.+E.+Gingrich&author=M.+S.+Albom&author=T.+S.+Angeles&author=M.+Cheng&author=D.+Galinis&author=G.+R.+Ott&author=J.+Parrish&author=L.+R.+Weinberg&author=B.+D.+Dorsey&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26atitle%3DImidazoles%2520and%2520other%2520heterocycles%2520as%2520amide%2520bioisosteres%2520for%2520the%2520inhibition%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ra17</span><span class="refDoi">Â DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22277784" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&issue=120&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">â</span> <span class="NLM_lpage">1739</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lj-q-6fHwAVMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10038</span><span class="NLM_x">â</span> <span class="NLM_lpage">10043</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=The+neuroblastoma-associated+F1174L+ALK+mutation+causes+resistance+to+an+ALK+kinase+inhibitor+in+ALK-translocated+cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520neuroblastoma-associated%2520F1174L%2520ALK%2520mutation%2520causes%2520resistance%2520to%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520ALK-translocated%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">â</span> <span class="NLM_lpage">6825</span><span class="refDoi">Â DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded Î²-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0lj-q-6fHwAVMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Sims, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCammon, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sefton, B. M.</span><span> </span><span class="NLM_article-title">Relative contributions of desolvation, inter- and intramolecular interactions to binding affinity in protein kinase systems</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">681</span><span class="refDoi">Â DOI: 10.1002/jcc.20207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fjcc.20207" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=668-681&author=P.+A.+Simsauthor=C.+F.+Wongauthor=D.+Vugaauthor=J.+A.+McCammonauthor=B.+M.+Sefton&title=Relative+contributions+of+desolvation%2C+inter-+and+intramolecular+interactions+to+binding+affinity+in+protein+kinase+systems&doi=10.1002%2Fjcc.20207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20207%26sid%3Dliteratum%253Aachs%26aulast%3DSims%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DC.%2BF.%26aulast%3DVuga%26aufirst%3DD.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26aulast%3DSefton%26aufirst%3DB.%2BM.%26atitle%3DRelative%2520contributions%2520of%2520desolvation%252C%2520inter-%2520and%2520intramolecular%2520interactions%2520to%2520binding%2520affinity%2520in%2520protein%2520kinase%2520systems%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D668%26epage%3D681%26doi%3D10.1002%2Fjcc.20207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span> </span><span class="NLM_article-title">Treating ALK-positive lung cancerâearly successes and future challenges</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">â</span> <span class="NLM_lpage">277</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2012.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fnrclinonc.2012.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22473102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlGgurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=268-277&author=D.+R.+Camidgeauthor=R.+C.+Doebele&title=Treating+ALK-positive+lung+cancer%E2%80%94early+successes+and+future+challenges&doi=10.1038%2Fnrclinonc.2012.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Treating ALK-positive lung cancer-early successes and future challenges</span></div><div class="casAuthors">Camidge, D. Ross; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">268-277</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Crizotinib has provided dramatic and prolonged benefit for patients with the ALK-pos. subtype of non-small-cell lung cancer.  Despite these early successes, many challenges remain including understanding the mechanisms of resistance to crizotinib.  This Review examines what we already know and the major emerging questions assocd. with optimal management of this disease.  Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease.  Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-pos. (ALK+) NSCLC in assocn. with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clin. use in this molecularly defined subgroup of lung cancer.  Many new ALK inhibitors are being developed and understanding the challenges of detg. and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be crit. in the future for informing the optimal therapy of ALK+ NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoux5Y1cifBo7Vg90H21EOLACvtfcHk0liniiiOxERwMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlGgurk%253D&md5=19969175b805e023229ca8716897d8d8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.43%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTreating%2520ALK-positive%2520lung%2520cancer%25E2%2580%2594early%2520successes%2520and%2520future%2520challenges%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D268%26epage%3D277%26doi%3D10.1038%2Fnrclinonc.2012.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span> </span><span class="NLM_article-title">Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">805</span><span class="refDoi">Â DOI: 10.1007/s10555-015-9592-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10555-015-9592-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26342831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWhsLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=797-805&author=G.+Toyokawaauthor=T.+Setoauthor=M.+Takenoyamaauthor=Y.+Ichinose&title=Insights+into+brain+metastasis+in+patients+with+ALK%2B+lung+cancer%3A+is+the+brain+truly+a+sanctuary%3F&doi=10.1007%2Fs10555-015-9592-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?</span></div><div class="casAuthors">Toyokawa, Gouji; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">797-805</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and ceritinib, than with chemotherapy.  Despite the excellent efficacy of ALK inhibitors, resistance to these drugs is inevitably encountered in most ALK-rearranged pts.  Cases of resistance are subtyped into three groups, i.e., systemic, oligo, and central nervous system (CNS) types, with the CNS being used to be considered a sanctuary.  With regard to the management of CNS lesions in pts with ALK+ NSCLC, a growing body of evidence has gradually demonstrated the intracranial (IC) efficacy of ALK inhibitor (ALKi) in ALK+ NSCLC pts with brain metastases (BMs).  Although the efficacy of crizotinib for the CNS lesions remains controversial, a recent retrospective investigation of ALK+ pts with BM enrolled in PROFILE 1005 and PROFILE 1007 demonstrated that crizotinib is assocd. with a high disease control rate for BM.  However, BM comprises the most common site of progressive disease in pts with or without baseline BMs, which is a serious problem for crizotinib.  Furthermore, alectinib can be used to achieve strong and long-lasting inhibitory effects on BM.  In addn. to alectinib, the IC efficacy of other next-generation ALK inhibitors, such as ceritinib, AP26113 and PF-06463922, has been demonstrated.  In this article, we review the latest evidence regarding the BM and IC efficacy of ALK inhibitors in pts with ALK+ NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBwkFYAW4O0bVg90H21EOLACvtfcHk0liniiiOxERwMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWhsLrM&md5=a9f603248214b3d8027df8cb91838737</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10555-015-9592-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-015-9592-y%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakenoyama%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DY.%26atitle%3DInsights%2520into%2520brain%2520metastasis%2520in%2520patients%2520with%2520ALK%252B%2520lung%2520cancer%253A%2520is%2520the%2520brain%2520truly%2520a%2520sanctuary%253F%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2015%26volume%3D34%26spage%3D797%26epage%3D805%26doi%3D10.1007%2Fs10555-015-9592-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">Dose normalized to 1 mg oral AUC values for comparison purposes.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Khor, T.; Vasquez, D.; Katz, A.; Baia, G.; Ciznadija, D.; Sidransky, S.; Paz, K.</span><span> </span><span class="NLM_article-title">The Champions TumorGraft Bank: A Demographically-Rich Repository of Preclinical TumorGraft Models</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, U.S., 2014; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract 1187. See also <a href="http://www.championsoncology.com" class="extLink">www.championsoncology.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Khor&author=D.+Vasquez&author=A.+Katz&author=G.+Baia&author=D.+Ciznadija&author=S.+Sidransky&author=K.+Paz&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKhor%26aufirst%3DT.%26atitle%3DThe%2520Champions%2520TumorGraft%2520Bank%253A%2520A%2520Demographically-Rich%2520Repository%2520of%2520Preclinical%2520TumorGraft%2520Models%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Salem, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsalahi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chervoneva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburto, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, S. V.</span><span> </span><span class="NLM_article-title">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-52&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+vitro+and+in+vivo+on+inflammatory+breast+cancer+cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0lg4ewPp5rCduA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520on%2520inflammatory%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D52%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>ClinicalTrials.gov identifier: NCT01922752.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+identifier%3A+NCT01922752."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Crivello, J. V.</span><span> </span><span class="NLM_article-title">Nitrations and oxidations with inorganic nitrate salts in trifluoroacetic anhydride</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3056</span><span class="NLM_x">â</span> <span class="NLM_lpage">3060</span><span class="refDoi">Â DOI: 10.1021/jo00328a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00328a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADyaL3MXksVamsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1981&pages=3056-3060&author=J.+V.+Crivello&title=Nitrations+and+oxidations+with+inorganic+nitrate+salts+in+trifluoroacetic+anhydride&doi=10.1021%2Fjo00328a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrations and oxidations with inorganic nitrate salts in trifluoroacetic anhydride</span></div><div class="casAuthors">Crivello, J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3056-60</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Metal nitrates in (CF3CO)2O nitrate many arom. compds. in high yields at room temp., including polymers with arom. groups.  However, this system oxidizes phenols to quinoid products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq739OW8d6AO7Vg90H21EOLACvtfcHk0lg4ewPp5rCduA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXksVamsr8%253D&md5=cc74e3e39a148569596b1225cdf34e40</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjo00328a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00328a013%26sid%3Dliteratum%253Aachs%26aulast%3DCrivello%26aufirst%3DJ.%2BV.%26atitle%3DNitrations%2520and%2520oxidations%2520with%2520inorganic%2520nitrate%2520salts%2520in%2520trifluoroacetic%2520anhydride%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1981%26volume%3D46%26spage%3D3056%26epage%3D3060%26doi%3D10.1021%2Fjo00328a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':[],'ref32':[],'ref33':['cit33'],'ref34':[],'ref35':[],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':[],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 43 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yueheng Qi, Ye Li, Yu Fang, Hang Gao, Bingchao Qiang, Shuxia Wang, <span class="NLM_string-name hlFld-ContribAuthor">Huabei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Biological Evaluation, and Molecular Docking of 2,4-Diaminopyrimidine Derivatives Targeting Focal Adhesion Kinase as Tumor Radiotracers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (4)
                                     , 1634-1642. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c01088" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c01088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c01088%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BBiological%252BEvaluation%25252C%252Band%252BMolecular%252BDocking%252Bof%252B2%25252C4-Diaminopyrimidine%252BDerivatives%252BTargeting%252BFocal%252BAdhesion%252BKinase%252Bas%252BTumor%252BRadiotracers%26aulast%3DQi%26aufirst%3DYueheng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D04112020%26date%3D09032021%26date%3D09032021%26date%3D19032021%26volume%3D18%26issue%3D4%26spage%3D1634%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian J. Groendyke, Behnam Nabet, Mikaela L. Mohardt, Haisheng Zhang, Ke Peng, Eriko Koide, Calvin R. Coffey, Jianwei Che, David A. Scott, Adam J. Bass, <span class="NLM_string-name hlFld-ContribAuthor">Nathanael S. Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 30-38. <a href="https://doi.org/10.1021/acsmedchemlett.0c00338" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00338%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPyrimidothiazolodiazepinone%252Bas%252Ba%252BPotent%252Band%252BSelective%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252BInhibitor%26aulast%3DGroendyke%26aufirst%3DBrian%2BJ.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18062020%26date%3D18112020%26date%3D14122020%26volume%3D12%26issue%3D1%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Lu, <span class="NLM_string-name hlFld-ContribAuthor">Haiying Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14382-14403. <a href="https://doi.org/10.1021/acs.jmedchem.0c01248" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01248%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecular%252BInhibitors%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%26aulast%3DLu%26aufirst%3DYang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17072020%26date%3D15102020%26volume%3D63%26issue%3D23%26spage%3D14382%26epage%3D14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Philipp
M. Cromm, Kusal T. G. Samarasinghe, John Hines, <span class="NLM_string-name hlFld-ContribAuthor">Craig M. Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (49)
                                     , 17019-17026. <a href="https://doi.org/10.1021/jacs.8b08008" title="DOI URL">https://doi.org/10.1021/jacs.8b08008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b08008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b08008%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAddressing%252BKinase-Independent%252BFunctions%252Bof%252BFak%252Bvia%252BPROTAC-Mediated%252BDegradation%26aulast%3DCromm%26aufirst%3DPhilipp%2BM.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03082018%26date%3D28112018%26date%3D16112018%26volume%3D140%26issue%3D49%26spage%3D17019%26epage%3D17026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas BostrÃ¶m</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Jung Hee  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Kukcheol  Ahn</span>, <span class="hlFld-ContribAuthor ">Soyeon  Choi</span>, <span class="hlFld-ContribAuthor ">Hyun Seop  Tae</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Jin Kyung  Rho</span>, <span class="hlFld-ContribAuthor ">Jae Cheol  Lee</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (22)
                                     , 9205-9221. <a href="https://doi.org/10.1021/acs.jmedchem.7b01039" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B4-Phenoxyquinoline%252BBased%252BInhibitors%252Bfor%252BL1196M%252BMutant%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bby%252BStructure-Based%252BDesign%26aulast%3DMah%26aufirst%3DShinmee%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17072017%26date%3D09112017%26date%3D22112017%26date%3D01112017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shawn P.  Allwein</span>, <span class="hlFld-ContribAuthor ">Dale R.  Mowrey</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Petrillo</span>, <span class="hlFld-ContribAuthor ">James J.  Reif</span>, <span class="hlFld-ContribAuthor ">Vikram C.  Purohit</span>, <span class="hlFld-ContribAuthor ">Karen L.  Milkiewicz</span>, <span class="hlFld-ContribAuthor ">Roger P.  Bakale</span>, <span class="hlFld-ContribAuthor ">Michael A.  Christie</span>, <span class="hlFld-ContribAuthor ">Mark A.  Olsen</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Neville</span>, and <span class="hlFld-ContribAuthor ">Gregory J.  Gilmartin</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Process Route to the FAK/ALK Dual Inhibitor TEV-37440. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (5)
                                     , 740-747. <a href="https://doi.org/10.1021/acs.oprd.7b00070" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00070%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BProcess%252BRoute%252Bto%252Bthe%252BFAK%25252FALK%252BDual%252BInhibitor%252BTEV-37440%26aulast%3DAllwein%26aufirst%3DShawn%2BP.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D28022017%26date%3D01052017%26date%3D19052017%26date%3D25042017%26volume%3D21%26issue%3D5%26spage%3D740%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shan  Wang</span>, <span class="hlFld-ContribAuthor ">Rong-Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Chan  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Yang</span>, <span class="hlFld-ContribAuthor ">Yong-Long  Zhao</span>, <span class="hlFld-ContribAuthor ">Guo-Yi  Yan</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Xu</span>, <span class="hlFld-ContribAuthor ">Huan-Yu  Guan</span>, <span class="hlFld-ContribAuthor ">Yan-Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Dong-Bing  Cui</span>, <span class="hlFld-ContribAuthor ">Ting  Liu</span>, <span class="hlFld-ContribAuthor ">Yong-Jun  Li</span>, <span class="hlFld-ContribAuthor ">Shang-Gao  Liao</span>, <span class="hlFld-ContribAuthor ">Meng  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113573. <a href="https://doi.org/10.1016/j.ejmech.2021.113573" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113573%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C4-diamino%252Bpyrimidine%252Bderivatives%252Bas%252Bpotent%252BFAK%252Binhibitors%252Bwith%252Banti-cancer%252Band%252Banti-angiogenesis%252Bactivities%26aulast%3DWang%26aufirst%3DShan%26date%3D2021%26volume%3D222%26spage%3D113573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Amer Ali  Abd El-Hafeez</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Gajanan D.  Katkar</span>, <span class="hlFld-ContribAuthor ">Yaser A.  Mostafa</span>, <span class="hlFld-ContribAuthor ">Pradipta  Ghosh</span>, <span class="hlFld-ContribAuthor ">Alaa M.  Hayallah</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113569. <a href="https://doi.org/10.1016/j.ejmech.2021.113569" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113569%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bfirst-in-class%252Banticancer%252Bdual%252BHDAC2%25252FFAK%252Binhibitors%252Bbearing%252Bhydroxamates%25252Fbenzamides%252Bcapped%252Bby%252Bpyridinyl-1%25252C2%25252C4-triazoles%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2021%26volume%3D222%26spage%3D113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Amer Ali  Abd El-Hafeez</span>, <span class="hlFld-ContribAuthor ">Dalia A  Abdelhafeez</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Yaser A  Mostafa</span>, <span class="hlFld-ContribAuthor ">Pradipta  Ghosh</span>, <span class="hlFld-ContribAuthor ">Alaa M  Hayallah</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din  A Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">FAK inhibitors as promising anticancer targets: present and future directions. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>7 </em><a href="https://doi.org/10.4155/fmc-2021-0015" title="DOI URL">https://doi.org/10.4155/fmc-2021-0015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2021-0015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2021-0015%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DFAK%252Binhibitors%252Bas%252Bpromising%252Banticancer%252Btargets%25253A%252Bpresent%252Band%252Bfuture%252Bdirections%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2021%26date%3D2021%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Kemin  Shen</span>, <span class="hlFld-ContribAuthor ">Shijun  Wang</span>, <span class="hlFld-ContribAuthor ">Zhijun  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Su</span>, <span class="hlFld-ContribAuthor ">Xi  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaoqin  Hu</span>, <span class="hlFld-ContribAuthor ">Mengyao  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Lintao  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4187. <a href="https://doi.org/10.3390/molecules26144187" title="DOI URL">https://doi.org/10.3390/molecules26144187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144187%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252BNovel%252B2%25252C4-Dianilinopyrimidine%252BDerivatives%252BContaining%252B4-%252528Morpholinomethyl%252529phenyl%252Band%252BN-Substituted%252BBenzamides%252Bas%252BPotential%252BFAK%252BInhibitors%252Band%252BAnticancer%252BAgents%26aulast%3DHan%26aufirst%3DChun%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangfang  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Ran  Li</span>, <span class="hlFld-ContribAuthor ">Zhihai  Sui</span>, <span class="hlFld-ContribAuthor ">Guijuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Bo  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Arabian Journal of Chemistry</span><span> <strong>2021,</strong> <em>14 </em>
                                    (6)
                                     , 103144. <a href="https://doi.org/10.1016/j.arabjc.2021.103144" title="DOI URL">https://doi.org/10.1016/j.arabjc.2021.103144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arabjc.2021.103144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arabjc.2021.103144%26sid%3Dliteratum%253Aachs%26jtitle%3DArabian%2520Journal%2520of%2520Chemistry%26atitle%3DMolecular%252Bdescription%252Bof%252Bpyrimidine-based%252Binhibitors%252Bwith%252Bactivity%252Bagainst%252BFAK%252Bcombining%252B3D-QSAR%252Banalysis%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%26aulast%3DWang%26aufirst%3DFangfang%26date%3D2021%26volume%3D14%26issue%3D6%26spage%3D103144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akshita  Chauhan</span>, <span class="hlFld-ContribAuthor ">Tabassum  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Focal adhesion kinaseâAn emerging viable target in cancer and development of focal adhesion kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 774-794. <a href="https://doi.org/10.1111/cbdd.13808" title="DOI URL">https://doi.org/10.1111/cbdd.13808</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13808%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DFocal%252Badhesion%252Bkinase%2525E2%252580%252594An%252Bemerging%252Bviable%252Btarget%252Bin%252Bcancer%252Band%252Bdevelopment%252Bof%252Bfocal%252Badhesion%252Bkinase%252Binhibitors%26aulast%3DChauhan%26aufirst%3DAkshita%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D774%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pouria  Shirvani</span>, <span class="hlFld-ContribAuthor ">Afshin  Fassihi</span>. </span><span class="cited-content_cbyCitation_article-title">In silico
              design of novel FAK inhibitors using integrated molecular docking, 3D-QSAR and molecular dynamics simulation studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>6 </em>, 1-19. <a href="https://doi.org/10.1080/07391102.2021.1875880" title="DOI URL">https://doi.org/10.1080/07391102.2021.1875880</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1875880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1875880%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIn%252Bsilico%252Bdesign%252Bof%252Bnovel%252BFAK%252Binhibitors%252Busing%252Bintegrated%252Bmolecular%252Bdocking%25252C%252B3D-QSAR%252Band%252Bmolecular%252Bdynamics%252Bsimulation%252Bstudies%26aulast%3DShirvani%26aufirst%3DPouria%26date%3D2021%26date%3D2021%26volume%3D6%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuan-ce  Sun</span>, <span class="hlFld-ContribAuthor ">Li-jun  Feng</span>, <span class="hlFld-ContribAuthor ">Xiao-hua  Sun</span>, <span class="hlFld-ContribAuthor ">Ri-lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yan-yan  Chu</span>, <span class="hlFld-ContribAuthor ">Cong-min  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Study on the interactions of pyrimidine derivatives with FAK by 3D-QSAR, molecular docking and molecular dynamics simulation. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (45)
                                     , 19499-19507. <a href="https://doi.org/10.1039/D0NJ02136A" title="DOI URL">https://doi.org/10.1039/D0NJ02136A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ02136A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ02136A%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DStudy%252Bon%252Bthe%252Binteractions%252Bof%252Bpyrimidine%252Bderivatives%252Bwith%252BFAK%252Bby%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulation%26aulast%3DSun%26aufirst%3DChuan-ce%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D45%26spage%3D19499%26epage%3D19507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongming  Xie</span>, <span class="hlFld-ContribAuthor ">Xinglong  Lin</span>, <span class="hlFld-ContribAuthor ">Yingjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Fuxing  Tan</span>, <span class="hlFld-ContribAuthor ">Bo  Chi</span>, <span class="hlFld-ContribAuthor ">Zhihong  Peng</span>, <span class="hlFld-ContribAuthor ">Wanrong  Dong</span>, <span class="hlFld-ContribAuthor ">Delie  An</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (21)
                                     , 127459. <a href="https://doi.org/10.1016/j.bmcl.2020.127459" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127459%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bring-fused%252Bpyrazoloamino%252Bpyridine%25252Fpyrimidine%252Bderivatives%252Bas%252Bpotential%252BFAK%252Binhibitors%26aulast%3DXie%26aufirst%3DHongming%26date%3D2020%26volume%3D30%26issue%3D21%26spage%3D127459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-xia  Gao</span>, <span class="hlFld-ContribAuthor ">Meng-bo  Wang</span>, <span class="hlFld-ContribAuthor ">Si-jing  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Niu</span>, <span class="hlFld-ContribAuthor ">Jing  Xue</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Xin-xia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Hub Genes and Key Pathways Associated with Peripheral T-cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Current Medical Science</span><span> <strong>2020,</strong> <em>40 </em>
                                    (5)
                                     , 885-899. <a href="https://doi.org/10.1007/s11596-020-2250-9" title="DOI URL">https://doi.org/10.1007/s11596-020-2250-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11596-020-2250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11596-020-2250-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medical%2520Science%26atitle%3DIdentification%252Bof%252BHub%252BGenes%252Band%252BKey%252BPathways%252BAssociated%252Bwith%252BPeripheral%252BT-cell%252BLymphoma%26aulast%3DGao%26aufirst%3DHai-xia%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D5%26spage%3D885%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Xiangxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Sijia  Yu</span>, <span class="hlFld-ContribAuthor ">Yixuan  Chen</span>, <span class="hlFld-ContribAuthor ">Hengxian  Cui</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>102 </em>, 104092. <a href="https://doi.org/10.1016/j.bioorg.2020.104092" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104092%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BFAK%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DWang%26aufirst%3DRuifeng%26date%3D2020%26volume%3D102%26spage%3D104092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Chun-Nan  Kuo</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase inhibitors: an updated patent review (2014â2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (5)
                                     , 351-373. <a href="https://doi.org/10.1080/13543776.2020.1738389" title="DOI URL">https://doi.org/10.1080/13543776.2020.1738389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1738389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1738389%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252B%2525282014%2525E2%252580%2525932018%252529%26aulast%3DLiu%26aufirst%3DYi-Min%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D351%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmet Sureyya  Rifaioglu</span>, <span class="hlFld-ContribAuthor ">Esra  Nalbat</span>, <span class="hlFld-ContribAuthor ">Volkan  Atalay</span>, <span class="hlFld-ContribAuthor ">Maria Jesus  Martin</span>, <span class="hlFld-ContribAuthor ">Rengul  Cetin-Atalay</span>, <span class="hlFld-ContribAuthor ">Tunca  DoÄan</span>. </span><span class="cited-content_cbyCitation_article-title">DEEPScreen: high performance drugâtarget interaction prediction with convolutional neural networks using 2-D structural compound representations. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 2531-2557. <a href="https://doi.org/10.1039/C9SC03414E" title="DOI URL">https://doi.org/10.1039/C9SC03414E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03414E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03414E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DDEEPScreen%25253A%252Bhigh%252Bperformance%252Bdrug%2525E2%252580%252593target%252Binteraction%252Bprediction%252Bwith%252Bconvolutional%252Bneural%252Bnetworks%252Busing%252B2-D%252Bstructural%252Bcompound%252Brepresentations%26aulast%3DRifaioglu%26aufirst%3DAhmet%2BSureyya%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D9%26spage%3D2531%26epage%3D2557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Sijia  Yu</span>, <span class="hlFld-ContribAuthor ">Xiangxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Yixuan  Chen</span>, <span class="hlFld-ContribAuthor ">Bowen  Yang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112024. <a href="https://doi.org/10.1016/j.ejmech.2019.112024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnovel%252Bthieno%25255B3%25252C2-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252BFAK%252Binhibitors%26aulast%3DWang%26aufirst%3DRuifeng%26date%3D2020%26volume%3D188%26spage%3D112024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Ai</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Tengyue  Ma</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Lixue  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103408. <a href="https://doi.org/10.1016/j.bioorg.2019.103408" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103408</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103408%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bdiphenylpyrimidine%252Bderivatives%252B%252528DPPYs%252529%252Bas%252Bpotential%252Bdual%252BEGFR%252BT790M%252Band%252BFAK%252Binhibitors%252Bagainst%252Ba%252Bdiverse%252Brange%252Bof%252Bcancer%252Bcell%252Blines%26aulast%3DAi%26aufirst%3DMin%26date%3D2020%26volume%3D94%26spage%3D103408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yixuan  Chen</span>, <span class="hlFld-ContribAuthor ">Xiangxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Sijia  Yu</span>, <span class="hlFld-ContribAuthor ">Bowen  Yang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111716. <a href="https://doi.org/10.1016/j.ejmech.2019.111716" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111716%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotential%252BFAK%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DRuifeng%26date%3D2019%26volume%3D183%26spage%3D111716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Su</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Xianling  Ning</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Lin</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Juntuo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Yuxin  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>177 </em>, 32-46. <a href="https://doi.org/10.1016/j.ejmech.2019.05.048" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.048%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-diarylaminopyrimidine%252Bderivatives%252Bbearing%252Bdithiocarbamate%252Bmoiety%252Bas%252Bnovel%252BFAK%252Binhibitors%252Bwith%252Bantitumor%252Band%252Banti-angiogenesis%252Bactivities%26aulast%3DSu%26aufirst%3DYue%26date%3D2019%26volume%3D177%26spage%3D32%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N. V.  Stolpovskaya</span>, <span class="hlFld-ContribAuthor ">A. A.  Kruzhilin</span>, <span class="hlFld-ContribAuthor ">A. V.  Zorina</span>, <span class="hlFld-ContribAuthor ">Kh. S.  Shikhaliev</span>, <span class="hlFld-ContribAuthor ">I. V.  Ledeneva</span>, <span class="hlFld-ContribAuthor ">E. A.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">D. Yu.  Vandyshev</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Substituted Aminopyrimidines as Novel Promising Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>55 </em>
                                    (9)
                                     , 1322-1328. <a href="https://doi.org/10.1134/S1070428019090094" title="DOI URL">https://doi.org/10.1134/S1070428019090094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428019090094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428019090094%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BSubstituted%252BAminopyrimidines%252Bas%252BNovel%252BPromising%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DStolpovskaya%26aufirst%3DN.%2BV.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D9%26spage%3D1322%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin Ling  Gan</span>, <span class="hlFld-ContribAuthor ">Bo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of 3-amino-2-hydroxy-6-methoxybenzamide hydrate, C16H22N4O7. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift fÃ¼r Kristallographie - New Crystal Structures</span><span> <strong>2019,</strong> <em>234 </em>
                                    (4)
                                     , 747-748. <a href="https://doi.org/10.1515/ncrs-2019-0088" title="DOI URL">https://doi.org/10.1515/ncrs-2019-0088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2019-0088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2019-0088%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DCrystal%252Bstructure%252Bof%252B3-amino-2-hydroxy-6-methoxybenzamide%252Bhydrate%25252C%252BC16H22N4O7%26aulast%3DGan%26aufirst%3DLin%2BLing%26date%3D2019%26volume%3D234%26issue%3D4%26spage%3D747%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Min  Ai</span>, <span class="hlFld-ContribAuthor ">Jiawen  Yu</span>, <span class="hlFld-ContribAuthor ">Lingling  Jin</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Luo</span>, <span class="hlFld-ContribAuthor ">Wenshun  Guan</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 154-162. <a href="https://doi.org/10.1016/j.ejmech.2019.04.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bmodification%252Bof%252Bcarbonyl-diphenylpyrimidines%252B%252528Car-DPPYs%252529%252Bas%252Ba%252Bnovel%252Bfocal%252Badhesion%252Bkinase%252B%252528FAK%252529%252Binhibitor%252Bagainst%252Bvarious%252Bstubborn%252Bcancer%252Bcells%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2019%26volume%3D172%26spage%3D154%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaoqi  Weng</span>, <span class="hlFld-ContribAuthor ">Ercheng  Wang</span>, <span class="hlFld-ContribAuthor ">Fu  Chen</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing the performance of MM/PBSA and MM/GBSA methods. 9. Prediction reliability of binding affinities and binding poses for proteinâpeptide complexes. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2019,</strong> <em>21 </em>
                                    (19)
                                     , 10135-10145. <a href="https://doi.org/10.1039/C9CP01674K" title="DOI URL">https://doi.org/10.1039/C9CP01674K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CP01674K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CP01674K%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DAssessing%252Bthe%252Bperformance%252Bof%252BMM%25252FPBSA%252Band%252BMM%25252FGBSA%252Bmethods.%252B9.%252BPrediction%252Breliability%252Bof%252Bbinding%252Baffinities%252Band%252Bbinding%252Bposes%252Bfor%252Bprotein%2525E2%252580%252593peptide%252Bcomplexes%26aulast%3DWeng%26aufirst%3DGaoqi%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D19%26spage%3D10135%26epage%3D10145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Zheng</span>, <span class="hlFld-ContribAuthor ">Feng-Cheng  Jia</span>, <span class="hlFld-ContribAuthor ">Yun-Feng  Chen</span>, <span class="hlFld-ContribAuthor ">An-Xin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative ring-opening of isatins for the synthesis of 2-aminobenzamides and 2-aminobenzoates. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (11)
                                     , 1497-1503. <a href="https://doi.org/10.1016/j.tet.2019.01.067" title="DOI URL">https://doi.org/10.1016/j.tet.2019.01.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.01.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.01.067%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DOxidative%252Bring-opening%252Bof%252Bisatins%252Bfor%252Bthe%252Bsynthesis%252Bof%252B2-aminobenzamides%252Band%252B2-aminobenzoates%26aulast%3DWang%26aufirst%3DYu-Wei%26date%3D2019%26volume%3D75%26issue%3D11%26spage%3D1497%26epage%3D1503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  SpÃ¤ter</span>, <span class="hlFld-ContribAuthor ">Isabelle  MÃ¼ller</span>, <span class="hlFld-ContribAuthor ">Hermann  Eichler</span>, <span class="hlFld-ContribAuthor ">Michael D.  Menger</span>, <span class="hlFld-ContribAuthor ">Matthias W.  Laschke</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Ampofo</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2018,</strong> <em>29 </em>
                                    (3)
                                     , 277-287. <a href="https://doi.org/10.1080/09537104.2017.1306040" title="DOI URL">https://doi.org/10.1080/09537104.2017.1306040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2017.1306040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2017.1306040%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DDual%252Binhibition%252Bof%252BPI3K%252Band%252BmTOR%252Bby%252BVS-5584%252Bsuppresses%252Bthrombus%252Bformation%26aulast%3DSp%25C3%25A4ter%26aufirst%3DThomas%26date%3D2018%26date%3D2017%26volume%3D29%26issue%3D3%26spage%3D277%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Drug resistance in anaplastic lymphoma kinaseârearranged lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2018,</strong> <em>109 </em>
                                    (3)
                                     , 572-580. <a href="https://doi.org/10.1111/cas.13504" title="DOI URL">https://doi.org/10.1111/cas.13504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13504%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DDrug%252Bresistance%252Bin%252Banaplastic%252Blymphoma%252Bkinase%2525E2%252580%252590rearranged%252Blung%252Bcancer%26aulast%3DKatayama%26aufirst%3DRyohei%26date%3D2018%26date%3D2018%26volume%3D109%26issue%3D3%26spage%3D572%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">FAK inhibitors in Cancer, a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2018,</strong> <em>28 </em>
                                    (2)
                                     , 139-145. <a href="https://doi.org/10.1080/13543776.2018.1414183" title="DOI URL">https://doi.org/10.1080/13543776.2018.1414183</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2018.1414183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2018.1414183%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFAK%252Binhibitors%252Bin%252BCancer%25252C%252Ba%252Bpatent%252Breview%26aulast%3DLv%26aufirst%3DPeng-Cheng%26date%3D2018%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Shaowei  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Yucheng  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 123-136. <a href="https://doi.org/10.1016/j.ejmech.2017.11.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bto%252Bovercome%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DWang%26aufirst%3DYu%26date%3D2018%26volume%3D143%26spage%3D123%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Zaman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Sulman  Basit</span>, <span class="hlFld-ContribAuthor ">Abdul  Ghaffar</span>, <span class="hlFld-ContribAuthor ">Muhammad Sohail  Zafar</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>, <span class="hlFld-ContribAuthor ">Sultan Ayoub  Meo</span>. </span><span class="cited-content_cbyCitation_article-title">Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (30)
                                     , 16470-16493. <a href="https://doi.org/10.1039/C8RA01934G" title="DOI URL">https://doi.org/10.1039/C8RA01934G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA01934G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA01934G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DLatest%252Bperspectives%252Bof%252Borally%252Bbioavailable%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252B%252528DAAPalogues%252529%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Bdiscovery%252Band%252Bclinical%252Bdevelopments%26aulast%3DLatif%26aufirst%3DMuhammad%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D30%26spage%3D16470%26epage%3D16493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Liu</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Huang</span>, <span class="hlFld-ContribAuthor ">Shijie  Song</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jihong  Yao</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Yongming  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (24)
                                     , 6313-6321. <a href="https://doi.org/10.1016/j.bmc.2017.09.041" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.09.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.09.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.09.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPhosphamide-containing%252Bdiphenylpyrimidine%252Banalogues%252B%252528PA-DPPYs%252529%252Bas%252Bpotent%252Bfocal%252Badhesion%252Bkinase%252B%252528FAK%252529%252Binhibitors%252Bwith%252Benhanced%252Bactivity%252Bagainst%252Bpancreatic%252Bcancer%252Bcell%252Blines%26aulast%3DLiu%26aufirst%3DHe%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6313%26epage%3D6321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brent M  Kuenzi</span>, <span class="hlFld-ContribAuthor ">Lily L  Remsing Rix</span>, <span class="hlFld-ContribAuthor ">Paul A  Stewart</span>, <span class="hlFld-ContribAuthor ">Bin  Fang</span>, <span class="hlFld-ContribAuthor ">Fumi  Kinose</span>, <span class="hlFld-ContribAuthor ">Annamarie T  Bryant</span>, <span class="hlFld-ContribAuthor ">Theresa A  Boyle</span>, <span class="hlFld-ContribAuthor ">John M  Koomen</span>, <span class="hlFld-ContribAuthor ">Eric B  Haura</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology-based ceritinib repurposing using integrated functional proteomics. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2017,</strong> <em>13 </em>
                                    (12)
                                     , 1222-1231. <a href="https://doi.org/10.1038/nchembio.2489" title="DOI URL">https://doi.org/10.1038/nchembio.2489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.2489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.2489%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DPolypharmacology-based%252Bceritinib%252Brepurposing%252Busing%252Bintegrated%252Bfunctional%252Bproteomics%26aulast%3DKuenzi%26aufirst%3DBrent%2BM%26date%3D2017%26date%3D2017%26volume%3D13%26issue%3D12%26spage%3D1222%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>177 </em>, 1-8. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.015" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTherapeutic%252Bstrategies%252Band%252Bmechanisms%252Bof%252Bdrug%252Bresistance%252Bin%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529-rearranged%252Blung%252Bcancer%26aulast%3DKatayama%26aufirst%3DRyohei%26date%3D2017%26volume%3D177%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niki  Karachaliou</span>, <span class="hlFld-ContribAuthor ">Mariacarmela  Santarpia</span>, <span class="hlFld-ContribAuthor ">Maria  Gonzalez Cao</span>, <span class="hlFld-ContribAuthor ">Cristina  Teixido</span>, <span class="hlFld-ContribAuthor ">Aaron E.  Sosa</span>, <span class="hlFld-ContribAuthor ">Jordi  Berenguer</span>, <span class="hlFld-ContribAuthor ">Alejandra  Rodriguez Capote</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Altavilla</span>, <span class="hlFld-ContribAuthor ">Rafael  Rosell</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (6)
                                     , 713-722. <a href="https://doi.org/10.1080/13543784.2017.1324572" title="DOI URL">https://doi.org/10.1080/13543784.2017.1324572</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1324572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1324572%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252Binhibitors%252Bin%252Bphase%252BI%252Band%252Bphase%252BII%252Bclinical%252Btrials%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DKarachaliou%26aufirst%3DNiki%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D6%26spage%3D713%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raffaele  Palmirotta</span>, <span class="hlFld-ContribAuthor ">Davide  Quaresmini</span>, <span class="hlFld-ContribAuthor ">Domenica  Lovero</span>, <span class="hlFld-ContribAuthor ">Franco  Silvestris</span>. </span><span class="cited-content_cbyCitation_article-title">ALK
              gene alterations in cancer: biological aspects and therapeutic implications. </span><span class="cited-content_cbyCitation_journal-name">Pharmacogenomics</span><span> <strong>2017,</strong> <em>18 </em>
                                    (3)
                                     , 277-292. <a href="https://doi.org/10.2217/pgs-2016-0166" title="DOI URL">https://doi.org/10.2217/pgs-2016-0166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/pgs-2016-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fpgs-2016-0166%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacogenomics%26atitle%3DALK%252Bgene%252Balterations%252Bin%252Bcancer%25253A%252Bbiological%252Baspects%252Band%252Btherapeutic%252Bimplications%26aulast%3DPalmirotta%26aufirst%3DRaffaele%26date%3D2017%26volume%3D18%26issue%3D3%26spage%3D277%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors of ALK. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 435-467. <a href="https://doi.org/10.1007/7355_2017_18" title="DOI URL">https://doi.org/10.1007/7355_2017_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_18%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bof%252BALK%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2017%26spage%3D435%26epage%3D467%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0023.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Teva small molecule ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Retrosynthetic disconnections for 4-chloro-2,6-diaminopyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) morpholine, NaBH(OAc)<sub>3</sub>, AcOH, THF (99%); (b) KNO<sub>3</sub>, TFAA, MeCN (19%); (c) H<sub>2</sub>, Pd/C, EtOH (99%).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) KNO<sub>3</sub>, TFAA, MeCN (36%); (b) amine, NaBH(OAc)<sub>3</sub>, AcOH, THF (24â85%); (c) H<sub>2</sub>, Pd/C, EtOH (61â99%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) methanesulfonic acid, 1-methoxy-2-propanol, Î or microwave.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF; (b) <b>12a</b> or <b>12d</b> or (<i>R</i>)-<b>12d</b> or (<i>S</i>)-<b>12d</b>, methanesulfonic acid, 1-methoxy-2-propanol, Î or microwave.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) Chiralcel OJ-H (3 cm Ã 15 cm), 15% MeOH, 0.2% diethylamine, CO<sub>2</sub> (SFC); (b) <i>p</i>-Br-benzoyl chloride.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major sites of metabolism from in vitro liver microsome incubation (10 Î¼M concentration for 120 min in the presence of NADPH and analysis by LC/MS/MS.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Glide docking of <b>27b</b> (gray) and <b>1</b> (yellow): left panel, ALK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LZT">3LZT</a>); right panel, FAK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BZ3">3BZ3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro cytotoxicity and caspase 3/7 activation results for <b>27b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK/PD of <b>27b</b> (single 30 mg/kg, po dose) in NPM-ALK+ ALCL tumor xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>27b</b> on ALK+ ALCL and NSCLC animal xenograft models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PK/PD of <b>27b</b> (single 55 mg/kg, po dose) in FAK+ CWR22 tumor xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Activity of <b>27b</b> in HCC-827 human NSCLC xenograft (ALKâ/FAK+).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/medium/jm-2016-004872_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Activity of <b>27b</b> in CTG-0977 human SCCHN PDX (ALKâ/FAK+) and CTG-0785 sarcoma PDX (ALKâ/FAK+).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00487&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Jackson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, J. D.</span><span> </span><span class="NLM_article-title">Personalised cancer medicine</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">266</span><span class="refDoi">Â DOI: 10.1002/ijc.28940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fijc.28940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=24789362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=262-266&author=S.+E.+Jacksonauthor=J.+D.+Chester&title=Personalised+cancer+medicine&doi=10.1002%2Fijc.28940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Personalised cancer medicine</span></div><div class="casAuthors">Jackson, Sarah E.; Chester, John D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-266</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The evolving field of personalised medicine is playing an increasingly important role in cancer prevention, diagnosis, prognosis and therapeutics.  Its importance in clin. management is demonstrated by the recent introduction into routine clin. practice of various individualised, molecularly targeted therapies with increased efficacy and/or reduced toxicity.  The identification of cancer predisposition genes, such as the BRCA genes in breast cancer, permits screening programs to identify patients "at-risk" of developing cancer and helps them make decisions on individual risk-modification behaviors.  Personalised medicine also plays an increasingly important role in cancer treatment.  It is increasingly clear that there are molecularly distinct subtypes of various common cancers, with different therapeutic approaches required for each subtype, for example, the use of the monoclonal antibodies (trastuzumab and cetuximab) in HER2-pos. breast cancer and wild-type KRAS colorectal cancer; tyrosine kinase inhibitors (imatinib, gefitinib, erlotinib and crizotinib) in chronic myeloid leukemia, gastrointestinal stromal tumors and non-small-cell lung cancer and intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast and prostate cancer.  The efficacy of various targeted therapies in such disparate tumors suggests that we are entering an era in which treatment decisions will be based on tumor mol. abnormality profile or "signature," rather than tumor tissue type or anatomical site of origin, improving patient prognosis and quality of life.  This mini review focuses on the role of personalised medicine in cancer prevention and treatment as well as its future direction in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkKhyy6q2P7Vg90H21EOLACvtfcHk0lhLfCrtS0su2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWrs70%253D&md5=d578457bd70e94b526810de9df34cfdf</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fijc.28940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28940%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BE.%26aulast%3DChester%26aufirst%3DJ.%2BD.%26atitle%3DPersonalised%2520cancer%2520medicine%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D262%26epage%3D266%26doi%3D10.1002%2Fijc.28940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Russo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franchina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricciardi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosaria, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanghi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toscano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): Old successes and future perspectives</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26814</span><span class="NLM_x">â</span> <span class="NLM_lpage">26825</span><span class="refDoi">Â DOI: 10.18632/oncotarget.4254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.18632%2Foncotarget.4254" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=26814-26825&author=A.+Russoauthor=T.+Franchinaauthor=G.+Ricciardiauthor=R.+Rosariaauthor=A.+Piconeauthor=G.+Ferraroauthor=M.+Zanghiauthor=G.+Toscanoauthor=V.+Adamoauthor=A.+Giordano&title=A+decade+of+EGFR+inhibition+in+EGFR-mutated+non-small+cell+lung+cancer+%28NSCLC%29%3A+Old+successes+and+future+perspectives&doi=10.18632%2Foncotarget.4254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4254%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%26aulast%3DRosaria%26aufirst%3DR.%26aulast%3DPicone%26aufirst%3DA.%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DZanghi%26aufirst%3DM.%26aulast%3DToscano%26aufirst%3DG.%26aulast%3DAdamo%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DA%2520decade%2520of%2520EGFR%2520inhibition%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520Old%2520successes%2520and%2520future%2520perspectives%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D26814%26epage%3D26825%26doi%3D10.18632%2Foncotarget.4254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Tan, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilligan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacey, S.</span><span> </span><span class="NLM_article-title">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">e447</span><span class="NLM_x">â</span> <span class="NLM_lpage">e459</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00246-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2FS1470-2045%2815%2900246-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26370354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=e447-e459&author=C.-S.+Tanauthor=D.+Gilliganauthor=S.+Pacey&title=Treatment+approaches+for+EGFR-inhibitor-resistant+patients+with+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2815%2900246-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span></div><div class="casAuthors">Tan, Chee-Seng; Gilligan, David; Pacey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e447-e459</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant non-small-cell lung cancer (NSCLC).  At present, first-line treatment with EGFR TKIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.  These agents improve response rates, time to progression, and overall survival.  Unfortunately, patients develop resistance, limiting patient benefit and posing a challenge to oncologists.  Optimum treatment after progression is not clearly defined.  A more detailed understanding of the biol. of EGFR-mutant NSCLC and the mechanisms of resistance to targeted therapy mean that an era of treatment approaches based on rationally developed drugs or therapeutic strategies has begun.  Combination approaches-eg, dual EGFR blockade-to overcome resistance have been trialled and seem to be promising but are potentially limited by toxicity.  Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumors, the most common mechanism of EGFR TKI resistance, have entered clin. trials, and exciting, albeit preliminary, efficacy data have been reported.  In this Review, we summarise the scientific literature and evidence on therapy options after EGFR TKI treatment for patients with NSCLC, aiming to provide a guide to oncologists, and consider how to maximise therapeutic advances in outcomes in this rapidly advancing area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CJqM1DDS3rVg90H21EOLACvtfcHk0lhTptgqeP91pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM&md5=1e04e573a62e12a4abeb88e0c4f8acb2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900246-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900246-6%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DGilligan%26aufirst%3DD.%26aulast%3DPacey%26aufirst%3DS.%26atitle%3DTreatment%2520approaches%2520for%2520EGFR-inhibitor-resistant%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3De447%26epage%3De459%26doi%3D10.1016%2FS1470-2045%2815%2900246-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span><span class="refDoi">Â DOI: 10.1038/clpt.2013.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fclpt.2013.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=24091716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyrt77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=15-23&author=B.+Solomonauthor=K.+D.+Wilnerauthor=A.+T.+Shaw&title=Current+Status+of+Targeted+Therapy+for+Anaplastic+Lymphoma+Kinase-Rearranged+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fclpt.2013.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Solomon, B.; Wilner, K. D.; Shaw, A. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in â¼3-5Ì of non-small cell lung cancer (NSCLC) tissues and the demonstration that the first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for NSCLC.  Single-arm studies demonstrating rapid and durable responses in the majority of ALK-pos. NSCLC patients treated with crizotinib have been followed by a randomized phase III clin. trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-pos. NSCLC patients.  However, despite the initial responses, most patients develop acquired resistance to crizotinib.  Several novel therapeutic approaches targeting ALK-pos. NSCLC are currently under evaluation in clin. trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802802), and AP26113, and heat shock protein 90 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYefH2xXnpLVg90H21EOLACvtfcHk0lhTptgqeP91pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyrt77E&md5=2e551a95ae9b6862cdc487b122720d55</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.200%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DCurrent%2520Status%2520of%2520Targeted%2520Therapy%2520for%2520Anaplastic%2520Lymphoma%2520Kinase-Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D95%26spage%3D15%26epage%3D23%26doi%3D10.1038%2Fclpt.2013.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Scarborough, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGregori, J.</span><span> </span><span class="NLM_article-title">Personalized one-two punches for lung cancer</span> <span class="citation_source-journal">Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span><span class="refDoi">Â DOI: 10.1038/cr.2014.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fcr.2014.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25547118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Chsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=269-270&author=H.+A.+Scarboroughauthor=P.+A.+Bunnauthor=J.+DeGregori&title=Personalized+one-two+punches+for+lung+cancer&doi=10.1038%2Fcr.2014.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized one-two punches for lung cancer</span></div><div class="casAuthors">Scarborough, Hannah A.; Bunn, Paul A.; DeGregori, James</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-270</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Genetic characterization of tumors and the subsequent use of TKIs as targeted therapies has become a mainstream treatment modality for a subset of non-small cell lung cancer (NSCLC).  Patients with NSCLCs harboring EGFR activating mutations or ALK translocations often respond initially to TKIs but, in what has become a common storyline of many oncogene-driven cancers, varied mechanisms of resistance develop and relapse inevitably occurs.  Resistance usually occurs in one of two ways: 1) as a result of a secondary mutation in the oncogene that prevents inhibition by the targeted agent (e.g., EGFR T790M1,2 and ALK L1196M3,4) or 2) through accessing a compensatory signaling pathway that bypasses the necessity of the oncogene for proliferation and survival5 (Figure 1).  An understanding of these "bypass tracks" is driving current efforts to develop drug combinations that overcome resistance in NSCLC.  These efforts have historically taken two forms: recapitulating the development of resistance in vitro using cell lines, and performing genetic anal. on biopsies to identify new drivers of resistance.  While the identification of resistance mechanisms that develop in vitro provides insight into the range of such mechanisms, such discoveries are of limited clin. relevance for individual patients.  On the other hand, genetic anal. of individual patient biopsies can reveal post-resistance mutations that can be treated with specific second- and third-generation inhibitors, which can produce high response rates6.  In a recent study published in Science, Crystal et al.7 describe a methodol. to screen individual patient biopsies for drug combinations that overcome clin.-developed resistance.  The authors take advantage of methods recently described in Liu et al.8 that allowed them to create cell lines directly from patient specimens with a 50% success rate, which conferred the power of cell culture models to patient-derived tumor cells.  They tested a panel of 76 targeted agents (in various phases of FDA approval) in the presence and absence of the original TKI against these patient-derived resistant lines, (11 EGFR-resistant and 9 ALK-resistant) and in vitro derived resistant lines, and detd. the resultant change in cell viability and growth using in vitro proliferation assays.  To compare the information yielded by genetic anal. to that yielded by their panel, they analyzed each of the patient-derived models by next-generation sequencing.  The extensive drug panel includes agents that target other receptor tyrosine kinases (RTKs; e.g., ErbB2, Flt3, FGFR), components of the original target's signaling pathway (e.g., PI3K, BRAF) and master regulators of proliferation and survival (e.g., STAT, Survivin, AKT).  The panel also includes regulators of apoptosis, transcription, protein-folding machinery and DNA damage sensors.  These drug targets represent crit. components of pathways that could be activated in lung cancers to provide resistance to the original targeted therapy.  As proof of concept, the authors performed the screen on five previously-established cell lines with known mechanisms of resistance, and found that drugs that target those mechanisms were among those producing the greatest responses.  Among the 60 models screened, a total of 201 "hits" were identified, and at least one hit was identified in 50 of 60 lines.  Hits were identified for 83% (8/11) of the EGFR-TKI resistant models and 89% (8/9) of the ALK-TKI resistant models.  The screen demonstrated considerable robustness; drugs known to have overlapping specificity were found to have overlapping activity across cell lines, and consistent with previously published reports, EGFR inhibitors tended to be hits in both ALK- and MET-driven resistant lines.  Addnl., three patient-derived and two in vitro derived lines were tested as xenografts and demonstrated substantial tumor regression only when treated with the drug combination revealed through this screen.  Importantly, the authors identified SRC family kinase inhibitors as hits across several patient-derived ALK-pos. resistance models, for the first time implicating SRC signaling as a potential mechanism of resistance to ALK inhibition.  Overexpression of kinase-dead SRC and shRNA-mediated knockdown of SRC recapitulated the effects of pharmacol. SRC inhibitors, validating SRC as the relevant target.  In subsequent expts., they showed that both direct inhibition of ALK and inhibition of its downstream pathways in these cells resulted in robust upregulation of SRC activity.  Suppression of redundant tyrosine kinases by an oncogene-driven cancer (and their subsequent reactivation upon oncogenic inhibition) is a well-established mechanism of intrinsic TKI resistance in EGFR-driven cancers9.  Their findings here support a model in which ALK activity broadly suppresses SRC activity in ALK-driven cancers.  Clin. protocols at many sites call for targeted genetic typing of resistant biopsies.  Importantly, this study demonstrated the inadequacy of genetic profiling in identifying effective drug combinations.  Despite the fact that multiple SRC family kinase inhibitors were effective across several patient-derived resistant models, next-generation sequencing failed to identify mutations in these genes or other known regulators of SRC activity.  Addnl., a MEK inhibitor, selumetinib was revealed to be a potent hit in one line derived from an ALK-pos. cancer that had become resistant to ceritinib (a second-generation ALK inhibitor).  Next-generation sequencing revealed no mutations in MEK, but did reveal a MAP2K1 mutation and an activating JAK3 mutation (V722I).  MAP2K1 (an activator of MEK10) has not previously been described in the setting of resistance to ALK inhibition and thus would likely not have registered as an actionable mutation from the genetic screen.  Of note, the JAK3 inhibitor tofacitinib was not a hit in the screen, and the cells did not express a high level of JAK3.  This was also the first report of the use of a MEK inhibitor to resensitize ALK-pos. cancers to ALK inhibitors and was obsd. only in one patient-derived line, illustrating the potential for this approach to identify efficacious, patient-specific drug combinations.  In summary, this study presents a potentially interesting methodol. that can contribute to both the identification of effective drug combinations in TKI-resistant NSCLCs and the discovery of novel mechanisms of resistance, though some addnl. issues need to be addressed.  Despite the innovations of the authors' approach, there remain questions of this platform's applicability in the clinic.  It took 2-6 mo to establish the biopsies as cell lines, a timeline which may not allow for fast enough turnaround to inform clin. decisions.  Further studies comparing clin. outcomes based on strategies derived from relapsed tumors to those from the method presented here are needed before it is clear how these approaches can affect patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHj_0euIe51LVg90H21EOLACvtfcHk0lhTptgqeP91pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Chsw%253D%253D&md5=a87d2e3b2e1208b58d49f50b8d19bc79</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fcr.2014.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2014.168%26sid%3Dliteratum%253Aachs%26aulast%3DScarborough%26aufirst%3DH.%2BA.%26aulast%3DBunn%26aufirst%3DP.%2BA.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DPersonalized%2520one-two%2520punches%2520for%2520lung%2520cancer%26jtitle%3DCell%2520Res.%26date%3D2015%26volume%3D25%26spage%3D269%26epage%3D270%26doi%3D10.1038%2Fcr.2014.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popat, S.</span><span> </span><span class="NLM_article-title">Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer</span> <span class="citation_source-journal">Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">295</span><span class="refDoi">Â DOI: 10.2147/PGPM.S55339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.2147%2FPGPM.S55339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25278773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSjsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=285-295&author=T.+A.+Yapauthor=S.+Popat&title=Toward+precision+medicine+with+next-generation+EGFR+inhibitors+in+non-small-cell+lung+cancer&doi=10.2147%2FPGPM.S55339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer</span></div><div class="casAuthors">Yap, Timothy A.; Popat, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics and Personalized Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">PPMHAD</span>;
        ISSN:<span class="NLM_cas:issn">1178-7066</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The use of genomics to discover novel targets and biomarkers has placed the field of oncol. at the forefront of precision medicine.  First-generation epidermal growth factor receptor (EGFR) inhibitors have transformed the therapeutic landscape of EGFR mutant non-small-cell lung carcinoma through the genetic stratification of tumors from patients with this disease.  Somatic EGFR mutations in lung adenocarcinoma are now well established as predictive biomarkers of response and resistance to small-mol. EGFR inhibitors.  Despite early patient benefit, primary resistance and subsequent tumor progression to first-generation EGFR inhibitors are seen in 10%-30% of patients with EGFR mutant non-small-cell lung carcinoma.  Acquired drug resistance is also inevitable, with patients developing disease progression after only 10-13 mo of antitumor therapy.  This review details strategies pursued in circumventing T790M-mediated drug resistance to EGFR inhibitors, which is the most common mechanism of acquired resistance, and focuses on the clin. development of second-generation EGFR inhibitors, exemplified by afatinib (BIBW2992).  We discuss the rationale, mechanism of action, clin. efficacy, and toxicity profile of afatinib, including the LUX-Lung studies.  We also discuss the emergence of third-generation irreversible mutant-selective inhibitors of EGFR and envision the future management of EGFR mutant lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwLvdY0f8G7Vg90H21EOLACvtfcHk0liv_I_jEDiQLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSjsr7E&md5=001e2f061e439b7a316d95b3ed5605f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S55339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S55339%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DPopat%26aufirst%3DS.%26atitle%3DToward%2520precision%2520medicine%2520with%2520next-generation%2520EGFR%2520inhibitors%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2014%26volume%3D7%26spage%3D285%26epage%3D295%26doi%3D10.2147%2FPGPM.S55339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">â</span> <span class="NLM_lpage">965</span><span class="refDoi">Â DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0liv_I_jEDiQLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passiglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germonpre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil-Bazo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaenepoel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wilde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronte, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Meerbeeck, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, P.</span><span> </span><span class="NLM_article-title">ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.3978/j.issn.2218-6751.2014.03.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.3978%2Fj.issn.2218-6751.2014.03.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25806308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=250-261&author=C.+Rolfoauthor=F.+Passigliaauthor=M.+Castigliaauthor=L.+E.+Raezauthor=P.+Germonpreauthor=I.+Gil-Bazoauthor=K.+Zwaenepoelauthor=A.+De+Wildeauthor=G.+Bronteauthor=A.+Russoauthor=J.+P.+Van+Meerbeeckauthor=P.+Van+Schilauthor=P.+Pauwels&title=ALK+and+crizotinib%3A+after+the+honeymoon...what+else%3F+Resistance+mechanisms+and+new+therapies+to+overcome+it&doi=10.3978%2Fj.issn.2218-6751.2014.03.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it</span></div><div class="casAuthors">Rolfo, Christian; Passiglia, Francesco; Castiglia, Marta; Raez, Luis E.; Germonpre, Paul; Gil-Bazo, Ignacio; Zwaenepoel, Karen; De Wilde, Annemieke; Bronte, Giuseppe; Russo, Antonio; Van Meerbeeck, Jan P.; Van Schil, Paul; Pauwels, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">250-261</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of "oncogenic drivers" and the subsequent development of targeted therapies.  The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC and the subsequent clin. development of crizotinib has been an amazing success story in lung cancer translational-research, and its accelerated approval [only 4 years from the discovery of ALK rearrangement in NSCLC to the approval by the Food and Drug Administration (FDA)] marked the beginning of the new decade of targeted therapy.  However, common to all targeted therapies, despite an initial benefit, patients inevitably experience tumor progression, due to the development of resistance.  Several mol. mechanisms are responsible for acquired resistance, such as secondary mutations of ALK kinase domain or amplification of ALK fusion gene, or the activation of other oncogenic drivers, which may cause resistance independently of ALK genetic alterations.  Pre-clin. data and early clin. trials showed the promising efficacy of a new class of ALK-inhibitors in overcoming acquired resistance.  The inhibition of the mol. chaperone, HSP90, represents another promising strategy to overcome crizotinib resistance in ALK-rearranged NSCLC.  Several mols. are currently under investigation in order to establish their specific role in the treatment of ALK-rearranged NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBSgZUk10SYLVg90H21EOLACvtfcHk0liFM46y1ZuubQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7rK&md5=596bcc9dee00ec764635a66eaf1e37e7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.03.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.03.01%26sid%3Dliteratum%253Aachs%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DPassiglia%26aufirst%3DF.%26aulast%3DCastiglia%26aufirst%3DM.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DGermonpre%26aufirst%3DP.%26aulast%3DGil-Bazo%26aufirst%3DI.%26aulast%3DZwaenepoel%26aufirst%3DK.%26aulast%3DDe%2BWilde%26aufirst%3DA.%26aulast%3DBronte%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DVan%2BMeerbeeck%26aufirst%3DJ.%2BP.%26aulast%3DVan%2BSchil%26aufirst%3DP.%26aulast%3DPauwels%26aufirst%3DP.%26atitle%3DALK%2520and%2520crizotinib%253A%2520after%2520the%2520honeymoon...what%2520else%253F%2520Resistance%2520mechanisms%2520and%2520new%2520therapies%2520to%2520overcome%2520it%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2014%26volume%3D3%26spage%3D250%26epage%3D261%26doi%3D10.3978%2Fj.issn.2218-6751.2014.03.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Costa, D. B.</span><span> </span><span class="NLM_article-title">Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer</span> <span class="citation_source-journal">Transl. Lung Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">375</span><span class="refDoi">Â DOI: 10.3978/j.issn.2218-6751.2014.08.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.3978%2Fj.issn.2218-6751.2014.08.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25806324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=373-375&author=D.+B.+Costa&title=Clinical+development+and+approval+of+second+generation+ALK+inhibitors+for+ALK+rearranged+lung+cancer&doi=10.3978%2Fj.issn.2218-6751.2014.08.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer</span></div><div class="casAuthors">Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">373-375</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">This article discusses about the clin. development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXaMn6tWwAx7Vg90H21EOLACvtfcHk0liFM46y1ZuubQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCms7nK&md5=7c64737722f7bdd2474b2dce2d4db722</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.08.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.08.01%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DClinical%2520development%2520and%2520approval%2520of%2520second%2520generation%2520ALK%2520inhibitors%2520for%2520ALK%2520rearranged%2520lung%2520cancer%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2014%26volume%3D3%26spage%3D373%26epage%3D375%26doi%3D10.3978%2Fj.issn.2218-6751.2014.08.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Singh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B. A.</span><span> </span><span class="NLM_article-title">Improving Prospects for Targeting RAS</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3650</span><span class="NLM_x">â</span> <span class="NLM_lpage">3659</span><span class="refDoi">Â DOI: 10.1200/JCO.2015.62.1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1200%2FJCO.2015.62.1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26371146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ciu7rM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3650-3659&author=H.+Singhauthor=D.+L.+Longoauthor=B.+A.+Chabner&title=Improving+Prospects+for+Targeting+RAS&doi=10.1200%2FJCO.2015.62.1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improving prospects for targeting RAS</span></div><div class="casAuthors">Singh, Harshabad; Longo, Dan L.; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3650-3659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">RAS mutations are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors and around a fifth of common myeloid malignancies, but they have evaded therapeutic interventions, despite being the focus of intense research over the last three decades.  Recent discoveries lend new understanding about the structure, function, and signaling of RAS and have opened new avenues for development of much needed new therapies.  We discuss the various approaches under investigation to target mutant RAS proteins.  The recent development of direct RAS inhibitors specific to KRAS G12C mutations represents a landmark discovery that promises to change the perception about RAS's druggability.  Multiple clin. trials targeting synthetically lethal partners and/or downstream signaling partners of RAS are underway.  Novel inhibitors targeting various arms ofRAS processing and signaling have yielded encouraging results in the lab., but refinement of the drug-like properties of these mols. is required before they will be ready for the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_bVkE2AIejLVg90H21EOLACvtfcHk0ljZIv-1dC7Ojw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ciu7rM&md5=fb3835d9053ae4cf95abe0271f9c62aa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.62.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.62.1052%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DLongo%26aufirst%3DD.%2BL.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DImproving%2520Prospects%2520for%2520Targeting%2520RAS%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3650%26epage%3D3659%26doi%3D10.1200%2FJCO.2015.62.1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cameron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">â</span> <span class="NLM_lpage">1070</span><span class="refDoi">Â DOI: 10.1007/s40265-015-0415-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs40265-015-0415-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1059-1070&author=L.+Cameronauthor=B.+Solomon&title=Treatment+of+ALK-Rearranged+Non-Small+Cell+Lung+Cancer%3A+Recent+Progress+and+Future+Directions&doi=10.1007%2Fs40265-015-0415-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0415-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0415-9%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DL.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520ALK-Rearranged%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Recent%2520Progress%2520and%2520Future%2520Directions%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1059%26epage%3D1070%26doi%3D10.1007%2Fs40265-015-0415-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">â</span> <span class="NLM_lpage">2235</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+Targeting+of+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer%3A+A+Paradigm+for+Precision+Cancer+Medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0ljZIv-1dC7Ojw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%253A%2520A%2520Paradigm%2520for%2520Precision%2520Cancer%2520Medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Gainor, J. F.; Shaw, A. T.</span><span> </span><span class="NLM_article-title">Targeting ALK rearrangements</span>. In  <span class="citation_source-book">Lung Cancer</span>, <span class="NLM_edition">4</span>th ed.; <span class="NLM_contrib-group">Roth, J. A.; Hong, W. K.; Komaki, R. U.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">541</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span>, DOI: <span class="refDoi">Â DOI: 10.1002/9781118468791.ch35</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2F9781118468791.ch35" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=541-556&author=J.+F.+Gainor&author=A.+T.+Shawauthor=J.+A.+Roth&author=W.+K.+Hong&author=R.+U.+Komaki&title=Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2F9781118468791.ch35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118468791.ch35%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26atitle%3DTargeting%2520ALK%2520rearrangements%26btitle%3DLung%2520Cancer%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2014%26spage%3D541%26epage%3D556%26doi%3D10.1002%2F9781118468791.ch35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amzallag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalsy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Caraballo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elamine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faber, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Patient-derived models of acquired resistance can identify effective drug combinations for cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x"> (</span><span class="NLM_issue">6216</span><span class="NLM_x">) </span> <span class="NLM_fpage">1480</span><span class="NLM_x">â</span> <span class="NLM_lpage">1486</span><span class="refDoi">Â DOI: 10.1126/science.1254721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1126%2Fscience.1254721" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1480-1486&issue=6216&author=A.+S.+Crystalauthor=A.+T.+Shawauthor=L.+V.+Sequistauthor=L.+Fribouletauthor=M.+J.+Niederstauthor=E.+L.+Lockermanauthor=R.+L.+Friasauthor=J.+F.+Gainorauthor=A.+Amzallagauthor=P.+Greningerauthor=D.+Leeauthor=A.+Kalsyauthor=M.+Gomez-Caraballoauthor=L.+Elamineauthor=E.+Howeauthor=W.+Hurauthor=E.+Lifshitsauthor=H.+E.+Robinsonauthor=R.+Katayamaauthor=A.+C.+Faberauthor=M.+M.+Awadauthor=S.+Ramaswamyauthor=M.+Mino-Kenudsonauthor=A.+J.+Iafrateauthor=C.+H.+Benesauthor=J.+A.+Engelman&title=Patient-derived+models+of+acquired+resistance+can+identify+effective+drug+combinations+for+cancer&doi=10.1126%2Fscience.1254721"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1254721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1254721%26sid%3Dliteratum%253Aachs%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DKalsy%26aufirst%3DA.%26aulast%3DGomez-Caraballo%26aufirst%3DM.%26aulast%3DElamine%26aufirst%3DL.%26aulast%3DHowe%26aufirst%3DE.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DRobinson%26aufirst%3DH.%2BE.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DPatient-derived%2520models%2520of%2520acquired%2520resistance%2520can%2520identify%2520effective%2520drug%2520combinations%2520for%2520cancer%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6216%26spage%3D1480%26epage%3D1486%26doi%3D10.1126%2Fscience.1254721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchionni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3392</span><span class="NLM_x">â</span> <span class="NLM_lpage">3408</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+As+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0liFqeKCfC7O5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520As%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haltiwanger, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">4580</span><span class="NLM_x">â</span> <span class="NLM_lpage">4593</span><span class="refDoi">Â DOI: 10.1021/jm201550q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201550q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4580-4593&issue=10&author=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+A.+Curryauthor=M.+Chengauthor=M.+Quailauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+C.+Haltiwangerauthor=K.+Wells-Knechtauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=M.+A.+Atorauthor=B.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+an+Orally+Efficacious+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm201550q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201550q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201550q%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4580%26epage%3D4593%26doi%3D10.1021%2Fjm201550q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">â</span> <span class="NLM_lpage">679</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+Highly+Potent+and+Selective+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-11-0776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0liDbVQKH1-uuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679%26doi%3D10.1158%2F1535-7163.MCT-11-0776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haltiwanger, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-tetraazatetracyclo[14.3.1.1<sup>3,7</sup>.1<sup>9,13</sup>]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">464</span><span class="refDoi">Â DOI: 10.1021/jm201333e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201333e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=449-464&author=H.+J.+Breslinauthor=B.+M.+Laneauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=M.+Chengauthor=W.+Wanauthor=R.+C.+Haltiwangerauthor=K.+J.+Wells-Knechtauthor=B.+D.+Dorsey&title=Design%2C+Synthesis%2C+and+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitory+Activity+for+a+Novel+Series+of+2%2C4%2C8%2C22-tetraazatetracyclo%5B14.3.1.13%2C7.19%2C13%5Ddocosa-1%2820%29%2C3%2822%29%2C4%2C6%2C9%2821%29%2C10%2C12%2C16%2C18-nonaene+Macrocycles&doi=10.1021%2Fjm201333e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm201333e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201333e%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DLane%26aufirst%3DB.%2BM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitory%2520Activity%2520for%2520a%2520Novel%2520Series%2520of%25202%252C4%252C8%252C22-tetraazatetracyclo%255B14.3.1.13%252C7.19%252C13%255Ddocosa-1%252820%2529%252C3%252822%2529%252C4%252C6%252C9%252821%2529%252C10%252C12%252C16%252C18-nonaene%2520Macrocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D449%26epage%3D464%26doi%3D10.1021%2Fjm201333e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with In Vivo Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">â</span> <span class="NLM_lpage">6341</span><span class="refDoi">Â DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+New+Variant+of+an+Old+Template+and+Application+to+the+Discovery+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+In+Vivo+Antitumor+Activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0liOSbiUFnlvPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520New%2520Variant%2520of%2520an%2520Old%2520Template%2520and%2520Application%2520to%2520the%2520Discovery%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520In%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Learn, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: Identification of potent inhibitors of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">â</span> <span class="NLM_lpage">1142</span><span class="refDoi">Â DOI: 10.1039/c2md20061a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1039%2Fc2md20061a" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1138-1142&author=K.+S.+Learnauthor=J.+C.+Wagnerauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=A.+K.+Ghoseauthor=W.+Wanauthor=M.+Chengauthor=B.+D.+Dorseyauthor=G.+R.+Ott&title=Design+of+7-amino-6-chloro-3H-imidazo%5B4%2C5-b%5Dpyridine+scaffold+from+5-chloro-2%2C4-diaminopyrimidine+pharmacophore%3A+Identification+of+potent+inhibitors+of+Anaplastic+Lymphoma+Kinase&doi=10.1039%2Fc2md20061a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc2md20061a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20061a%26sid%3Dliteratum%253Aachs%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%2BC.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DDesign%2520of%25207-amino-6-chloro-3H-imidazo%255B4%252C5-b%255Dpyridine%2520scaffold%2520from%25205-chloro-2%252C4-diaminopyrimidine%2520pharmacophore%253A%2520Identification%2520of%2520potent%2520inhibitors%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1138%26epage%3D1142%26doi%3D10.1039%2Fc2md20061a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span> </span><span class="NLM_article-title">Signal transduction by focal adhesion kinase in cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">49</span><span class="refDoi">Â DOI: 10.1007/s10555-008-9165-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10555-008-9165-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=19169797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hslSrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=35-49&author=J.+Zhaoauthor=J.+L.+Guan&title=Signal+transduction+by+focal+adhesion+kinase+in+cancer&doi=10.1007%2Fs10555-008-9165-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction by focal adhesion kinase in cancer</span></div><div class="casAuthors">Zhao Jihe; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer metastasis reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">35-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cellular interactions with extracellular matrix play essential roles in tumor initiation, progression and metastasis.  Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase identified as a key mediator of signaling by integrins, a major family of cell surface receptors for extracellular matrix, as well as other receptors in both normal and cancer cells.  FAK is activated by integrins through disruption of an auto-inhibitory intra-molecular interaction between its kinase domain and the amino terminal FERM domain.  The activated FAK forms a binary complex with Src family kinases which can phosphorylate other substrates and trigger multiple intracellular signaling pathways to regulate various cellular functions.  Subcellular localization of FAK in focal adhesions is essential for FAK signaling, which is another distinguishing feature of the kinase.  Integrin-FAK signaling has been shown to activate a number of signaling pathways through phosphorylation and protein-protein interactions to promote tumorigenesis.  FAK also plays a prominent role in tumor progression and metastasis through its regulation of both cancer cells and their microenvironments including cancer cell migration, invasion, epithelial to mesenchymal transition, and angiogenesis.  More recently, a role for FAK in tumor initiation and progression has been demonstrated directly using xenograft as well as conditional knockout mouse models.  In agreement with these experimental data, overexpression and activation of FAK have been found in a variety of human cancers.  A number of small molecule inhibitors for FAK have been developed and in various phases of testing for cancer treatments.  Overall, the intensive research on FAK signaling in cancer have yielded a wealth of information on this pivotal kinase and these and future studies are leading to potentially novel therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgWNHWmc0hKDjk2McQZ6XmfW6udTcc2ebfnYpRqudu57ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hslSrtA%253D%253D&md5=d2e0e4cb32e0c691eb8ed45a239fd7d0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9165-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9165-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DSignal%2520transduction%2520by%2520focal%2520adhesion%2520kinase%2520in%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2009%26volume%3D28%26spage%3D35%26epage%3D49%26doi%3D10.1007%2Fs10555-008-9165-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Schwock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D. W.</span><span> </span><span class="NLM_article-title">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span><span class="refDoi">Â DOI: 10.1517/14728220903460340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1517%2F14728220903460340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=20001212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=77-94&author=J.+Schwockauthor=N.+Dhaniauthor=D.+W.+Hedley&title=Targeting+focal+adhesion+kinase+signaling+in+tumor+growth+and+metastasis&doi=10.1517%2F14728220903460340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span></div><div class="casAuthors">Schwock, Joerg; Dhani, Neesha; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-94</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Focal adhesion kinase (FAK), a crucial mediator of integrin and growth factor signaling, is a novel and promising target in cancer therapy.  FAK resides within focal adhesions which are contact points between extracellular matrix (ECM) and cytoskeleton, and increased expression of the kinase has been linked with cancer cell migration, proliferation and survival.  The aim of this review is to summarize the current research in the area and to assess the potential of different FAK-targeting strategies for cancer therapy.  Areas covered in this review: We briefly examine the evidence pointing towards FAK as potential anti-cancer target since its discovery in 1992.  Then, we summarize different approaches developed to interfere with FAK signaling and important results reported from these expts.  Finally, we discuss the potential of these strategies to accomplish inhibition of tumor growth and distant spread as well as potentially meaningful combinations with other therapeutic modalities in the context of the currently available evidence.  What the reader will gain: The review emphasizes the link between FAK biol. and the consequences of interference with FAK signaling.  Based on this foundation an opinion is formed with regard to the future of FAK as therapeutic target.  Take home message: Inhibition of FAK harbors the potential to restrain malignant growth and progression with minimal side effects in normal tissues.  Small mol. inhibitors of the kinase should be examd. in further clin. studies and combinations with existing therapies need to be explored.  More efforts are required to identify markers which predict response towards FAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSMva2-GtqbVg90H21EOLACvtfcHk0ljBcDk7uYgEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM&md5=feed68cfd6aece3dc89d3568a16c1b36</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14728220903460340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903460340%26sid%3Dliteratum%253Aachs%26aulast%3DSchwock%26aufirst%3DJ.%26aulast%3DDhani%26aufirst%3DN.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520signaling%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2010%26volume%3D14%26spage%3D77%26epage%3D94%26doi%3D10.1517%2F14728220903460340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lee, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timpson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span> </span><span class="NLM_article-title">FAK signaling in human cancer as a target for therapeutics</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">â</span> <span class="NLM_lpage">149</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.pharmthera.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=25316657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=132-149&author=B.+Y.+Leeauthor=P.+Timpsonauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=FAK+signaling+in+human+cancer+as+a+target+for+therapeutics&doi=10.1016%2Fj.pharmthera.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in human cancer as a target for therapeutics</span></div><div class="casAuthors">Lee, Brian Y.; Timpson, Paul; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-149</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key regulator of growth factor receptor- and integrin-mediated signals, governing fundamental processes in normal and cancer cells through its kinase activity and scaffolding function.  Increased FAK expression and activity occurs in primary and metastatic cancers of many tissue origins, and is often assocd. with poor clin. outcome, highlighting FAK as a potential determinant of tumor development and metastasis.  Indeed, data from cell culture and animal models of cancer provide strong lines of evidence that FAK promotes malignancy by regulating tumorigenic and metastatic potential through highly-coordinated signaling networks that orchestrate a diverse range of cellular processes, such as cell survival, proliferation, migration, invasion, epithelial-mesenchymal transition, angiogenesis and regulation of cancer stem cell activities.  Such an integral role in governing malignant characteristics indicates that FAK represents a potential target for cancer therapeutics.  While pharmacol. targeting of FAK scaffold function is still at an early stage of development, a no. of small mol.-based FAK tyrosine kinase inhibitors are currently undergoing pre-clin. and clin. testing.  In particular, PF-00562271, VS-4718 and VS-6063 show promising clin. activities in patients with selected solid cancers.  Clin. testing of rationally designed FAK-targeting agents with implementation of predictive response biomarkers, such as merlin deficiency for VS-4718 in mesothelioma, may help improve clin. outcome for cancer patients.  In this article, we have reviewed the current knowledge regarding FAK signaling in human cancer, and recent developments in the generation and clin. application of FAK-targeting pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnxnFQsOShLVg90H21EOLACvtfcHk0ljBcDk7uYgEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN&md5=7359c2a7671631f97a9d46ccef1ab68f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFAK%2520signaling%2520in%2520human%2520cancer%2520as%2520a%2520target%2520for%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D146%26spage%3D132%26epage%3D149%26doi%3D10.1016%2Fj.pharmthera.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Serrels, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lund, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kriegsheim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Cuadrado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunton, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frame, M. C.</span><span> </span><span class="NLM_article-title">Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">â</span> <span class="NLM_lpage">173</span><span class="refDoi">Â DOI: 10.1016/j.cell.2015.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.cell.2015.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26406376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=160-173&author=A.+Serrelsauthor=T.+Lundauthor=B.+Serrelsauthor=A.+Byronauthor=R.+C.+McPhersonauthor=A.+von+Kriegsheimauthor=L.+Gomez-Cuadradoauthor=M.+Canelauthor=M.+Muirauthor=J.+E.+Ringauthor=E.+Maniatiauthor=A.+H.+Simsauthor=J.+A.+Pachterauthor=V.+G.+Bruntonauthor=N.+Gilbertauthor=S.+M.+Andertonauthor=R.+J.+B.+Nibbsauthor=M.+C.+Frame&title=Nuclear+FAK+Controls+Chemokine+Transcription%2C+Tregs%2C+and+Evasion+of+Anti-tumor+Immunity&doi=10.1016%2Fj.cell.2015.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity</span></div><div class="casAuthors">Serrels, Alan; Lund, Tom; Serrels, Bryan; Byron, Adam; McPherson, Rhoanne C.; von Kriegsheim, Alexander; Gomez-Cuadrado, Laura; Canel, Marta; Muir, Morwenna; Ring, Jennifer E.; Maniati, Eleni; Sims, Andrew H.; Pachter, Jonathan A.; Brunton, Valerie G.; Gilbert, Nick; Anderton, Stephen M.; Nibbs, Robert J. B.; Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) promotes anti-tumor immune evasion.  Specifically, the kinase activity of nuclear-targeted FAK in squamous cell carcinoma (SCC) cells drives exhaustion of CD8+ T cells and recruitment of regulatory T cells (Tregs) in the tumor microenvironment by regulating chemokine/cytokine and ligand-receptor networks, including via transcription of Ccl5, which is crucial.  These changes inhibit antigen-primed cytotoxic CD8+ T cell activity, permitting growth of FAK-expressing tumors.  Mechanistically, nuclear FAK is assocd. with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression.  Furthermore, FAK's immuno-modulatory nuclear activities may be specific to cancerous squamous epithelial cells, as normal keratinocytes do not have nuclear FAK.  Finally, the authors show that a small-mol. FAK kinase inhibitor, VS-4718, which is currently in clin. development, also drives depletion of Tregs and promotes a CD8+ T cell-mediated anti-tumor response.  Therefore, FAK inhibitors may trigger immune-mediated tumor regression, providing previously unrecognized therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6uPdKmBkvArVg90H21EOLACvtfcHk0ljBcDk7uYgEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrrL&md5=1dbae170a594fbdab85c77fa53607248</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DSerrels%26aufirst%3DA.%26aulast%3DLund%26aufirst%3DT.%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DByron%26aufirst%3DA.%26aulast%3DMcPherson%26aufirst%3DR.%2BC.%26aulast%3Dvon%2BKriegsheim%26aufirst%3DA.%26aulast%3DGomez-Cuadrado%26aufirst%3DL.%26aulast%3DCanel%26aufirst%3DM.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DManiati%26aufirst%3DE.%26aulast%3DSims%26aufirst%3DA.%2BH.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DGilbert%26aufirst%3DN.%26aulast%3DAnderton%26aufirst%3DS.%2BM.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DNuclear%2520FAK%2520Controls%2520Chemokine%2520Transcription%252C%2520Tregs%252C%2520and%2520Evasion%2520of%2520Anti-tumor%2520Immunity%26jtitle%3DCell%26date%3D2015%26volume%3D163%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.cell.2015.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fernandez, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburto-Chumpitaz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, K. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boley, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span> </span><span class="NLM_article-title">Inflammatory breast cancer (IBC): clues for targeted therapies</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span><span class="refDoi">Â DOI: 10.1007/s10549-013-2600-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10549-013-2600-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=23784380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaju73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=23-33&author=S.+V.+Fernandezauthor=F.+M.+Robertsonauthor=J.+Peiauthor=L.+Aburto-Chumpitazauthor=Z.+Muauthor=K.+Chuauthor=R.+K.+Alpaughauthor=Y.+Huangauthor=Y.+Caoauthor=Z.+Yeauthor=K.+Q.+Caiauthor=K.+M.+Boleyauthor=A.+J.+Klein-Szantoauthor=K.+Devarajanauthor=S.+Addyaauthor=M.+Cristofanilli&title=Inflammatory+breast+cancer+%28IBC%29%3A+clues+for+targeted+therapies&doi=10.1007%2Fs10549-013-2600-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory breast cancer (IBC): clues for targeted therapies</span></div><div class="casAuthors">Fernandez, Sandra V.; Robertson, Fredika M.; Pei, Jianming; Aburto-Chumpitaz, Lucy; Mu, Zhaomei; Chu, Khoi; Alpaugh, R. K.; Huang, Yong; Cao, Yu; Ye, Zaiming; Cai, Kathy Q.; Boley, Kimberly M.; Klein-Szanto, Andres J.; Devarajan, Karthik; Addya, Sankar; Cristofanilli, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis.  Since there are few preclin. models of IBC, there is a general lack of understanding of the complexity of the disease.  Recently, we have developed a new model of IBC derived from the pleural effusion of a woman with metastatic secondary IBC.  FC-IBC02 cells are triple neg. and form clusters (mammospheres) in suspension that are strongly pos. for E-cadherin, Î²-catenin and TSPAN24, all adhesion mols. that play an important role in cell migration and invasion.  FC-IBC02 cells expressed stem cell markers and some, but not all of the characteristics of cells undergoing epithelial mesenchymal transition (EMT).  Breast tumor FC-IBC02 xenografts developed quickly in SCID mice with the presence of tumor emboli and the development of lymph node and lung metastases.  Remarkably, FC-IBC02 cells were able to produce brain metastasis in mice on intracardiac or i.p. injections.  Genomic studies of FC-IBC02 and other IBC cell lines showed that IBC cells had important amplification of 8q24 where MYC, ATAD2 and the focal adhesion kinase FAK1 are located.  MYC and ATAD2 showed between 2.5 and 7 copies in IBC cells.  FAK1, which plays important roles in anoikis resistance and tumor metastasis, showed 6-4 copies in IBC cells.  Also, CD44 was amplified in triple-neg. IBC cells (10-3 copies).  Addnl., FC-IBC02 showed amplification of ALK and NOTCH3.  These results indicate that MYC, ATAD2, CD44, NOTCH3, ALK and/or FAK1 may be used as potential targeted therapies against IBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9sCvV9l7U7Vg90H21EOLACvtfcHk0liFDYZIxfykHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaju73N&md5=c221114e258bbafd11a884b10a72252b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2600-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2600-4%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DRobertson%26aufirst%3DF.%2BM.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DAburto-Chumpitaz%26aufirst%3DL.%26aulast%3DMu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DBoley%26aufirst%3DK.%2BM.%26aulast%3DKlein-Szanto%26aufirst%3DA.%2BJ.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DCristofanilli%26aufirst%3DM.%26atitle%3DInflammatory%2520breast%2520cancer%2520%2528IBC%2529%253A%2520clues%2520for%2520targeted%2520therapies%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26spage%3D23%26epage%3D33%26doi%3D10.1007%2Fs10549-013-2600-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">211</span><span class="refDoi">Â DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+inhibitory+activities+against+both+wild-type+and+mutant+ALK+kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520inhibitory%2520activities%2520against%2520both%2520wild-type%2520and%2520mutant%2520ALK%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwight, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4948</span><span class="NLM_x">â</span> <span class="NLM_lpage">4964</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.+S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lgJ-r8m4sXd6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span><span class="refDoi">Â DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lgJ-r8m4sXd6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjork, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csoregh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helander, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenne, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anden, N.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacksell, U.</span><span> </span><span class="NLM_article-title">(R)- and (S)-5,6,7,8-Tetrahydro-l-hydroxy-N,N-dipropyl-9H-benzocyclohepten-8-ylamine. Stereoselective Interactions with 5-HT1A receptors in the Brain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2311</span><span class="NLM_x">â</span> <span class="NLM_lpage">2318</span><span class="refDoi">Â DOI: 10.1021/jm00130a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00130a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2311-2318&author=Y.+Liuauthor=C.+Mellinauthor=L.+Bjorkauthor=B.+Svenssonauthor=I.+Csoreghauthor=A.+Helanderauthor=L.+Kenneauthor=N.-E.+Andenauthor=U.+Hacksell&title=%28R%29-+and+%28S%29-5%2C6%2C7%2C8-Tetrahydro-l-hydroxy-N%2CN-dipropyl-9H-benzocyclohepten-8-ylamine.+Stereoselective+Interactions+with+5-HT1A+receptors+in+the+Brain&doi=10.1021%2Fjm00130a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00130a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00130a015%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMellin%26aufirst%3DC.%26aulast%3DBjork%26aufirst%3DL.%26aulast%3DSvensson%26aufirst%3DB.%26aulast%3DCsoregh%26aufirst%3DI.%26aulast%3DHelander%26aufirst%3DA.%26aulast%3DKenne%26aufirst%3DL.%26aulast%3DAnden%26aufirst%3DN.-E.%26aulast%3DHacksell%26aufirst%3DU.%26atitle%3D%2528R%2529-%2520and%2520%2528S%2529-5%252C6%252C7%252C8-Tetrahydro-l-hydroxy-N%252CN-dipropyl-9H-benzocyclohepten-8-ylamine.%2520Stereoselective%2520Interactions%2520with%25205-HT1A%2520receptors%2520in%2520the%2520Brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2311%26epage%3D2318%26doi%3D10.1021%2Fjm00130a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hacksell, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvidsson, L.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. L. G.</span><span> </span><span class="NLM_article-title">Monophenolic 2-( Dipropylamino)indans and Related Compounds: Central Dopamine-Receptor Stimulating Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">434</span><span class="refDoi">Â DOI: 10.1021/jm00136a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00136a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=429-434&author=U.+Hacksellauthor=L.-E.+Arvidssonauthor=U.+Svenssonauthor=J.+L.+G.+Nilsson&title=Monophenolic+2-%28+Dipropylamino%29indans+and+Related+Compounds%3A+Central+Dopamine-Receptor+Stimulating+Activity&doi=10.1021%2Fjm00136a012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm00136a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00136a012%26sid%3Dliteratum%253Aachs%26aulast%3DHacksell%26aufirst%3DU.%26aulast%3DArvidsson%26aufirst%3DL.-E.%26aulast%3DSvensson%26aufirst%3DU.%26aulast%3DNilsson%26aufirst%3DJ.%2BL.%2BG.%26atitle%3DMonophenolic%25202-%2528%2520Dipropylamino%2529indans%2520and%2520Related%2520Compounds%253A%2520Central%2520Dopamine-Receptor%2520Stimulating%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D429%26epage%3D434%26doi%3D10.1021%2Fjm00136a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="note"><p class="first last">Unless otherwise noted in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, intermediates were commercially available.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">For experimental details and results, see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a>. The coordinates of compound <b>31</b> have been deposited in the CCDB.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Zificsak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theroff, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâKane, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1016%2Fj.bmcl.2011.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22169263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=133-137&author=C.+A.+Zificsakauthor=D.+E.+Gingrichauthor=H.+J.+Breslinauthor=D.+D.+Dunnauthor=K.+L.+Milkiewiczauthor=J.+P.+Theroffauthor=T.+V.+Thieuauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+Savilleauthor=J.+Hustenauthor=T.+S.+Angelesauthor=J.+P.+Finnauthor=M.+Janauthor=T.+M.+O%E2%80%99Kaneauthor=P.+Dobrzanskiauthor=B.+D.+Dorsey&title=Optimization+of+a+novel+kinase+inhibitor+scaffold+for+the+dual+inhibition+of+JAK2+and+FAK+kinases&doi=10.1016%2Fj.bmcl.2011.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span></div><div class="casAuthors">Zificsak, Craig A.; Gingrich, Diane E.; Breslin, Henry J.; Dunn, Derek D.; Milkiewicz, Karen L.; Theroff, Jay P.; Thieu, Tho V.; Underiner, Ted L.; Weinberg, Linda R.; Aimone, Lisa D.; Albom, Mark S.; Mason, Jennifer L.; Saville, Lisa; Husten, Jean; Angeles, Thelma S.; Finn, James P.; Jan, Mahfuza; O'Kane, Teresa M.; Dobrzanski, Pawel; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjTGeVZ-5KLVg90H21EOLACvtfcHk0li7GTpkGuPYVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D&md5=849448a392e70c11a0b1df1c9d54e8b5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%2BD.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DSaville%26aufirst%3DL.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DFinn%26aufirst%3DJ.%2BP.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DT.%2BM.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DOptimization%2520of%2520a%2520novel%2520kinase%2520inhibitor%2520scaffold%2520for%2520the%2520dual%2520inhibition%2520of%2520JAK2%2520and%2520FAK%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D133%26epage%3D137%26doi%3D10.1016%2Fj.bmcl.2011.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="note"><p class="first last">For a list of kinases tested, % inhibition, and <i>K</i><sub>d</sub> values see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">The rat PK parameters for <b>1</b> in this manuscript that are used for comparison were performed using the same protocol design (1 mg/kg, iv and 5 mg/kg, po doses) as that for all other analogues tested. It is of note that this protocol differs from that reported for compound <b>1</b> in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a> with respect to dosage. Differences were noted between the two independent studies. See <a href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf" class="ext-link">Supporting Information</a> for the parameters used in this study.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structureâactivity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2- (isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">â</span> <span class="NLM_lpage">5690</span><span class="refDoi">Â DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N4-%282-+%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N4-%25282-%2520%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lisko, J. G.; Gingrich, D. E.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Galinis, D.; Ott, G. R.; Parrish, J.; Weinberg, L. R.; Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Imidazoles and other heterocycles as amide bioisosteres for the inhibition of anaplastic lymphoma kinase (ALK)</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 241st National Meeting and Exposition of the American Chemical Society, Anaheim, CA, U.S., 2011; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>MEDI-256.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+G.+Lisko&author=D.+E.+Gingrich&author=M.+S.+Albom&author=T.+S.+Angeles&author=M.+Cheng&author=D.+Galinis&author=G.+R.+Ott&author=J.+Parrish&author=L.+R.+Weinberg&author=B.+D.+Dorsey&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26atitle%3DImidazoles%2520and%2520other%2520heterocycles%2520as%2520amide%2520bioisosteres%2520for%2520the%2520inhibition%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">120</span><span class="NLM_x">) </span> <span class="NLM_fpage">120ra17</span><span class="refDoi">Â DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22277784" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&issue=120&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D120%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">â</span> <span class="NLM_lpage">1739</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lhJYxyZcmf5cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10038</span><span class="NLM_x">â</span> <span class="NLM_lpage">10043</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=The+neuroblastoma-associated+F1174L+ALK+mutation+causes+resistance+to+an+ALK+kinase+inhibitor+in+ALK-translocated+cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520neuroblastoma-associated%2520F1174L%2520ALK%2520mutation%2520causes%2520resistance%2520to%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520ALK-translocated%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">â</span> <span class="NLM_lpage">6825</span><span class="refDoi">Â DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded Î²-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0li_ZaTPXgF6tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Sims, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCammon, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sefton, B. M.</span><span> </span><span class="NLM_article-title">Relative contributions of desolvation, inter- and intramolecular interactions to binding affinity in protein kinase systems</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">681</span><span class="refDoi">Â DOI: 10.1002/jcc.20207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1002%2Fjcc.20207" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=668-681&author=P.+A.+Simsauthor=C.+F.+Wongauthor=D.+Vugaauthor=J.+A.+McCammonauthor=B.+M.+Sefton&title=Relative+contributions+of+desolvation%2C+inter-+and+intramolecular+interactions+to+binding+affinity+in+protein+kinase+systems&doi=10.1002%2Fjcc.20207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20207%26sid%3Dliteratum%253Aachs%26aulast%3DSims%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DC.%2BF.%26aulast%3DVuga%26aufirst%3DD.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26aulast%3DSefton%26aufirst%3DB.%2BM.%26atitle%3DRelative%2520contributions%2520of%2520desolvation%252C%2520inter-%2520and%2520intramolecular%2520interactions%2520to%2520binding%2520affinity%2520in%2520protein%2520kinase%2520systems%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D668%26epage%3D681%26doi%3D10.1002%2Fjcc.20207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span> </span><span class="NLM_article-title">Treating ALK-positive lung cancerâearly successes and future challenges</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">â</span> <span class="NLM_lpage">277</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2012.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1038%2Fnrclinonc.2012.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=22473102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlGgurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=268-277&author=D.+R.+Camidgeauthor=R.+C.+Doebele&title=Treating+ALK-positive+lung+cancer%E2%80%94early+successes+and+future+challenges&doi=10.1038%2Fnrclinonc.2012.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Treating ALK-positive lung cancer-early successes and future challenges</span></div><div class="casAuthors">Camidge, D. Ross; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">268-277</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Crizotinib has provided dramatic and prolonged benefit for patients with the ALK-pos. subtype of non-small-cell lung cancer.  Despite these early successes, many challenges remain including understanding the mechanisms of resistance to crizotinib.  This Review examines what we already know and the major emerging questions assocd. with optimal management of this disease.  Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease.  Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-pos. (ALK+) NSCLC in assocn. with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clin. use in this molecularly defined subgroup of lung cancer.  Many new ALK inhibitors are being developed and understanding the challenges of detg. and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be crit. in the future for informing the optimal therapy of ALK+ NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoux5Y1cifBo7Vg90H21EOLACvtfcHk0li_ZaTPXgF6tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlGgurk%253D&md5=19969175b805e023229ca8716897d8d8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.43%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DTreating%2520ALK-positive%2520lung%2520cancer%25E2%2580%2594early%2520successes%2520and%2520future%2520challenges%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D268%26epage%3D277%26doi%3D10.1038%2Fnrclinonc.2012.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span> </span><span class="NLM_article-title">Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">805</span><span class="refDoi">Â DOI: 10.1007/s10555-015-9592-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1007%2Fs10555-015-9592-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=26342831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWhsLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=797-805&author=G.+Toyokawaauthor=T.+Setoauthor=M.+Takenoyamaauthor=Y.+Ichinose&title=Insights+into+brain+metastasis+in+patients+with+ALK%2B+lung+cancer%3A+is+the+brain+truly+a+sanctuary%3F&doi=10.1007%2Fs10555-015-9592-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?</span></div><div class="casAuthors">Toyokawa, Gouji; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">797-805</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and ceritinib, than with chemotherapy.  Despite the excellent efficacy of ALK inhibitors, resistance to these drugs is inevitably encountered in most ALK-rearranged pts.  Cases of resistance are subtyped into three groups, i.e., systemic, oligo, and central nervous system (CNS) types, with the CNS being used to be considered a sanctuary.  With regard to the management of CNS lesions in pts with ALK+ NSCLC, a growing body of evidence has gradually demonstrated the intracranial (IC) efficacy of ALK inhibitor (ALKi) in ALK+ NSCLC pts with brain metastases (BMs).  Although the efficacy of crizotinib for the CNS lesions remains controversial, a recent retrospective investigation of ALK+ pts with BM enrolled in PROFILE 1005 and PROFILE 1007 demonstrated that crizotinib is assocd. with a high disease control rate for BM.  However, BM comprises the most common site of progressive disease in pts with or without baseline BMs, which is a serious problem for crizotinib.  Furthermore, alectinib can be used to achieve strong and long-lasting inhibitory effects on BM.  In addn. to alectinib, the IC efficacy of other next-generation ALK inhibitors, such as ceritinib, AP26113 and PF-06463922, has been demonstrated.  In this article, we review the latest evidence regarding the BM and IC efficacy of ALK inhibitors in pts with ALK+ NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBwkFYAW4O0bVg90H21EOLACvtfcHk0li_ZaTPXgF6tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWhsLrM&md5=a9f603248214b3d8027df8cb91838737</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10555-015-9592-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-015-9592-y%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakenoyama%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DY.%26atitle%3DInsights%2520into%2520brain%2520metastasis%2520in%2520patients%2520with%2520ALK%252B%2520lung%2520cancer%253A%2520is%2520the%2520brain%2520truly%2520a%2520sanctuary%253F%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2015%26volume%3D34%26spage%3D797%26epage%3D805%26doi%3D10.1007%2Fs10555-015-9592-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">Dose normalized to 1 mg oral AUC values for comparison purposes.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Khor, T.; Vasquez, D.; Katz, A.; Baia, G.; Ciznadija, D.; Sidransky, S.; Paz, K.</span><span> </span><span class="NLM_article-title">The Champions TumorGraft Bank: A Demographically-Rich Repository of Preclinical TumorGraft Models</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, U.S., 2014; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract 1187. See also <a href="http://www.championsoncology.com" class="extLink">www.championsoncology.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Khor&author=D.+Vasquez&author=A.+Katz&author=G.+Baia&author=D.+Ciznadija&author=S.+Sidransky&author=K.+Paz&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKhor%26aufirst%3DT.%26atitle%3DThe%2520Champions%2520TumorGraft%2520Bank%253A%2520A%2520Demographically-Rich%2520Repository%2520of%2520Preclinical%2520TumorGraft%2520Models%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Salem, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsalahi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chervoneva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburto, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, S. V.</span><span> </span><span class="NLM_article-title">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-52&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+vitro+and+in+vivo+on+inflammatory+breast+cancer+cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0lg6WsXzf1vPIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520on%2520inflammatory%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D52%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>ClinicalTrials.gov identifier: NCT01922752.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+identifier%3A+NCT01922752."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Crivello, J. V.</span><span> </span><span class="NLM_article-title">Nitrations and oxidations with inorganic nitrate salts in trifluoroacetic anhydride</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3056</span><span class="NLM_x">â</span> <span class="NLM_lpage">3060</span><span class="refDoi">Â DOI: 10.1021/jo00328a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00328a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;key=1%3ACAS%3A528%3ADyaL3MXksVamsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1981&pages=3056-3060&author=J.+V.+Crivello&title=Nitrations+and+oxidations+with+inorganic+nitrate+salts+in+trifluoroacetic+anhydride&doi=10.1021%2Fjo00328a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrations and oxidations with inorganic nitrate salts in trifluoroacetic anhydride</span></div><div class="casAuthors">Crivello, J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3056-60</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Metal nitrates in (CF3CO)2O nitrate many arom. compds. in high yields at room temp., including polymers with arom. groups.  However, this system oxidizes phenols to quinoid products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq739OW8d6AO7Vg90H21EOLACvtfcHk0lg6WsXzf1vPIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXksVamsr8%253D&md5=cc74e3e39a148569596b1225cdf34e40</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjo00328a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00328a013%26sid%3Dliteratum%253Aachs%26aulast%3DCrivello%26aufirst%3DJ.%2BV.%26atitle%3DNitrations%2520and%2520oxidations%2520with%2520inorganic%2520nitrate%2520salts%2520in%2520trifluoroacetic%2520anhydride%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1981%26volume%3D46%26spage%3D3056%26epage%3D3060%26doi%3D10.1021%2Fjo00328a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LZT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LZT','PDB','3LZT'); return false;">PDB: 3LZT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BZ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BZ3','PDB','3BZ3'); return false;">PDB: 3BZ3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00487">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_08826"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00487">10.1021/acs.jmedchem.6b00487</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental conditions for X-ray data collection and solution, PK for compound <b>1</b>, DiscoveRx kinase selectivity data for <b>27b</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00487/suppl_file/jm6b00487_si_001.pdf">jm6b00487_si_001.pdf (282.91 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00487%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00487" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f32e6e0121e5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
